RRM Glossary: A Detailed Reference to Restorative Reproductive Medicine

Overview

This glossary defines the clinical terms, methods, and conditions used in restorative reproductive medicine (RRM), drawn from peer-reviewed research and active clinical practice, and maintained by RRM Academy for patients and clinicians.

Restorative Reproductive Medicine (RRM) is a specialized field of medicine that focuses on identifying the underlying health conditions contributing to reproductive dysfunction, then treating them to restore the natural functions of the reproductive system. Unlike conventional approaches that suppress or bypass normal physiology, RRM seeks to cooperate with the body: diagnosing, understanding, and addressing underlying health concerns to improve overall wellness and restore reproductive abilities. This glossary provides a thorough, well-cited reference for the terminology, methods, conditions, and procedures encountered within the RRM framework.¹

Core RRM Principles

Restorative Reproductive Medicine (RRM) is a specialized field of medicine that identifies and treats the underlying health conditions causing reproductive dysfunction in women and men, working with the body's natural physiology rather than bypassing or suppressing it.¹ RRM applies across the reproductive lifespan to conditions including infertility, recurrent miscarriage, PCOS, endometriosis, PMS/PMDD, irregular or painful periods, hormonal dysfunction, male factor conditions, and perimenopause. Care draws on cycle charting as a clinical diagnostic instrument, targeted medical workup, hormone and pharmacologic therapies, restorative surgery and andrology, and lifestyle interventions.² RRM is an umbrella field. NaProTechnology is one well-developed method within it; others include FEMM Medical Management and NeoFertility. The goal is a body functioning at its healthy physiologic state, with fertility restored as a natural outcome of that health.³

Open full entry →

Root cause diagnosis is the foundational RRM principle that reproductive health problems (including infertility, abnormal bleeding, and chronic pain) are symptoms of identifiable underlying causes, not final diagnoses in themselves.⁴ Underlying causes may include hormonal imbalances, structural abnormalities (e.g., tubal blockage, uterine defects), inflammatory conditions, autoimmune disorders, metabolic dysfunction, iatrogenic factors such as C-section scar defects, or male-factor contributions such as sperm DNA fragmentation and varicocele. Both partners are evaluated systematically, including semen analysis with DNA fragmentation index. RRM does not accept "unexplained infertility" as a final answer. That label almost always means under-investigated.³

Open full entry →

In RRM, 'restorative' refers to the goal of repairing, healing, and optimizing the natural function of the reproductive system, in contrast to suppressive or bypass approaches. The restorative approach contrasts with suppressive therapies (e.g., hormonal contraception used to mask cycle symptoms) and bypass therapies (e.g., IVF circumventing tubal disease without treating it). It encompasses removal of problematic devices, reversal of prior procedures such as tubal ligation, and male-side correction such as varicocele repair. Each intervention works with the body's biology rather than substituting for it.¹ The term is specific to RRM and does not appear in standard medical classification systems. Clinicians across multiple specialties apply the principle, but reproductive medicine has made it most explicit as a framework for guiding both diagnosis and treatment decisions.

Open full entry →

Natural fertility is the inherent biological capacity of a couple to achieve pregnancy through natural conception, without removing gametes, without external fertilization, and without bypassing any part of the reproductive system.⁸⁷ In healthy couples, the chance of conception in a given cycle is approximately 20-25%, declining with age and with unaddressed conditions such as endometriosis, tubal disease, ovulatory dysfunction, or male-factor impairment including sperm DNA fragmentation and low sperm count.³ RRM treats the conditions that have impaired natural fertility rather than substituting a laboratory step for impaired physiology. Medical treatment, surgical correction, and cycle-timed protocols support conception through native reproductive pathways. Restoring natural fertility for couples who want it is RRM's primary clinical goal.

Open full entry →

Body literacy is an informed understanding of the body's biological signs and reproductive cycle, developed through systematic fertility charting and education. The concept of body literacy as a distinct framework emerged from women's health advocacy and is foundational to fertility awareness-based methods (FABMs).⁸⁸ Body literacy enables couples to recognize cycle abnormalities early, time intercourse and diagnostics appropriately, and engage actively in clinical care. For the male partner, it includes understanding how lifestyle factors affect sperm health and fertility timing. In RRM, body literacy converts raw cycle observations into clinical data that guides root-cause diagnosis and treatment.¹

Open full entry →

In RRM, comprehensive evaluation is a systematic diagnostic workup of both partners, designed to find the root cause of reproductive dysfunction rather than assign a descriptive label. Tools include detailed cycle charting (using the Creighton Model or other FABMs), cycle-timed hormonal blood draws (taken at biologically meaningful days post-ovulation, not arbitrary cycle days), transvaginal ultrasound series (including saline infusion sonohysterogram -- a fluid-enhanced ultrasound to assess uterine cavity), hysterosalpingogram (HSG -- an X-ray procedure to evaluate tubal openness), semen analysis with DNA fragmentation index, and targeted testing for endocrine, immune, clotting, or genetic factors. Diagnostic laparoscopy and hysteroscopy (camera-based visualization of the pelvis and uterine interior) are employed when indicated for definitive diagnosis of endometriosis, pelvic adhesions, chronic endometritis, and isthmoceles.³

Open full entry →

In RRM, personalized treatment is built on what the diagnostic evaluation finds, not on the presenting symptom. No two couples with infertility have the same diagnosis, and treatment in RRM reflects that. Plans are assembled from cycle-timed diagnostics and may include targeted hormonal therapy, ovulation induction, luteal phase support, nutritional and lifestyle prescription, and specialized surgery.³ Patient goals shape surgical decisions: a woman who wants future fertility and a woman who does not require different approaches to the same structural finding. Male-partner treatment is personalized in the same framework -- varicocele repair timing, antioxidant protocols, and hormonal correction are determined by each man's specific workup, not a uniform andrology algorithm.¹

Open full entry →

The RRM principle that reproductive dysfunction rarely involves one organ system in isolation. In clinical practice, this means evaluating the endocrine, immune, metabolic, and inflammatory systems alongside pelvic anatomy, in both partners, to understand what is driving the presenting problem.¹ Thyroid dysfunction alters cycle length and luteal function. Insulin resistance drives anovulation in PCOS. Chronic inflammation affects implantation. These connections are not incidental. RRM treats them as primary diagnostic targets. The same framework applies to male reproductive health: systemic conditions such as metabolic syndrome and hormonal imbalance directly impair sperm production and function. This approach is grounded in internal medicine diagnostics and differs from "holistic" wellness language. The evaluation is clinical, systematic, and evidence-based.

Open full entry →

Reproductive health optimization is the overarching RRM goal of improving the overall health and function of the reproductive system, encompassing fertility, cycle regularity, absence of pain or abnormal bleeding, hormonal balance, and long-term gynecologic wellness. Achieving pregnancy is a result of restored health, not a standalone procedural endpoint.¹ The menstrual cycle itself carries independent health value: regular ovulation protects bone density, cardiometabolic function, and mood across a woman's lifespan.⁸⁹ For this reason, RRM serves women who are not trying to conceive as fully as those who are. Male reproductive health optimization follows the same logic: sperm quality, hormonal health, and lifestyle factors are evaluated and treated as part of couple-centered care.

Open full entry →

RRM corrects the conditions causing reproductive dysfunction; it does not circumvent them, suppress them, or remove the affected organ.² Corrective approaches include surgical repair of the fallopian tubes, isthmocele reconstruction, adhesion excision, hormonal correction of luteal phase deficiency, antibiotic treatment of chronic endometritis, and varicocele repair for male-factor infertility. Each targets the cause. Bypass therapies circumvent the problem without treating it: IVF routes around a blocked tube, leaving the disease in place. Suppressive therapies quiet the symptom: hormonal contraception controls endometriosis pain while disease continues to progress. Hysterectomy removes the organ entirely. RRM treats none of these as acceptable defaults when a corrective path exists.¹

Open full entry →

Fertility Awareness and Charting Methods

Fertility Awareness-Based Methods (FABMs) are scientific methods used to monitor and interpret biological signs of fertility (biomarkers) throughout the menstrual cycle. FABMs can be used for health monitoring, timing diagnostics and treatments in RRM, and achieving or avoiding pregnancy. A 2025 systematic review of 20,339 participants from 16 studies found FABMs, when used correctly, were associated with a success rate of over 90% for both contraceptive and conception purposes.⁶ FABMs encourage partner involvement, improve communication, and enhance body literacy by tracking biomarkers to determine fertility status. They also aid in identifying ovulation-related disorders such as PCOS and endometriosis. Specific methods include the Creighton Model FertilityCare System, the Billings Ovulation Method, the Sympto-Thermal Method, and the Marquette Method. Note: The Creighton Model FertilityCare System is specifically classified as an NFP method by its developers and is distinct from the FABM umbrella.⁵

Open full entry →

Fertility Charting is the systematic daily recording of fertility biomarkers according to a specific standardized method, such as the Creighton Model or another FABM. Biomarkers recorded typically include cervical mucus quality and quantity, cycle bleeding patterns, and supplementary signs such as basal body temperature or urinary hormone levels. Chart data function analogously to an ECG for the reproductive system, revealing hormonal patterns, potential abnormalities, and optimal windows for diagnostics, treatment timing, and intercourse. Tracking these observations across multiple cycles is essential: patterns invisible in a single cycle become diagnostically clear over time. Changes in charting patterns serve as a form of biofeedback to assess treatment efficacy.¹¹⁰⁰

Open full entry →

Biomarkers, in reproductive medicine, are observable biological signals that change predictably across the menstrual cycle and reflect underlying hormonal and physiologic events. Primary biomarkers include cervical mucus quality and sensation (rising estrogen), basal body temperature (rises after ovulation with progesterone release), urinary LH and estrogen metabolites (E1G), and serum hormone levels drawn at cycle-phase-specific intervals. Each marker maps to a distinct physiologic event rather than representing a single undifferentiated measure of fertility.⁸⁹

Ultrasound follicle observation adds a structural layer to hormonal data. Serial follicle tracking documents recruitment, maturation, and rupture. Combined with mucus and hormonal markers, it allows direct confirmation of ovulation rather than inference from cycle length alone.¹¹⁷

In FABM charting and RRM-informed workups, biomarkers function as clinical data, not passive observations. Charted mucus patterns identify the fertile window. BBT shift confirms the post-peak phase transition. Cycle-phase-specific hormone draws time the workup to the moment when each value is physiologically meaningful. Without biomarker tracking, cycle-phase interpretation requires estimation. With it, the clinician reads actual cycle behavior.⁸⁷

Secondary biomarkers include premenstrual symptom patterns (see molimina), cycle length consistency, bleeding characteristics, and vulvar observation. These support pattern recognition across cycles rather than documenting a single event. Fertility charting integrates primary and secondary biomarkers into a longitudinal clinical record.⁸⁹

Open full entry →

Natural Family Planning (NFP) is the traditional, values-based umbrella term for methods of achieving or avoiding pregnancy by tracking the body's natural fertility signs. The term carries historical roots in Catholic teaching and healthcare, where observing the cycle was understood as cooperation with natural physiology. In clinical and secular contexts today, Fertility Awareness-Based Methods (FABMs) is the broader, more common term; NFP and FABMs overlap substantially but are not identical categories.⁶

NFP methods teach users to identify the fertile window by observing biological markers, including cervical mucus, basal body temperature, or urinary hormone levels, and to apply rules that distinguish fertile from infertile days of the cycle. Specific NFP systems include the Billings Ovulation Method, the Sympto-Thermal Method, the Marquette Method, and the Creighton Model FertilityCare System, each with distinct observation protocols and teaching structures.⁵

NFP methods share the restorative principle at the core of cycle-charting medicine: the cycle itself is a source of diagnostic information. Charting observations does not merely serve family planning goals. The same data that identifies the fertile window can reveal irregularities in mucus quality, cycle length, or luteal phase duration that may point to underlying gynecological conditions.⁸⁹ This is the bridge between NFP as a planning tool and its broader role in body literacy and reproductive health assessment.

Effectiveness depends on the method chosen and the consistency of use. Across well-studied NFP methods, perfect-use pregnancy rates range from approximately 0.4 to 5 per 100 woman-years, with typical-use rates varying more widely by method and user population.⁸⁵ Couples exploring NFP for family planning or health monitoring benefit most from instruction by a trained educator in the specific method they choose.

Open full entry →

The Creighton Model FertilityCare System (CrMS) is a standardized, prospective method of natural family planning based on daily systematic observation and classification of cervical mucus at the vulva. Developed by Dr. Thomas Hilgers at the Pope Paul VI Institute, CrMS uses a precise notation system for mucus characteristics including color, consistency, and sensation. It is used by couples to achieve or avoid pregnancy and, in conjunction with NaProTECHNOLOGY, to identify cycle-phase abnormalities that guide targeted medical and surgical treatment. The CEIBA prospective cohort study, conducted across 17 CrMS centers in the USA and Canada, reported a 13-cycle pregnancy rate of 89.6% among couples using correct CrMS technique and timing intercourse to peak-type mucus days.⁸ CrMS is distinct from other fertility awareness-based methods: its developers classify it specifically as an NFP method, and its standardized notation forms the diagnostic data layer that NaProTECHNOLOGY relies on for cycle-timed blood tests and interventions. The Peak Day reference point established in CrMS charting is central to NaPro's hormone evaluation protocols.

Open full entry →

Peak Day is the last day in a menstrual cycle on which cervical mucus is clear, stretchy (like raw egg white), or lubricative, and is used as a primary ovulation reference point in mucus-based fertility awareness methods, including the Creighton Model FertilityCare System.⁸ Peak Day correlates closely with follicular rupture, occurring within plus or minus two days of ovulation in approximately 95% of cycles.⁸ Crucially, Peak Day is identified retrospectively: a woman recognizes it the day after it occurs, when fertile-type mucus has ceased. The day after Peak Day is called post-peak day 1 (P+1). In NaProTECHNOLOGY, Peak Day is the reference anchor for cycle-timed diagnostic blood draws, particularly the post-peak day 7 (P+7) progesterone and estradiol measurements used to evaluate luteal phase adequacy. Accurate Peak Day identification is foundational to NaPro hormonal support protocols and to the diagnostic value of the entire charting system.

Open full entry →

The Billings Ovulation Method (BOM) is a mucus-only fertility awareness method developed by Australian physicians Drs. John and Evelyn Billings in the 1950s, based on the recognition that cervical mucus characteristics at the vulva change predictably across the cycle in response to estrogen and progesterone.⁷⁴ No thermometer, monitor, or instrument is required. BOM is taught through observation of sensation and appearance alone, making it one of the most globally accessible fertility awareness systems across varied cultural and resource settings.

Users observe and record daily the sensation of dryness, moisture, or slipperiness at the vulva, along with any visible mucus. As estrogen rises in the pre-ovulatory phase, mucus becomes more abundant, clearer, and increasingly slippery. The Peak Symptom marks the last day of this fertile-type mucus, corresponding closely to the time of ovulation.¹⁰⁰ Post-Peak rules then define the infertile phase. Teaching is provided through a network of certified Billings educators, with materials adapted to dozens of languages.

The World Health Organization supported multicountry field trials of BOM in the 1970s and 1980s to evaluate its effectiveness in diverse populations. Published effectiveness data support low method-failure rates when the method is correctly understood and applied.⁸⁵ BOM is the foundational mucus-based method from which the Creighton Model FertilityCare System was later standardized; both methods share core mucus observation principles while operating as distinct systems with separate teaching networks and rule structures.

Among Fertility Awareness-Based Methods, BOM holds a distinct position as one of the oldest scientifically studied mucus-based systems, with a publication record dating to the 1970s and a clinical literature on mucus pattern interpretation that continues to inform modern FABM research.⁶

Open full entry →

FEMM (Fertility Education and Medical Management) is a physician-integrated fertility awareness program that pairs cycle charting with hormonal science education and a structured framework for medical management based on cycle data. FEMM was developed through the Reproductive Health Research Institute and is taught through a tiered curriculum for both patients and clinicians.¹³³

FEMM teaches users to observe and chart cervical mucus patterns, then layers hormonal science education to explain the endocrine events underlying those observations. The program offers distinct levels for different clinical and educational contexts: from basic cycle literacy through structured medical management for adolescents, adults managing gynecological conditions, and women seeking to support fertility.⁶ Physician training in FEMM prepares clinicians to interpret cycle charts alongside standard diagnostic workups.

FEMM's integration of hormonal education with cycle charting distinguishes it from methods focused on observation rules alone. Users learn not just what to observe, but why those observations reflect the underlying hormonal state of the cycle. This framework supports identifying patterns associated with irregular cycles, anovulation, or luteal phase issues, which in turn informs the kind of root-cause evaluation central to restorative reproductive medicine.⁵

For detail on how FEMM is applied in clinical settings, see FEMM Medical Management and FEMM Levels. FEMM sits within the broader family of Fertility Awareness-Based Methods, sharing the foundational principle that the menstrual cycle carries diagnostic information worthy of clinical attention.

Open full entry →

The Sympto-Thermal Method (STM) is a fertility awareness approach that combines observation of cervical mucus changes with basal body temperature (BBT) tracking to identify both the opening and closing of the fertile window within each cycle. Cervical mucus signs identify the beginning of the fertile phase as estrogen rises; the sustained rise in basal body temperature after ovulation confirms that the fertile phase has ended, as progesterone from the corpus luteum elevates resting temperature by approximately 0.2 to 0.5 degrees Celsius.

Using two independent biomarkers gives STM a cross-confirmation structure. Mucus observations identify pre-ovulatory fertility; temperature tracking confirms post-ovulatory infertility. Together, they define both boundaries of the fertile window more precisely than either sign alone. Some users also include cervical position as an optional third observation. Standardized STM systems include Sensiplan, developed in Germany with a published efficacy record, and the Couple to Couple League method, widely taught in the United States.⁶

Effectiveness studies of well-defined STM protocols, particularly Sensiplan, report low method-failure rates when the method is correctly applied, consistent with published data across well-studied Fertility Awareness-Based Methods.⁸⁵ STM charts also carry clinical value beyond family planning: shortened luteal phases, irregular temperature shift patterns, or poor-quality mucus can signal hormonal abnormalities worth investigating. The menstrual cycle observed through STM becomes a biomarker of reproductive health, not just a planning calendar.⁸⁹

STM sits alongside the Billings Ovulation Method, the Marquette Method, and the Creighton Model within the wider family of Fertility Awareness-Based Methods. Where Billings relies on mucus alone and Marquette uses urinary hormone monitoring, STM's defining feature is its dual-biomarker confirmation structure.

Open full entry →

The Marquette Method is a fertility awareness approach developed at Marquette University's Institute for Natural Family Planning that uses the Clearblue fertility monitor to measure urinary metabolites of estrogen and luteinizing hormone (LH), providing objective low, high, and peak fertility readings in addition to optional cervical mucus observation.¹³⁴ The monitor's hormonal readings reduce the interpretive variability that can occur with mucus-only or temperature-only methods, particularly for women with atypical cycle patterns.

Users test first-morning urine with monitor strips each day; the Clearblue monitor reads the strips and displays a fertility status. The method can be used with the monitor alone or supplemented with cervical mucus observation and basal body temperature recording for additional confirmation. Supplementing with mucus observation is particularly common during transitional reproductive phases, such as postpartum, perimenopause, or cycles following discontinuation of suppressive medications, where hormonal patterns may be irregular.⁵

Published effectiveness data from prospective cohort studies support low pregnancy rates with correct use of the Marquette Method for avoiding pregnancy, consistent with other well-studied Fertility Awareness-Based Methods.⁸⁵ The objective hormone readout also carries clinical value: a pattern of absent or blunted LH surge readings can flag anovulatory cycles for further evaluation, while consistently suppressed estrogen readings may point to follicular insufficiency. Clinicians trained in FABM interpretation can use charted data as a starting point for diagnostic workup.

The Marquette Method sits within the broader family of Fertility Awareness-Based Methods. For the clinical application protocol used in medical management contexts, see Marquette Method Clinical Protocol.

Open full entry →

Basal Body Temperature (BBT) is the body's resting temperature, measured orally or vaginally first thing in the morning after at least three hours of uninterrupted sleep and before any activity, eating, or drinking. BBT rises 0.2 to 0.5 degrees C within one to three days after ovulation due to the thermogenic effect of progesterone released by the corpus luteum; this sustained shift produces a characteristic biphasic pattern on a cycle chart.⁹⁹ A thermal shift confirms that ovulation has occurred but cannot predict ovulation in advance. BBT is therefore useful for retrospective ovulation confirmation, luteal phase length measurement, and detection of anovulation, but is not reliable as the sole marker for identifying the fertile window. Accuracy depends on consistent timing, adequate sleep, and the absence of confounders (illness, alcohol, disturbed sleep, shift work). BBT is a core component of sympto-thermal methods and a secondary confirmatory marker in several other FABMs.

Open full entry →

The mucus pattern is the recognizable sequence of cervical secretion changes that unfolds across a single menstrual cycle, observable through vulvar sensation and visual inspection. Estrogen produced by the maturing follicle stimulates cervical crypts to generate secretions that become progressively more fluid, stretchy, and lubricative as ovulation approaches. After ovulation, progesterone shifts the pattern abruptly: secretions become sparse, tacky, or absent entirely. This estrogen-to-progesterone transition marks the boundary between the pre-peak phase and the post-peak phase of the cycle.⁷⁴

Every mucus-based FABM uses the mucus pattern as its primary observational data. The Creighton Model FertilityCare System, the Billings Ovulation Method, the Sympto-Thermal Method, and FEMM each use standardized descriptors for mucus quality, sensation, and appearance.⁶ Charted consistently across cycles, the pattern documents estrogen activity, timing of the fertile window, and the cycle's overall hormonal architecture. These observations are recorded in a fertility chart and become the foundation of clinical interpretation.

A disrupted mucus pattern carries diagnostic weight. Sparse or absent fertile-type mucus despite confirmed ovulation points toward poor cervical mucus or cervical factor infertility. Mucus appearing well outside the expected fertile window can reflect hormonal dysregulation, chronic cervicitis, or the after-effects of suppressive medications. Identifying where in the mucus cycle the pattern breaks down guides clinicians toward a cause rather than a workaround.⁷⁴⁸⁷

The mucus pattern is the observational backbone of cycle-charting-informed reproductive care. It gives both the patient and the clinician direct evidence of cervical endocrine output, cycle by cycle, without laboratory panels. and mucus cycle score.

Open full entry →

The peak symptom is the last day in a menstrual cycle on which cervical mucus is observed as clear, stretchy, or lubricative, regardless of the total amount of discharge present. Quality is the marker, not volume. A day with abundant but cloudy or tacky mucus does not qualify. A day with minimal but clear or lubricative discharge does. This distinction matters because the peak symptom identifies the end of the fertile window with precision: research shows ovulation typically occurs within 24 to 48 hours before or after this day.¹⁰⁰

The peak symptom is the observation; Peak Day is the chart label assigned to that observation retrospectively, once the following days confirm that the pattern has ended. Users of the Creighton Model FertilityCare System and the Billings Ovulation Method learn to track the quality descriptors defined in their method's system rather than relying on volume estimates. The post-peak phase count cannot begin until the peak symptom day is correctly placed, so accurate identification has downstream consequences for both family planning use and clinical assessment.¹⁰⁰

Clinically, the peak symptom anchors the cycle chart. Cycle-timed hormonal assessments, progesterone draws, and the evaluation of luteal function all depend on knowing when the peak symptom occurred. A mucus pattern that lacks a recognizable peak, or one in which the peak symptom is difficult to identify, is itself a diagnostic finding worth exploring. and pre-peak phase.

Open full entry →

The pre-peak phase is the portion of the menstrual cycle that runs from the first day of menstruation through and including Peak Day, encompassing the follicular and periovulatory period. During this phase, estrogen rises progressively as a follicle matures, driving the mucus pattern from absent to increasingly fertile in quality. Cervical secretions become more fluid, stretchy, and lubricative as the cycle approaches the peak symptom.

The pre-peak phase is the variable half of the menstrual cycle. When ovulation is delayed by stress, illness, PCOS, or perimenopausal hormonal shifts, this phase extends. The post-peak phase, by contrast, remains relatively stable across cycles in the same individual. This asymmetry means that an irregular or lengthened cycle almost always reflects what is happening before ovulation, not after.⁸⁷

From a clinical standpoint, pre-peak phase length and the quality of the mucus progression within it tell a story about follicular development and estrogen output. A very short pre-peak phase may indicate follicular deficiency; a prolonged one with poor mucus development may suggest inadequate estrogen or cervical crypt dysfunction. These observations, read from a fertility chart, can focus the diagnostic workup before a single lab is drawn. and dry day.

Open full entry →

The post-peak phase is the portion of the menstrual cycle that runs from the day after Peak Day through the last day before the next menstrual bleed, corresponding to the progesterone-dominant luteal period. Once the peak symptom has passed and ovulation has occurred, progesterone produced by the corpus luteum takes over. Cervical secretions become sparse or absent. The mucus pattern shifts from fertile to non-fertile within a matter of days.

The post-peak phase is the stable half of the cycle. While the pre-peak phase can vary considerably in length from cycle to cycle, the post-peak phase typically runs 11 to 16 days in ovulatory cycles with adequate hormonal support.⁴⁴ This consistency is what makes it clinically reliable. When the post-peak phase is shortened, it is a signal that progesterone production may be insufficient to support the early stages of a potential pregnancy, a pattern associated with luteal phase deficiency.⁴⁵

The post-peak phase is the window used in cycle-timed assessments of progesterone output. Hormone levels drawn at specific days after the peak symptom reflect the corpus luteum's actual secretory function, not a population average. A shortened or hormonally weak post-peak phase, identified from the mucus pattern chart and confirmed with timed labs, is one of the earlier correctable findings in a fertility evaluation. and dry day.

Open full entry →

The Mucus Cycle is the discrete window of fertile-type cervical mucus within a single menstrual cycle, beginning at the Point of Change (the first observable shift from the dry baseline) and ending on Peak Day. The mucus cycle is the fertile window in practical terms. It is distinct from the mucus pattern, which refers to the full sequence of charted cervical observations across the entire cycle, including pre-Peak dry days, the mucus cycle itself, and post-Peak dry days. Hilgers documented this architecture in CrMS training materials, charting the mucus cycle as its own bounded phase between menstruation and post-Peak dryness.⁷⁹ The length and character of the mucus cycle varies. A shortened or atypical mucus cycle can indicate low estrogen output, cervical factor infertility, or approaching anovulation. Tracking the mucus cycle across several months reveals patterns invisible in single-cycle data.

Open full entry →

A dry day is a charted cycle day on which no cervical mucus is observed at the vulva, no bleeding is present, and no sensation of wetness or lubrication is noted. Dry days are a normal and expected feature of healthy cycles, appearing both before mucus begins to develop and after the peak symptom has passed. They are not days of abnormality. They are days of relative quiescence, each with a distinct hormonal explanation depending on where they fall.⁷⁴

Dry days reflect two different physiological states. In the pre-peak phase, early dry days indicate that follicular estrogen has not yet risen high enough to stimulate cervical crypt secretion. In the post-peak phase, dry days reflect progesterone-driven suppression of cervical mucus after ovulation. The Creighton Model FertilityCare System records these as distinct chart categories; the biological meaning of a dry day depends entirely on its position in the cycle.⁷

Accurate identification of dry days is foundational to reading a mucus pattern correctly. When mucus appears on days expected to be dry, that observation is clinically significant, not a charting error. Continuous or recurring mucus outside the normal fertile window can reflect a basic infertile pattern, hormonal dysregulation, or cervical irritation, each pointing toward a distinct cause worth investigating.

Open full entry →

Mucus quality descriptors are the standardized observation vocabulary used by fertility awareness-based methods (FABMs) to describe the physical characteristics of cervical secretions at each observation point in the cycle.⁷ Different methods use different vocabulary systems. The Creighton Model FertilityCare System (CrMS) defines a specific set of standardized descriptors that encode sensation, appearance, color, and stretch into a structured chart entry.⁷ The Billings Ovulation Method uses its own descriptor language, centered on the sensation experienced at the vulva.⁷⁴ Sympto-thermal approaches also incorporate mucus descriptors alongside basal body temperature observation.

The rationale for standardized descriptors is clinical, not administrative. Consistent vocabulary means that a chart produced by one woman, reviewed by a trained FertilityCare Practitioner, carries the same meaning as a chart produced by another woman seen by a different practitioner. Without a shared vocabulary, observation data cannot accumulate into population-level diagnostic patterns. Standardization is what converts subjective daily experience into reproducible clinical signal.

Descriptors typically encode two distinct channels: sensation at the vulva (lubricative, smooth, dry, or nothing) and visual characteristics of any discharge observed on tissue (stretch length, color, opacity). Some methods also record quantity. These channels together inform whether a given observation falls into the fertile or infertile range for that cycle day.⁸⁹

The descriptor set forms the input layer for more structured chart analysis tools such as the Vaginal Discharge Recording System (VDRS) in CrMS, and contributes to composite indicators like the Mucus Cycle Score. A well-described observation also enables identification of the Peak Symptom, the last day of the most-fertile mucus type in a given cycle.

Open full entry →

Vulvar observation is the practice of assessing cervical secretions at the external vulva, using folded white tissue and attention to sensation, appearance, and elasticity of any discharge present.⁷ It is the primary data-collection step in several FABMs, including the Creighton Model FertilityCare System, the Billings Ovulation Method, and FEMM. The observation is performed at each bathroom visit throughout the day.

Combining tactile sensation with visual inspection captures more information than visual inspection alone. Sensation at the vulva during routine daily movement often signals rising estrogen before discharge is visually detectable on tissue. That sensory signal, recorded alongside the tissue observation, extends the fertile window detection further into the pre-ovulatory phase.⁷⁴ Billings research established vulvar sensation as a reliable biological marker of the approach to ovulation, demonstrating that the cervical mucus changes perceptible at the vulva track the hormonal events of the cycle closely.

In CrMS, the external-only protocol is intentional. Internal or digital cervical sampling is not part of the method. The observation point is fixed at the vulva, at the moment of each bathroom visit, in consistent lighting. This standardization makes the observation reproducible across a full day of activity and across different practitioners reviewing the chart.⁸⁷

The practical importance of vulvar observation extends beyond cycle timing. Consistent, standardized external observations form the data layer that feeds structured chart analysis. All entries in the Vaginal Discharge Recording System derive from these observations. The quality of the observation determines the quality of the chart, and the quality of the chart determines what clinical patterns are detectable.⁸⁹

Open full entry →

The Vaginal Discharge Recording System (VDRS) is the structured observation-and-coding framework used in the Creighton Model FertilityCare System to convert each day's cervical mucus observation into a standardized chart entry that any trained clinician can read and interpret consistently.⁷ Each observation combines a mucus type descriptor, stretch measurement, color category, and sensation qualifier into a coded record.⁶⁴

The design purpose of the VDRS is interoperability. A chart produced by a woman using CrMS in one location carries the same vocabulary as a chart produced by another woman elsewhere. A FertilityCare Practitioner reviewing the chart can identify the Peak Symptom, assess mucus quality patterns, and flag observations consistent with hormonal irregularity without re-interviewing the patient. Standardization is what makes the chart clinically readable at a glance.

The VDRS transforms daily observations into the raw material for higher-order analysis. The Mucus Cycle Score is computed from VDRS-coded entries. Cycle-timed hormonal evaluations and surgical scheduling in NaProTechnology practice depend on accurate VDRS records to align interventions with specific phases of the cycle. A chart that uses inconsistent or imprecise coding is one that a clinician cannot interpret reliably.⁷⁸

Accurate VDRS records also support fertility charting as a longitudinal health tool rather than a single-cycle snapshot. Patterns across multiple cycles, including changes in mucus quality over time, carry diagnostic information that is only visible when each cycle uses the same coding standard.

Open full entry →

The Mucus Cycle Score (MCS) is a CrMS-derived quantitative measure that summarizes the cervical mucus observations across the pre-ovulatory phase of a single cycle to estimate the quality of estrogen-driven follicular activity for that cycle.⁷⁸ It provides a single-cycle index of mucus adequacy, derived entirely from external vulvar observations recorded through the VDRS.

Cervical mucus production during the follicular phase reflects estrogen output from the developing follicle. Rich, stretchy, lubricative mucus signals adequate estrogen stimulation of the cervical crypts. Sparse, tacky, or absent mucus in the pre-ovulatory window signals that follicular estrogen output may be insufficient. The MCS quantifies this pattern systematically, replacing subjective clinical impression with a reproducible numerical classification.⁸¹

Clinically, MCS classifications have been associated with differences in fertility outcomes. Cycles classified as limited or dry-cycle correlate with patterns consistent with follicular deficiency and have been associated with infertility and recurrent pregnancy loss in NaProTechnology patient populations. Cycles scoring in the regular range correlate with normal ovulatory hormonal patterns. This gives the chart diagnostic weight beyond cycle timing, supporting targeted evaluation of hormonal function.⁷⁸

The MCS is a concept-level diagnostic tool within CrMS practice. The scoring details and classification thresholds are part of the CrMS training curriculum and are applied by trained FertilityCare Practitioners and NaProTechnology clinicians.

Open full entry →

A limited mucus cycle is a CrMS chart pattern in which observable cervical mucus is significantly reduced in quality, quantity, or duration during the pre-ovulatory phase, reflecting suboptimal estrogen stimulation of the cervical crypts.⁷⁸ It represents one classification on the Mucus Cycle Score spectrum and signals that follicular estrogen output during that cycle was below the threshold associated with normal mucus production.

Cervical mucus is an estrogen-dependent secretion. As a follicle matures, rising estradiol stimulates the cervical crypts to produce fertile-quality mucus. When follicular development is inadequate, estrogen output is reduced, and mucus production is correspondingly diminished or absent across the pre-Peak window. A limited mucus cycle records this hormonal shortfall as observable chart data, visible without any laboratory test.⁸⁹

The clinical significance lies in what the pattern signals, not in the mucus itself. A limited mucus cycle points toward follicular deficiency as a potential underlying factor. In NaProTechnology practice, repeated limited mucus cycles across consecutive charts prompt evaluation of follicular phase hormonal support. The chart pattern is the clinical indicator; targeted hormonal assessment follows from it.⁷⁸

A limited mucus pattern on a well-kept chart is information, not a verdict. The underlying estrogen-deficient physiology is identifiable, measurable, and addressable through a cause-based evaluation.

Open full entry →

The Base Infertile Pattern (BIP) is a woman's individual baseline of dryness or unchanging, featureless discharge that persists across consecutive days in the pre-Peak phase, during which conception is unlikely.⁷⁴

The BIP concept originated in the Billings Ovulation Method. Because many women cannot apply a simple dry-day rule, the Billings Ovulation Method teaches users to identify their personal baseline over several consecutive cycles. The BIP is not a single observation. It is an established, repeating pattern. Once confirmed, any day that matches the BIP is treated as infertile. Any departure from it marks the Point of Change and signals the opening of the fertile window.

This matters especially for women who carry continuous or unchanging mucus across much of their mucus cycle: those who are postpartum, breastfeeding, transitioning off suppressive medications, or moving through perimenopause. For these women, standard fertile-window identification fails. The BIP restores interpretive clarity by anchoring the fertile window to a departure from their own baseline rather than to a fixed rule.

In the Creighton Model, a closely related concept applies under different nomenclature. In both systems, establishing the BIP requires observation across multiple cycles and instruction from a trained practitioner. The BIP is a tool for reading the body's own signal accurately, not for overriding it.

Open full entry →

The Point of Change (POC) is the cycle day when a woman's Base Infertile Pattern is broken for the first time: discharge changes in character, sensation shifts, and the fertile window opens.⁷⁴

In the Billings Ovulation Method, the POC functions as the equivalent of the first day of fertile-type mucus in a standard cycle. The departure from the BIP does not need to be dramatic. Any change in sensation or appearance, even a subtle one, qualifies. The rule is departure from sameness, not the appearance of a specific mucus type. From the POC forward, the woman treats each day as potentially fertile until her infertile pattern is re-established.

The POC is especially important for women whose cycles do not follow a predictable pattern, including those who are postpartum, breastfeeding, perimenopausal, or whose cycles have been disrupted by suppressive medications. In these populations, a fixed fertile-window rule does not apply. The POC gives the fertile window a reliable starting point anchored to that individual woman's baseline, not to population averages.

Identifying the POC correctly depends on a well-established BIP documented across prior consecutive days. Instruction from a trained practitioner is required before applying this rule in clinical or family-planning practice. The POC connects directly to the pre-Peak phase and precedes the Peak Symptom by a variable number of days depending on the individual cycle.

Open full entry →

The Essential Sameness Pattern (ESP) and Yellow Stamps are the CrMS construct for charting infertility windows when continuous discharge is present: the ESP defines pre-Peak infertile days through day-to-day identical observations, and Yellow Stamps are the chart symbol that records those days.⁷⁸

In women with chronic or continuous discharge, the standard green-stamp infertile day rule does not apply. The ESP addresses this. When a woman observes the same discharge pattern on consecutive days before Peak, those days carry the same fertility status as dry days in a standard cycle. The chart records them with a Yellow Stamp, indicating infertility despite the presence of discharge.

Post-Peak Yellow Stamps apply from Peak+4 onward in qualifying continuous-discharge cycles. Pre-Peak Yellow Stamps require the ESP criteria to be met. Both require formal instruction by a certified FertilityCare Practitioner. The ESP and Yellow Stamp system is what makes CrMS usable for women whose charts would otherwise appear uniformly fertile.

Open full entry →

Tail-End Brown Bleeding (TEB) is a Creighton Model biomarker defined as two or more days of brown or black discharge at the conclusion of menstrual flow, after the heavier bleeding days have passed.⁷⁸

Brown blood at the end of menses is old, incompletely shed endometrial tissue. In a well-functioning cycle, the endometrium clears cleanly. When it does not, TEB appears. The Creighton Model captures this pattern precisely on a standardized chart, distinguishing TEB from normal menstrual variation. The clinical question it raises is why the endometrium did not shed completely. Contributing causes include luteal phase deficiency and insufficient progesterone support in the prior cycle,⁴⁴⁴⁵ chronic endometritis,²⁶ endometriosis, uterine polyps, and fibroids. Each is a diagnosable, treatable condition.

Women frequently normalize TEB because they have lived with it for years and no clinician has flagged it. That is a missed diagnostic opportunity. A well-kept fertility chart gives the clinician a documented pattern across cycles rather than a single reported symptom. Pattern recognition is the point. One brown day at period's end means little. Two or more days, cycle after cycle, is a signal worth pursuing.

TEB on its own does not confirm a diagnosis. It directs the clinical evaluation toward the underlying cycle physiology. NaProTechnology-trained clinicians use TEB alongside other biomarkers and cycle-timed hormone measurements to identify which diagnosis is driving the pattern. Addressing the root cause typically resolves the bleeding irregularity.

Open full entry →

Premenstrual Bleeding (PMB) is a Creighton Model biomarker consisting of brown spotting or light bleeding that appears before the onset of true menstrual flow, on days that should be post-Peak infertile days.⁴⁴

A healthy menstrual cycle builds toward flow and then tapers: the pattern reflects a corpus luteum that maintained adequate progesterone support through the post-Peak phase and then regressed cleanly. PMB breaks that pattern. Spotting before the red flow begins signals that the endometrium started breaking down before the corpus luteum finished its work. The most common underlying cause is progesterone deficiency, specifically a corpus luteum that failed to sustain its output long enough.⁴⁵⁴⁴ Adenomyosis, uterine polyps, and fibroids can also produce this pattern, as can inflammatory conditions of the endometrium.⁴⁸⁴⁹⁵⁰

PMB matters beyond cycle tracking. Premature endometrial breakdown is associated with difficulty conceiving and with early pregnancy loss. A Creighton Model chart makes PMB visible and repeatable across cycles. A single episode of premenstrual spotting may be a normal variation. A recurring pattern of PMB on a well-kept fertility chart is a signal of luteal phase insufficiency or structural pathology that warrants investigation.

NaProTechnology-trained clinicians use PMB alongside cycle-timed hormone measurements and ultrasound findings to identify the underlying cause. The goal is to restore normal luteal function rather than mask the pattern.

Open full entry →

Fertility-focused intercourse (FFI) is the practice of a couple timing relations to align with the fertile window identified through FABM charting, particularly the days around and preceding the Peak Day.⁸³

In a 1992 cohort of 50 couples with apparently normal fertility, FFI using Creighton Model charting produced cumulative pregnancy rates of 76% by the first cycle, 90% by the third cycle, and 98% by the sixth cycle.⁸³ These figures carry a specific implication: when the fertile window is identified accurately, conception follows for nearly all couples without further intervention. The charting is the clinical act. Major professional societies recognize that timed intercourse aligned with the fertile window is a first-line strategy for couples pursuing pregnancy.⁸⁷

FFI reframes the clinical question. Standard evaluation asks whether a couple's biology can support pregnancy. FFI asks whether the fertile window was accurately identified and consistently used. For couples labeled with so-called "unexplained infertility," accurate mucus pattern identification through fertility charting is frequently the missing variable. The diagnosis was not unexplained. The fertile window was not found.

FFI is not a passive strategy. It requires both partners to understand the Peak Symptom and the days most likely to result in conception. Fertility awareness as a clinical tool is associated with improved reproductive outcomes and deeper body literacy for both the woman and her partner.⁸⁹ The couple becomes the diagnostic unit, not just the woman.

Open full entry →

Clinical Approaches

NaProTECHNOLOGY (Natural Procreative Technology) is a women's health science developed by Dr. Thomas Hilgers at the Pope Paul VI Institute that monitors and maintains reproductive and gynecologic health by working cooperatively with the menstrual and fertility cycles. It uses the Creighton Model FertilityCare System to identify biological markers of cycle function, then applies targeted medical (NaPro Medical) and surgical (NaPro Surgery) treatments to correct identified abnormalities. NaProTECHNOLOGY does not employ methods that are suppressive, circumventive, or destructive of reproductive function. It is the most extensively published clinical approach within Restorative Reproductive Medicine. Sanchez-Mendez et al. (2025), in a cohort of 1,310 couples, reported cumulative live-birth rates of 50% at 24 months and 62.1% at 36 months or longer.⁹³ These figures are comparable to, or exceed, cumulative live-birth rates reported after multiple IVF cycles in equivalent populations.

Open full entry →

NaPro Medical is the non-surgical treatment arm of NaProTECHNOLOGY, using Creighton Model cycle charts to guide hormone evaluation and corrective medical care. Rather than suppressing the cycle, NaPro Medical reads it. Trained NaPro clinicians use cycle charting data to time laboratory panels to specific phases of the menstrual cycle, identify patterns of hormonal dysfunction, and develop treatment plans targeted to the underlying condition.¹¹¹²

Cycle-timed diagnostics allow a NaPro clinician to evaluate hormonal output in context: the phase of the cycle matters, and drawing labs at the wrong time produces misleading results. This cycle-phase sensitivity is what separates NaPro Medical from standard hormonal workups and makes the Creighton Model chart central to the clinical process, not merely an adjunct.⁷⁸

Treatment categories addressed through NaPro Medical include luteal phase deficiency, low progesterone support, thyroid dysfunction, hyperprolactinemia, insulin resistance, ovulation disorders, and cycle-related immune conditions. Interventions are matched to the diagnosed finding and timed to the relevant peak day or cycle phase. No single protocol applies universally; the chart drives the clinical picture for each couple.⁷⁸¹³

NaPro Medical operates on a restorative model: treat the condition causing the hormonal dysfunction, not its symptoms. For couples facing infertility or pregnancy loss, that means identifying and correcting the root cause rather than circumventing it. The medical arm works alongside NaPro Surgery when surgical pathology is present, and both operate within the framework of NaProTECHNOLOGY as a whole.¹⁴

Open full entry →

NaPro Surgery is the specialized surgical arm of NaProTECHNOLOGY, applying reconstructive pelvic surgery techniques aimed at restoring anatomy and function rather than simply removing tissue. The hallmark principles are near-adhesion-free technique, excision-based treatment of endometriosis, and fertility preservation throughout every step of the procedure.¹⁰⁸⁰

Where standard surgical approaches often leave adhesions as a by-product of tissue handling, NaPro Surgery treats adhesion formation as a preventable complication. Anti-adhesion barriers are applied systematically. Published outcomes from the development of this technique documented mean adhesion scores dropping from 33.3 to 6.0 over a decade of protocol refinement, measured using standardized pelvic adhesion scoring.⁸⁰ The broader approach is described in detail under near-adhesion-free pelvic surgery and adhesion prevention.

For endometriosis, NaPro Surgery uses excision as the only endorsed approach. Fulguration and ablation destroy tissue at the surface but leave disease behind; excision removes it at the root. Surgical management also includes treatment of pelvic adhesions, endometriomas, and ovarian pathology, with ovarian wedge resection for ovulation disorders where appropriate.¹⁰

Tubal surgery is another core component. NaPro surgeons perform microsurgical tubal reconstruction and reversal, and selective salpingography to assess and address tubal obstruction. These procedures are fertility-preserving by design. They contrast with the bypass approach of IVF, which removes the fallopian tube from the equation rather than restoring it. NaPro Surgery integrates with NaPro Medical care before and after the operating room within the broader NaProTECHNOLOGY framework, with the goal of restoring the couple's reproductive function rather than bypassing it.¹⁰⁸⁰

Open full entry →

The Fertilitas Study is a 5-year retrospective cohort study of 1,310 infertile couples treated with NaProTECHNOLOGY at a specialized reproductive medicine clinic in Spain, published in 2025 in Frontiers in Reproductive Health. It is one of the largest single-center NaProTECHNOLOGY outcome datasets published to date and provides real-world effectiveness data across a population with multiple unfavorable prognostic factors.¹⁴⁹³

The headline finding: a crude take-home baby rate of 35.3% (463 of 1,310 couples) and an adjusted cumulative take-home baby rate of 62.1% over a median treatment duration of approximately 11 months. The study population was not a favorable one: 73.5% presented with primary infertility, prior ART attempts were recorded in 27.5% of couples, and mean age of female participants was 35 years. Adjusted cumulative rates varied by age, with higher rates in younger women and lower rates above 40. The methodology accounts for dropout through sensitivity analysis, making the 62.1% figure a conservative adjusted estimate rather than a raw completion rate.¹⁴

On the diagnostic side, the mean number of diagnoses per couple was 2.5. Independent predictors of successful take-home baby included female age, recurrent pregnancy loss as the reason for consultation, duration of infertility, and the presence of endometriosis, hormonal dysfunction, male factor, and endometrial disorders. This multi-diagnosis profile is consistent with NaProTECHNOLOGY's systematic approach: NaProTECHNOLOGY treats infertility as a symptom requiring diagnosis, not a condition requiring bypass.⁹³

The Fertilitas Study is clinically significant because it reports outcomes in a population that would conventionally be routed toward ART. Instead, NaProTECHNOLOGY identified and treated underlying conditions. A substantial portion of couples underwent surgery, most commonly hysteroscopy or laparoscopy, as part of the restorative care pathway. The study does not compare directly to a concurrent ART cohort, but it documents NaProTECHNOLOGY outcomes where ART had previously failed or was the presumed next step. Cross-reference: IVF vs. RRM for the head-to-head comparison literature and NaProTECHNOLOGY for the clinical framework.¹⁴

Open full entry →

FEMM Medical Management is the clinical treatment tier of the FEMM (Fertility Education and Medical Management) program, in which trained FEMM Medical Providers use cycle charting data and cycle-timed laboratory evaluation to identify and treat hormonal and reproductive disorders. It is developed and supported by the Reproductive Health Research Institute (RHRI) and represents the physician-level application of FEMM's restorative endocrinology framework.¹³³

FEMM Medical Providers use the FEMM charting system, which tracks cervical mucus observations alongside urinary hormone testing, to develop a cycle-by-cycle picture of a patient's reproductive health. That picture informs both diagnosis and treatment timing. Conditions addressed through the FEMM Medical Management framework include PCOS, thyroid disorders, luteal phase deficiency, anovulation, recurrent pregnancy loss, and perimenopause. Treatment is targeted to the identified root cause rather than applied generically across all patients with a given diagnosis.¹³³

FEMM Medical Management is distinct from NaProTECHNOLOGY in its charting method and institutional framework, though both are restorative in principle. FEMM uses a sympto-hormonal approach with integrated LH testing rather than the Creighton-only observation method. Both work from cycle data toward corrective treatment; neither suppresses the cycle as the primary intervention. For couples seeking care through this framework, fertility charting with the FEMM method is the starting point, not an optional add-on.¹³³

Within the FEMM education system, Medical Management sits at the top of three learning tiers. See FEMM Education Levels for how the program structures access across different audiences, from adolescents to trained clinicians. The Reproductive Health Research Institute supports both the research base and the professional training pathway that leads to FEMM Medical Provider certification.¹³³

Open full entry →

FEMM Education Levels are the three tiered learning pathways offered by the FEMM (Fertility Education and Medical Management) program, matched to the user's life stage and clinical need: Teen FEMM, Adult FEMM, and FEMM Medical Management. Each tier builds on the same underlying framework of restorative endocrinology and cycle-based health literacy, at different depths and with different applications.¹³³

Teen FEMM introduces adolescent girls to the hormonal and ovulatory basis of the menstrual cycle. The framing is health-oriented: the cycle is taught as a vital sign, not as a fertility or contraceptive tool. Menstrual symptoms, cycle irregularity, and hormonal patterns are presented as information about the body's function, establishing body literacy before reproductive-age decisions arise.¹³³

Adult FEMM teaches cycle charting using the FEMM sympto-hormonal method, which combines cervical mucus observation with optional urinary LH testing. The adult tier supports health monitoring, family planning, and fertility awareness. It gives users the tools to recognize cycle patterns, identify potential hormonal irregularities, and communicate meaningfully with a clinician, and bring a partner into the picture when fertility is the shared goal. This is the entry point for most women and couples seeking fertility charting through the FEMM system.¹³³

FEMM Medical Management is the clinical tier, in which trained FEMM Medical Providers use charting data and cycle-timed labs to diagnose and treat reproductive and hormonal disorders. It is the physician-facing application of the FEMM framework, developed through the Reproductive Health Research Institute (RHRI). See FEMM Medical Management for the clinical detail and FEMM for the program overview. The three levels together map a continuous pathway: from adolescent health literacy through adult cycle awareness to clinical restorative care. The Reproductive Health Research Institute maintains the research and training infrastructure for the program.¹³³

Open full entry →

The Reproductive Health Research Institute (RHRI) is a research and training organization focused on fertility-awareness-based medicine, founded to generate peer-reviewed evidence supporting cycle-informed clinical practice.¹⁴⁵ RHRI is the academic arm of the FEMM framework. Its published work spans FABM method efficacy, the health significance of chronic anovulation, and hormonal biomarker evaluation relevant to reproductive conditions including PCOS, thyroid-related cycle disruption, and immune-mediated pregnancy loss.

RHRI's research has helped establish that cycles characterized by chronic anovulation carry long-term health implications beyond infertility, including elevated risk for metabolic and cardiovascular disease. This evidence base informs the FEMM Medical Management protocol, in which cycle chart data drives clinical evaluation rather than functioning solely as contraceptive guidance.

By publishing in peer-reviewed journals, RHRI contributes to a growing body of evidence that fertility-awareness methods have diagnostic as well as family-planning applications.⁶ This positions RHRI as a key institutional contributor to the broader evidence base for restorative reproductive medicine.

Open full entry →

The sympto-hormonal method is a fertility awareness-based method (FABM) that combines physical fertility signs, specifically cervical mucus observation and basal body temperature, with objective urinary hormone testing to identify the fertile window and confirm ovulation.⁶ The urinary tests typically measure LH (luteinizing hormone) and estrone-3-glucuronide (E1G), a urinary estrogen metabolite. Together, these markers provide both a hormonal lead signal before ovulation and a biochemical confirmation after it.

The Marquette Method is the most studied sympto-hormonal approach, using the Clearblue Fertility Monitor to generate daily LH and E1G readings that are charted alongside physical observations.¹³⁴ This distinguishes the sympto-hormonal method from mucus-only methods like Billings and the Creighton Model, and from the purely temperature-and-mucus sympto-thermal method. The addition of hormonal data provides a second independent channel of ovulation confirmation, which is particularly useful when mucus patterns are unclear or atypical.

In reproductive medicine, the sympto-hormonal method is relevant to clinicians who use fertility awareness-based methods for diagnostic monitoring as well as family planning. When women with irregular cycles or suspected hormonal dysfunction record both mucus patterns and urinary hormone data, the combined chart provides richer information than either source alone. The hormonal dimension can surface blunted LH surges, prolonged E1G rises, or absent peaks that physical observation alone may miss.⁸⁵

Chart data from the sympto-hormonal method is compatible with basal body temperature review and is accepted by clinicians trained in multiple FABM frameworks. This makes it a flexible option for couples seeking both family planning effectiveness and cycle health monitoring in a single integrated system.

Open full entry →

NeoFertility is a restorative reproductive medicine clinical framework developed in Dublin, Ireland, that integrates cycle charting, targeted hormonal investigation, and surgical correction to identify and treat the root causes of infertility, recurrent pregnancy loss, and at-risk pregnancy.¹⁴⁶ The approach builds on the diagnostic foundation of NaProTechnology while expanding the evaluation panel to include reproductive immunology, androgen profiling, and in-depth assessment of both partners.

NeoFertility structures its work in three sequential phases. Phase 1 is diagnostic: a thorough workup of cycle patterns, hormonal function, anatomy, and immune markers for both partners. Phase 2 is treatment and cycle optimization: addressing the conditions identified, which may include surgical intervention, hormonal support, nutritional correction, or immunological management. Phase 3 focuses on conception timing, confirmed ovulation, and follow-through support from the peri-conception period.¹³²

NeoFertility is method-agnostic with respect to fertility charting: it accepts data from any FABM, not only the Creighton Model, and integrates ChartNeo as its digital charting platform. Its expanded hormonal panel includes evaluation for conditions such as diminished ovarian reserve, where DHEA supplementation may be considered alongside other restorative interventions based on the individual evaluation. Immune-related contributors to implantation failure and recurrent loss are assessed within the immune-modifying framework.

The framework is restorative in principle: the clinical question begins with why conception has not occurred or why pregnancies have not continued. Treatment targets those underlying causes rather than bypassing them. A 2025 retrospective cohort study examining restorative reproductive medicine outcomes reported clinically significant live birth rates in couples who had previously failed to conceive, supporting the model of root-cause diagnosis before any procedural intervention.¹³²

Open full entry →

ChartNeo is a digital cycle-charting platform developed by Dr. Phil Boyle as part of the NeoFertility restorative reproductive medicine framework.¹⁴⁶ It enables couples to record cycle observations, integrate hormonal monitoring data, and share charts with their clinician for cycle-timed evaluation and treatment.

In NeoFertility clinical practice, cycle chart data is the foundation of diagnostic work. ChartNeo provides the digital infrastructure that connects the couple's ongoing observations to the clinician's review. Charting data, hormonal results, and clinical findings enter a shared record that supports cycle-timed diagnostics without the delays or transcription errors of paper-based systems.

ChartNeo serves the same core clinical function as paper charting in other named methods: building a longitudinal, cycle-level record of the woman's fertility signals. It differs in that it was designed from the outset as a clinical workflow tool, not a standalone consumer app. The platform integrates with clinician-facing dashboards, enabling remote monitoring and telehealth delivery within the NeoFertility model.

The underlying charting logic reflects NeoFertility's use of the mucus cycle, Peak Day identification, and fertility charting principles. ChartNeo extends those principles into a format where the clinician can act on chart data in real time, supporting the kind of protocol-level responsiveness that NeoFertility's treatment model requires.

Open full entry →

Low-dose naltrexone (LDN) is naltrexone (an opioid antagonist) used at sub-therapeutic doses, far below the 50 mg dose prescribed for opioid or alcohol dependence. At low doses, transient opioid receptor blockade triggers a compensatory increase in the body's own endorphin production and modulates T-regulatory cell activity, reducing pro-inflammatory cytokines such as TNF-alpha and IL-6.⁹⁰ This immune-modulating effect has been studied in chronic inflammatory conditions including multiple sclerosis and fibromyalgia.⁹¹⁹⁰ In RRM, LDN is considered by some clinicians as an adjunct in patients with suspected immune-mediated implantation failure, clinical endorphin deficiency, or endometriosis-associated immune dysregulation. Its use for these indications is off-label. Clinicians considering LDN should evaluate the individual patient's immune profile and reproductive history. No specific dosing protocol is published here; consult an RRM clinician.

Open full entry →

DHEA (dehydroepiandrosterone) supplementation refers to the clinical use of this androgen precursor hormone to address low androgen levels in women with diminished ovarian reserve or related reproductive conditions. DHEA is produced primarily by the adrenal glands and serves as a precursor to both estrogen and testosterone. In the ovarian microenvironment, adequate androgen signaling supports follicular development and granulosa cell function. When androgen levels are low, follicular maturation may be impaired, and some clinicians consider DHEA supplementation as part of a broader restorative evaluation.¹⁴⁷

The evidence base for DHEA in reproductive medicine is mixed. Several meta-analyses have examined DHEA supplementation in women with poor ovarian response or diminished ovarian reserve (DOR), reporting modest improvements in ovarian response markers such as antral follicle count and oocyte yield. The evidence for improvement in live birth rate is less consistent and requires further investigation in well-designed trials.¹⁴⁷ Assessment of AMH and other ovarian reserve markers typically informs whether DHEA supplementation is relevant for a given patient.

Within restorative reproductive medicine, DHEA is used selectively by some named clinical methods. NeoFertility includes androgen evaluation as part of its expanded diagnostic panel, and DHEA supplementation may be considered when hypoandrogenemia is identified as a contributing factor. NaPro Medical similarly evaluates hormonal contributors to subfertility within a cycle-informed framework, and restorative androgen support may be part of that individualized assessment. The specific indication, timing, and approach are determined by the evaluating clinician based on the patient's full hormonal picture, not by a single field-wide protocol.

DHEA supplementation is not a standalone therapy. Its potential role is always considered in the context of identifying why ovarian reserve is diminished, which may involve thyroid function, nutritional status, immune factors, or other underlying conditions. This root-cause orientation distinguishes restorative use of DHEA from its application as a routine adjunct in ART stimulation protocols.

Open full entry →

The Immune-Modifying Framework is a clinical orientation adopted in some restorative reproductive medicine practices for couples experiencing recurrent pregnancy loss or unexplained implantation failure, in which immune system contributors are evaluated and addressed as part of the diagnostic workup. The framework is most explicitly developed within NeoFertility's clinical approach under Dr. Phil Boyle, though related immunological evaluation appears across multiple named-method practices. The core premise is that dysregulated immune activity at the implantation interface can be a diagnosable contributor to pregnancy failure, rather than an idiopathic outcome.³⁷²⁰⁹

Immune contributors that may be investigated include antiphospholipid syndrome, uterine natural killer cell activity, autoimmune thyroid disease, inherited or acquired thrombophilia, and chronic endometritis.²⁶⁵²⁶⁵ These are not investigated as a fixed panel applied uniformly. The framework is inherently individualized: which investigations a clinician pursues depends on the couple's clinical history, prior pregnancy outcomes, and the specific named method guiding that practice.³⁷ Investigation and treatment within this framework require direct physician oversight; the approach cannot be standardized across all restorative practices.

The immune-modifying orientation reflects a broader principle in restorative care: that recurrent pregnancy loss and implantation failure deserve diagnostic investigation rather than empiric bypass.²⁶ ART protocols address implantation failure by optimizing the embryo transfer environment or adding cycles; the immune-modifying framework asks instead whether a correctable physiological condition is present. This contrast is central to the corrective-vs-bypass distinction. and autoimmune-thrombophilic conditions.

The framework remains an active area of clinical investigation. Evidence standards for specific interventions vary considerably across the immune contributors involved. NeoFertility has published outcomes data on couples with implantation failure and recurrent loss,¹⁴⁶ and the OPTIMUM treatment strategy developed in Japan addresses overlapping immune and thrombotic contributors in a structured multi-modal protocol.¹³⁰ Couples with documented immune contributors benefit most from evaluation by a clinician trained in a named method that formally incorporates this framework.

Open full entry →

The Marquette Method Clinical Protocol is a structured approach to fertility charting developed at the Marquette University Institute for Natural Family Planning, principally by Dr. Richard Fehring and colleagues beginning in the late 1990s. The protocol centers on the Clearblue Easy Fertility Monitor, a device that reads urinary levels of estrone-3-glucuronide (E1G) and luteinizing hormone (LH) to identify the fertile window objectively. Optional cervical mucus observation is layered alongside the monitor readings, making it one of the earliest named sympto-hormonal methods in the fertility-awareness literature.¹³⁴²³¹

Marquette defines rules for identifying the beginning and end of the fertile window based on the monitor's peak readings and mucus observations. These rules govern both achieving and avoiding pregnancy, and the Institute has published prospective effectiveness data across multiple clinical sites.²³¹⁸⁵ Because the monitor generates hormone data rather than relying on subjective sign interpretation alone, some clinicians find the method well-suited for women with limited mucus production or atypical cycle patterns.⁵⁶

In the context of restorative care, the Marquette protocol's urinary hormone readings can serve as one input for cycle-timed diagnostics. Clinicians trained in the method use chart data alongside clinical evaluation, much as NaProTechnology and FEMM practitioners use Creighton and FEMM charts respectively. The Marquette protocol is distinct from the broader Marquette Method as a named fertility awareness-based method: the protocol refers specifically to the clinical application rules for charting and cycle interpretation, while the method encompasses instructor training, program infrastructure, and client education frameworks.

Couples using the Marquette protocol work with a trained Marquette instructor or clinician for both charting support and clinical interpretation. Cross-method use is documented: some practitioners integrate Marquette monitor data with mucus pattern scoring from other systems, particularly when a single data source is insufficient for confident peak-day identification.⁵

Open full entry →

An hCG trigger is an injectable dose of human chorionic gonadotropin given during a monitored cycle to induce final follicular maturation and ovulation by mimicking the body's natural LH surge. The trigger works because hCG is structurally similar to LH and binds the same receptor, producing the hormonal signal needed for the dominant follicle to complete maturation and rupture.¹²² Timing of the injection is guided by follicle development monitoring, typically via ultrasound assessment of follicular size alongside cycle observation data.

The hCG trigger is used across several clinical contexts. In assisted reproductive technology, including IVF and IUI, it serves to synchronize oocyte maturation with the procedure schedule, functioning as a component of the stimulation protocol rather than a therapeutic intervention in its own right.⁹⁵ These contexts differ fundamentally in purpose from restorative use. In ART, the trigger times a retrieval or insemination. In restorative care, the goal remains conception within the body. The two applications share a pharmacological mechanism but not a clinical paradigm.

Named methods in restorative reproductive medicine, including NaProTechnology, use hCG selectively for documented ovulatory dysfunction: a delayed or absent endogenous LH surge, inadequate follicular response, or timing variability that makes natural intercourse less precise.⁶⁰ Some NaProTechnology protocols also use post-ovulatory hCG to support corpus luteum function in the early luteal phase.⁶⁰¹²² Decisions about whether to use an hCG trigger, and when in the cycle to administer it, are made by the treating physician based on cycle chart data, ultrasound findings, and individual history. The treating clinician determines protocol design and timing; no standardized dose schedule applies uniformly across named methods or individual patients.

The hCG trigger should be distinguished from follicle stimulation agents such as clomiphene and letrozole, which act earlier in the cycle to promote follicular growth. The trigger does not stimulate follicle development; it signals a mature follicle to complete ovulation. In practice, the two interventions are often used sequentially in the same cycle: stimulation first, triggering when monitoring confirms follicular readiness.¹²² and luteal phase.

Open full entry →

Cooperative Progesterone Replacement Therapy (CPRT) is a NaProTechnology protocol, developed by Dr. Thomas W. Hilgers, that restores luteal phase progesterone production through cycle-timed supplementation in women with documented luteal phase deficiency or specific patterns of early pregnancy loss.⁷⁸

The clinical premise of CPRT is that the timing of progesterone support matters. Supplementation aligned with the post-Peak phase, based on Peak Day charting and serial hormone assays, allows clinicians to match the body's own progesterone rhythm rather than administer support on an arbitrary schedule. Hilgers documented that luteal phase progesterone production is measurable from the earliest days of the post-Peak phase, and that deficiencies at this stage are clinically significant for fertility and pregnancy maintenance.⁸¹

CPRT is used in the context of documented corpus luteum deficiency and specific patterns of recurrent early loss, and targets the underlying hormonal deficit rather than masking it. The corpus luteum is the primary source of progesterone in early pregnancy, and its failure to produce adequate progesterone is a well-recognized cause of implantation failure and early loss.⁴⁴ Major professional societies acknowledge luteal phase deficiency as a clinical entity requiring individualized evaluation and management.⁴⁵

The specific drug, dose, route, and duration of support in CPRT are determined by the treating clinician based on each patient's Peak Day charting, serial assay results, and clinical presentation. The word "cooperative" in the protocol name reflects the design intention: to work with the body's own cycle rather than override it. CPRT typically uses isomolecular hormones, hormone preparations that are chemically identical to those the body produces, as part of the NaProTechnology approach to physiologic-pattern restoration.⁸² This protocol operates within the broader framework of NaProTechnology medical management.

Open full entry →

Cooperative Estrogen Replacement Therapy (CERT) is a NaProTechnology protocol, developed by Dr. Thomas W. Hilgers, that targets estrogen deficiency across the reproductive cycle in specific clinical indications, including deficient cervical mucus production, selected subtypes of luteal phase deficiency, and other restorative care contexts where estrogen output is inadequate.⁷⁸

CERT is conceptually distinct from postmenopausal hormone replacement therapy. It addresses estrogen deficiency in reproductive-age women within an active cycle context, guided by Peak Day charting and hormonal assay results. The mucus cycle is a direct biomarker of estrogen activity in the pre-Peak phase, and deficient or absent mucus is one clinical presentation that may indicate a need for estrogen evaluation. Inadequate estrogen in the pre-Peak phase can impair both cervical mucus quality and the uterine environment.⁷⁹

As with CPRT, the word "cooperative" reflects the design intention: estrogen support is timed and calibrated to cooperate with the body's cycle, not to impose a fixed daily replacement dose regardless of cycle phase. The treating clinician determines the specific drug, dose, route, and timing based on each patient's chart data and assay findings. CERT uses isomolecular hormones, preparations chemically identical to endogenous estradiol, consistent with NaProTechnology's preference for physiologic-pattern matching over pharmacologic substitution.⁸²

CERT operates within the broader NaProTechnology medical management framework. Estrogen is a co-regulator of the entire reproductive cycle, and its adequacy in both pre-Peak and post-Peak phases affects follicle development, uterine receptivity, and luteal function. CERT reflects the NaProTechnology principle that restoring hormonal output, rather than bypassing it, is the clinical goal. Options include transdermal estrogen preparations among other routes, with selection individualized to the patient's clinical picture.

Open full entry →

Isomolecular hormones (IMH) are hormone preparations that are chemically identical to those the human body produces, including progesterone identical in molecular structure to that secreted by the corpus luteum and estradiol identical to that produced by the ovaries. The term was developed by Dr. Thomas W. Hilgers as part of NaProTechnology to distinguish these preparations from heteromolecular alternatives, hormone compounds that differ in molecular structure from endogenous hormones.⁸²

The clinical rationale for using isomolecular hormones in NaProTechnology rests on the principle of molecular-identity matching: a preparation that is structurally identical to the hormone the body makes is expected to interact with the same receptors in the same way, supporting physiologic function rather than approximating it. Hilgers and colleagues documented the use and safety profile of isomolecular progesterone in pregnancy support, distinguishing it from synthetic progestins and other heteromolecular compounds that do not share this molecular identity.⁸²

In the context of NaProTechnology's cooperative replacement protocols, isomolecular hormones form the pharmacological basis for both CPRT and CERT. The preference for isomolecular preparations reflects the broader NaProTechnology design principle of cooperating with the body's physiology rather than substituting a pharmacologically active analog for it. Synthetic progestins and conjugated equine estrogens, by contrast, carry structural differences that affect receptor binding and downstream effects.⁷⁸

Isomolecular progesterone is available in several preparations. The treating clinician selects the formulation, dose, and route based on the patient's clinical presentation, cycle chart data, and assay findings. Isomolecular hormones are a specific category within the broader pharmacology of hormone support; the term "isomolecular" is a NaProTechnology-originating designation and may not correspond to terminology used outside this clinical framework.

Open full entry →

Heteromolecular artimones (HMA) are hormone-like compounds whose molecular structure differs from the hormones the human body produces naturally. The term was coined by Dr. Thomas W. Hilgers as part of NaProTechnology, specifically to contrast with isomolecular hormones, which replicate endogenous molecular structure. Examples include norethindrone, medroxyprogesterone acetate, conjugated equine estrogens, and ethinyl estradiol: the active agents found in most oral contraceptives and many conventional hormone replacement formulations.⁷¹

Hilgers documented that the molecular difference between these compounds and endogenous hormones is not merely a matter of degree. Synthetic progestins bind progesterone receptors, but they also interact with androgen and glucocorticoid receptors in ways that endogenous progesterone does not. Conjugated equine estrogens and ethinyl estradiol differ metabolically and in tissue-specific activity from endogenous estradiol. These distinctions inform NaProTechnology's position that heteromolecular preparations and isomolecular preparations are not clinically interchangeable.⁸²

NaProTechnology's clinical approach, as developed by Hilgers, does not use heteromolecular preparations in hormone replacement or pregnancy support. Cooperative progesterone replacement and cooperative estrogen replacement specify isomolecular compounds throughout. When oral contraceptives appear in NaPro clinical discussions, Hilgers applies this category label to their active agents to clarify why they fall outside NaProTechnology's therapeutic framework.⁷⁸

The HMA designation matters for patients reviewing their medication history. A hormonal preparation that is heteromolecular will behave differently at the receptor level than one that is isomolecular, even if the two compounds are marketed for similar purposes. Clinicians practicing in the NaProTechnology framework distinguish between these categories when evaluating prior treatment history and planning restorative hormone support. and hormone replacement therapy.

Open full entry →

The compounding pharmacist collaboration in NaProTechnology is a structured clinical relationship connecting three roles: the NaProTechnology-trained physician, the FertilityCare practitioner, and a licensed compounding pharmacist who prepares individualized isomolecular hormone formulations. Dr. Thomas W. Hilgers formalized this clinical structure as part of NaProTechnology, not as an ancillary arrangement but as an integral component of the medical care model.⁷⁸

Many isomolecular hormone preparations used in NaProTechnology protocols are not available in standard commercial formulations. A compounding pharmacist who understands the clinical rationale behind cycle-timed hormone protocols, the individualized nature of the prescribing, and the coordination required with the treating physician is not interchangeable with a general dispensing pharmacist. The pharmacist compounds to physician specification; prescribing decisions remain with the physician, informed by the patient's charting data and clinical context.

The FertilityCare practitioner's role in this collaboration is to provide the detailed cycle charting that informs clinical decision-making. Cycle data, including mucus observations and biomarker correlates, guides the physician's assessment of hormonal state and timing. The NaProTechnology Medical Consultant integrates this information with laboratory results before any preparation is prescribed or compounded.

Hilgers' design treats the compounding pharmacist as a clinical collaborator rather than a vendor. The relationship is coordinated and ongoing: formulations may be adjusted based on follow-up assessment, and the pharmacist is expected to understand the framework well enough to support those adjustments accurately. This approach reflects NaProTechnology's broader principle that restorative hormone support requires individualized preparation, not one-size-fits-all commercial dispensing. and cooperative estrogen replacement.

Open full entry →

Prematurity Prevention is a NaProTechnology clinical protocol developed by Dr. Thomas W. Hilgers for managing pregnancies at elevated risk for preterm birth. It addresses a defined set of risk factors: prior preterm delivery, second-trimester pregnancy loss, cervical insufficiency, and specific obstetric histories that indicate heightened vulnerability. The Prematurity Prevention protocol is a structured approach to identifying and supporting at-risk pregnancies from early gestation rather than waiting for preterm labor to present.⁷⁸

The protocol's components fall into three categories of intervention: structured cervical assessment, hormone-state monitoring, and supportive interventions. What those interventions consist of in a specific pregnancy is determined by the treating physician based on the patient's individual risk profile, her documented hormonal history, and her clinical presentation. NaProTechnology's restorative principle applies throughout: support the body's own mechanisms for sustaining pregnancy rather than bypassing them.⁷⁹

A woman's cycle charting history, including pre-pregnancy hormone assay data documented through the Creighton Model, informs the clinical starting point. A documented luteal phase deficiency before conception is clinically relevant to early pregnancy management. The chart is not set aside at conception. It provides longitudinal context that shapes how the pregnancy is monitored and supported.

Prematurity Prevention sits within NaProTechnology's broader approach to early pregnancy loss and recurrent pregnancy loss, recognizing that the physiological vulnerabilities driving preterm birth often precede pregnancy itself. and NaProTechnology.

Open full entry →

The Achieving-Related Pregnancy Rate (ARPR) is a use-effectiveness statistic developed within the Creighton Model FertilityCare System to measure pregnancy outcomes specifically among couples who have transitioned from avoiding conception to actively attempting it.⁸³ Unlike generic cumulative pregnancy rates, the ARPR isolates cycles in which fertility-focused intercourse was timed to the fertile window identified by Creighton Model charting. The denominator is controlled for intent and method use, which makes the resulting rate a more meaningful measure of fertility potential than unselected exposure statistics.

The methodological distinction matters. Most fertility effectiveness figures in reproductive medicine, including per-cycle clinical pregnancy rates used in ART, count all exposure cycles regardless of whether intercourse was timed to the fertile phase. The ARPR accounts for intent and method adherence. A couple timing intercourse to peak fertility using cycle data is not statistically comparable to a couple having intercourse without cycle awareness, and the ARPR reflects that difference.⁸⁷

The ARPR is the foundational effectiveness measure underlying NaProTechnology achieving outcomes data and is referenced in treatment outcome analyses for conditions including luteal phase deficiency and endometriosis-related subfertility.⁷⁸ It is also used to contextualize outcomes in the Fertilitas Study, the largest published NaProTechnology infertility cohort to date.⁹³ For NaPro Medical clinicians, reporting in ARPR terms situates outcomes in a methodologically appropriate frame rather than borrowing metrics designed for cycles that involve no physiological insight into timing.

When comparing restorative reproductive medicine outcomes to those reported for IVF, the ARPR is one marker of the difference in starting assumptions. IVF per-embryo-transfer rates reflect a process that bypasses the need for cycle knowledge entirely. The ARPR reflects what is possible when the cycle is understood, respected, and used as both a diagnostic map and a timing guide. These are different questions, and the metrics measure different things.

Open full entry →

Diagnostic Tools and Techniques

A Follicle Maturation Study (FMS) is a series of transvaginal ultrasounds performed across the follicular phase of the menstrual cycle to track follicular growth, the ovulation event, and post-rupture changes in real time. A single scan cannot reveal how ovulation actually unfolds. The series does. By imaging the follicle from growth through collapse and corpus luteum formation, clinicians can distinguish normal ovulatory release from several distinct disorders that a single hormone level or standard cycle assessment would miss.

In NaProTechnology and Creighton Model-based practice, IIRRM-trained clinicians use the follicle maturation study to classify ovulatory function into specific categories. These include the luteinized unruptured follicle (LUF) syndrome, in which the follicle luteinizes without releasing the oocyte; Partial Rupture Syndrome (PRS); Delayed Rupture Syndrome (DRS); Empty Follicle Syndrome (EFS); Immature Follicle Syndrome (IFS); and complete absence of follicular development, classified as Afollicularism (AF). This classification system, detailed in the NaProTechnology medical and surgical textbook, provides a diagnostic resolution that standard cycle monitoring does not.⁷⁸

The study is timed relative to fertility cycle data, including the Peak Day as identified through Creighton Model charting. That timing anchors the scan series to the biological event being measured. Without cycle chart data, there is no reliable reference point for interpreting what the ultrasound shows. This is one reason the follicle maturation study functions as a cycle-timed diagnostic within NaProTechnology practice rather than a standalone test. Results from the FMS are integrated with sonographic ovulation classification to guide further evaluation.

For couples with undiagnosed infertility, the follicle maturation study can identify an ovulatory disorder that standard fertility panels miss entirely. LUF syndrome, for example, produces normal hormone levels and regular cycles. Progesterone rises. The chart looks fine. But ovulation never completed. That distinction requires imaging across the event, not a single post-Peak blood draw.⁷⁸

Open full entry →

A Saline Infusion Sonohysterogram (SIS) is a transvaginal ultrasound procedure in which sterile saline is infused into the uterine cavity to enhance visualization of the endometrium and detect structural abnormalities inside the uterus. By distending the cavity with fluid, the clinician gains a clear acoustic window that a standard pelvic ultrasound cannot provide. SIS detects endometrial polyps, submucosal fibroids, intrauterine adhesions, uterine septa, and can reveal an isthmocele (cesarean scar defect), including measurable defect dimensions and residual myometrial thickness.^1516160

SIS occupies a practical middle ground between basic imaging and operative intervention. It is substantially less invasive than diagnostic hysteroscopy and does not require anesthesia. For that reason, it is often considered before proceeding to hysteroscopy when the clinical picture warrants uterine cavity assessment. It also adds information a standard hysterosalpingogram (HSG) may not provide: HSG outlines the cavity contour with contrast; SIS evaluates wall texture, endometrial thickness, and focal lesion detail with ultrasound.

Structural findings from SIS directly inform the fertility workup. Submucosal fibroids, endometrial polyps, and uterine septa are all associated with implantation failure and early pregnancy loss. Asherman syndrome (intrauterine adhesions) may be suspected on SIS and confirmed hysteroscopically. Because these are correctable conditions, identifying them matters. A uterine cavity that appears normal on a standard ultrasound can harbor pathology that SIS resolves clearly.

Open full entry →

A hysterosalpingogram (HSG) is a radiographic procedure in which radiopaque contrast dye is injected through the cervix into the uterine cavity and fallopian tubes under fluoroscopic X-ray guidance.¹⁷ HSG provides a real-time image of uterine cavity shape and tubal patency. It detects structural uterine abnormalities including polyps, fibroids, intrauterine adhesions, and septal defects, as well as proximal or distal tubal obstruction. HSG has limitations: false-positive tubal occlusion results from tubal spasm occur, and peritoneal endometriosis or pelvic adhesions are not visible on HSG. In the RRM infertility evaluation, HSG is often an early step in the tubal assessment workup. It may be followed by diagnostic laparoscopy for definitive assessment of pelvic pathology. When proximal tubal obstruction is identified on HSG, clinicians may proceed to selective salpingography or transcervical catheterization of the fallopian tubes, a therapeutic extension of the diagnostic study that is a distinctive RRM/NaPro surgical technique.

Open full entry →

Selective salpingography is a fluoroscopic or hysteroscopic procedure in which a catheter is guided through the cervix and selectively positioned at the tubal ostium of each fallopian tube, allowing contrast dye to be injected into each tube individually to assess patency. Unlike a standard hysterosalpingogram (HSG), which fills both tubes simultaneously from the uterine cavity, selective salpingography isolates each tube to evaluate the proximal segment with greater precision.⁸⁴¹⁶¹

The procedure serves both diagnostic and therapeutic purposes. Diagnostically, it confirms or refutes proximal tubal obstruction identified on standard HSG, which carries a meaningful false-positive rate for proximal blockage due to tubal spasm during contrast injection. Therapeutically, when a proximal obstruction is confirmed, the catheter can be advanced through the occlusion to recanalize the tube, a procedure known as fallopian tube recanalization. The same session that identifies the obstruction may also resolve it, without surgery.⁸⁴¹⁶¹

This dual function makes selective salpingography particularly relevant in the evaluation of tubal factor infertility. A proximal occlusion that appears on HSG may be confirmed as true obstruction or reclassified as spasm-related artifact. When the occlusion is real, selective salpingography with recanalization offers a minimally invasive restorative option. The transcervical catheterization technique is foundational to this procedure.⁸⁴

Open full entry →

Diagnostic hysteroscopy is the direct endoscopic visualization of the uterine cavity and cervical canal using a thin, illuminated camera introduced through the cervix, without incision. It provides a real-time view of the endometrium and uterine walls that no imaging test fully replicates. Major professional society guidelines recognize diagnostic hysteroscopy as the definitive standard for evaluation of intrauterine pathology.¹⁷¹⁸

The procedure identifies endometrial polyps, submucosal fibroids, intrauterine adhesions consistent with Asherman syndrome, uterine septa, and an isthmocele (cesarean scar defect). Each of these findings carries implications for fertility and pregnancy outcomes. In premenopausal women with regular cycles, timing the procedure in the early follicular phase, after menstruation and before ovulation, gives the clearest view of the endometrial cavity.¹⁷

Diagnostic hysteroscopy is typically considered when imaging is inconclusive, when symptoms such as abnormal uterine bleeding or recurrent pregnancy loss point to a structural cause, or when implantation failure warrants a thorough uterine cavity evaluation. It relates closely to SIS (Saline Infusion Sonohysterogram), which offers a less invasive first-look option. When SIS identifies a lesion, diagnostic hysteroscopy confirms it visually and can proceed directly to treatment through operative hysteroscopy in the same session.¹⁸

Open full entry →

Operative hysteroscopy is the therapeutic use of a hysteroscope to treat intrauterine pathology identified during visualization, using specialized instruments passed through the operative channel of the scope. It extends the diagnostic procedure directly into treatment: the same cavity view used for diagnosis becomes the operative field, without abdominal incision or the need for a separate surgical admission in most cases.¹⁷¹⁸

Established indications include resection of endometrial polyps, submucosal fibroids (leiomyomas), division of a uterine septum, lysis of intrauterine adhesions in Asherman syndrome, and repair of an isthmocele. Removal of a malpositioned IUD and tubal cannulation are also performed hysteroscopically. For many of these indications, ambulatory (office-based) operative hysteroscopy produces comparable outcomes to operating room procedures, while avoiding general anesthesia and reducing cost.¹⁷¹⁸

In a root-cause fertility evaluation, operative hysteroscopy addresses structural conditions inside the uterine cavity that suppress implantation or contribute to pregnancy loss. A septum that divides the implantation surface, adhesions that restrict the cavity, or a polyp occupying the site where an embryo would implant are correctable causes. Treating them restores the uterine environment without bypassing it. For hysteroscopic isthmocele repair specifically, the procedure addresses the structural defect that the cesarean scar created in the lower uterine segment.

Operative hysteroscopy is preceded by diagnostic hysteroscopy or SIS to characterize the pathology before intervention. When both are performed in sequence, the transition from diagnosis to treatment occurs within the same procedure.¹⁸

Open full entry →

Diagnostic laparoscopy is a minimally invasive surgical procedure that directly visualizes the peritoneal cavity, pelvic organs, and abdominal structures through small incisions using a camera-equipped scope. It is the gold-standard method for diagnosing endometriosis and pelvic adhesions, conditions that imaging alone frequently fails to detect. Definitive diagnosis of endometriosis requires direct visualization and histological confirmation by biopsy.⁹⁸

The procedure is typically performed under general anesthesia. A small incision at the umbilicus allows passage of the laparoscope; one or two additional ports provide instrument access. The surgeon systematically examines all visible pelvic and relevant abdominal surfaces. When findings warrant immediate intervention, diagnostic laparoscopy is often combined with operative laparoscopy in the same setting, sparing the patient a second procedure.

Standard-distance laparoscopy misses a significant proportion of endometriotic lesions, particularly early-stage, subtle, or atypical implants. Close-approach techniques such as near-contact laparoscopy improve detection by bringing the camera within close proximity to the peritoneal surface, allowing higher-magnification evaluation of suspicious tissue. NaProTechnology and IIRRM-trained surgeons commonly integrate this approach into systematic pelvic examination protocols to reduce missed disease.¹²⁷

The decision to proceed to surgery requires careful clinical judgment. Diagnostic laparoscopy is generally indicated when there is clinical suspicion of endometriosis, pelvic adhesions, or other structural pathology that cannot be adequately characterized by imaging. When performed by a trained surgeon with the capacity for operative intervention, a single procedure can move a couple from diagnosis to treatment. The addition of adhesiolysis or excision in the same surgical episode depends on intraoperative findings and surgeon preparation.

Open full entry →

Operative laparoscopy is a minimally invasive surgical approach that treats pelvic and abdominal pathology identified during laparoscopic visualization, addressing structural causes of pain, infertility, or pregnancy loss in the same or a planned subsequent procedure. Conditions commonly treated include endometriosis (via excision), ovarian endometrioma (via cystectomy), and pelvic adhesions (via adhesiolysis). Additional indications include uterine fibroids, tubal disease, isthmocele, and laparoscopic ovarian wedge resection in selected PCOS cases.

For endometriosis, excision is the surgical standard that removes disease from its root. Ablation techniques destroy only the surface layer of visible lesions; they do not address deeper implants and are associated with higher recurrence rates.²⁷²⁸²⁹ For ovarian endometrioma, excision of the cyst wall is likewise preferred over drainage or ablation, as evidence supports lower recurrence and better preservation of ovarian reserve.³⁸ For the distinction between these approaches, see fulguration / ablation.

Operative laparoscopy in the restorative paradigm is not simply about removing disease. Reconstruction matters equally. Adhesion prevention technique, tissue handling, irrigation, and post-excision repair of peritoneal and ligamentous structures affect whether the pelvis heals functional or scarred. The goal is a pelvis that works, not just a pelvis that looks cleaner on the operative report. This is the surgical arm of pelvic excision and repair surgery.

Surgeons trained in NaProTechnology and IIRRM protocols approach operative laparoscopy with systematic pre-excision mapping to ensure no region of disease is overlooked before intervention begins. When a surgeon is prepared for both diagnostic and operative steps in the same setting, couples move from evaluation to treatment without delay.

Open full entry →

Near-contact laparoscopy is a surgical visualization technique in which the laparoscope is positioned in close proximity to the peritoneal surface, achieving higher magnification and improved resolution compared to standard operating distance. The technique was developed to identify subtle endometriotic implants: atypical, early-stage, or non-pigmented lesions that are routinely missed when the camera is positioned at conventional distance from tissue.¹⁷⁰ Standard laparoscopy, performed at working distances of 10 cm or more, can fail to resolve the fine detail needed to characterize peritoneal abnormality accurately.

The practical effect is meaningful. Many lesions dismissed as normal peritoneum at standard distance become identifiable when the scope is brought close. Color, texture, vascularity, and surface irregularity resolve more clearly at near-contact range. This distinction matters clinically: endometriosis staged or treated on the basis of inadequate visualization will be underestimated, undertreated, and more likely to recur. NaProTechnology and IIRRM-trained surgeons routinely use near-contact technique as part of systematic pelvic examination to reduce the rate of missed disease.

Near-contact laparoscopy is not a standalone operation. It functions as a visualization discipline within diagnostic and operative laparoscopy. It is most powerful when combined with a structured mapping protocol such as S-MAP, which ensures that every anatomic region receives close-approach inspection before the surgeon proceeds to excision. The combination of systematic mapping and near-contact technique addresses a core problem in endometriosis surgery: the lesions that cause the most persistent pain and the most fertility impact are often the ones that are hardest to see.

Excision of whatever is found during near-contact inspection is the appropriate surgical response. Identifying a lesion precisely and then ablating its surface defeats the diagnostic advantage. Thorough resection, with near-contact guidance for margin assessment, is consistent with the evidence supporting excision over ablation for endometriosis.

Open full entry →

S-MAP (Systematic Mapping of the Abdomen and Pelvis) is an operative protocol developed within NaProTechnology and refined by IIRRM-trained surgeons that requires a structured, sequential inspection of all abdominal and pelvic regions before any surgical intervention begins. The protocol establishes a reproducible examination sequence: every anatomic region is evaluated before excision, lysis, or reconstruction, so that no area of disease is passed over in the urgency of addressing the most visible pathology first.

The clinical rationale is direct. Surgeons who proceed immediately to obvious disease risk missing concurrent pathology in regions not yet examined. Endometriosis is rarely confined to a single location. Adhesions, diaphragmatic implants, appendiceal involvement, and upper abdominal disease are found at laparoscopy in a proportion of patients with pelvic pain or infertility that would surprise a surgeon who only looks where the patient reports pain. A systematic pre-intervention map changes what gets found. What gets found changes what gets treated.

S-MAP is performed in combination with near-contact laparoscopy. Close-approach visualization at each anatomic region, following the protocol sequence, allows identification of subtle or atypical lesions that standard-distance inspection would miss. The two techniques are complementary: near-contact provides resolution; S-MAP provides coverage. Together they address the two most common sources of surgical failure in endometriosis surgery: missed lesions and skipped regions.

S-MAP is an operative protocol within the NaProTechnology surgical framework and IIRRM training curriculum. It is applied in the context of diagnostic and operative laparoscopy and is part of the broader philosophy of pelvic excision and repair surgery. Training in the specific protocol sequence and anatomic mapping criteria is delivered through the IIRRM surgical training program. Couples seeking surgeons familiar with systematic pelvic mapping can look for providers with NaProTechnology surgical fellowship or IIRRM operative training.

Open full entry →

Semen analysis is the primary initial laboratory assessment for male-factor infertility, evaluating sperm concentration, total motility, progressive motility, morphology, semen volume, and additional parameters according to World Health Organization reference criteria.¹⁷¹ It is among the first investigations ordered when a couple presents with difficulty conceiving, reflecting that male factor is the sole cause in approximately 20% of couples and a contributing cause in an additional 30 to 40%.

A result within reference ranges does not rule out male-factor contribution. Semen analysis measures the quantity and movement of sperm; it does not assess the integrity of sperm DNA. Sperm DNA fragmentation can be elevated in men with normal concentration, motility, and morphology, and is independently associated with reduced fertilization, poor embryo development, and recurrent pregnancy loss.¹⁹²¹ A normal semen analysis in the context of unexplained infertility or recurrent loss should prompt evaluation of functional sperm parameters beyond standard morphology.

Oxidative stress is another male-factor contributor that standard semen analysis does not capture. Reactive oxygen species generated by lifestyle factors, infection, varicocele, and environmental exposures can impair sperm function even when conventional parameters appear normal.³⁵⁵⁷ Clinicians who evaluate both partners thoroughly from the outset do not stop at semen analysis when the result is normal and infertility persists.

The restorative approach to male factor treats the man as a patient in his own right, not as a sample source. Identifying and correcting the upstream cause: whether varicocele, hormonal imbalance, infection, or oxidative load, improves sperm quality at its origin. Semen analysis is the starting point of that evaluation, not the end of it. A couple whose male partner has a normal result but remains undiagnosed deserves the same diagnostic persistence that restorative medicine applies to female-factor conditions.

Open full entry →

Sperm DNA Fragmentation Index (DFI) is a measure of the proportion of sperm with damaged or broken DNA strands. Standard semen analysis evaluates sperm count, motility, and morphology. It does not assess DNA integrity. A semen sample can appear normal on standard analysis while carrying a high burden of DNA strand breaks.¹⁹

Elevated DFI associates with reduced natural conception rates, higher miscarriage risk, and impaired embryo development.²¹ The threshold commonly cited in the literature is a DFI above 15 to 25%, depending on the assay used. Above that range, fertility outcomes decline measurably.¹⁹

Three assays are in common use: TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling), SCSA (Sperm Chromatin Structure Assay), and the COMET assay. Each measures DNA strand breaks by a different mechanism. Results are not always interchangeable across assays. The clinical report should specify which assay was used.²²

The correctable causes of elevated DFI include oxidative stress, varicocele, infection, heat exposure, and certain medications. When a correctable cause is identified, addressing it directly often reduces DFI and improves outcomes. Antioxidant therapy is frequently studied as a supportive measure. Varicocele repair, when clinically indicated, can reduce DFI and improve sperm parameters.²¹²²

DFI testing is most clinically relevant in unexplained infertility, recurrent pregnancy loss, and cases where standard semen parameters appear normal but the couple has not conceived. The male factor contributes to fertility outcomes in the majority of couples, and DNA integrity is one dimension of male fertility that standard analysis leaves unevaluated.¹⁹²⁰

Open full entry →

ERA (Endometrial Receptivity Analysis) is a molecular diagnostic test that analyzes gene expression in an endometrial biopsy sample to estimate the personalized timing of the window of implantation (WOI): the period during which the endometrium is receptive to embryo implantation. The test analyzes the expression profile of several hundred genes. Based on results, the laboratory classifies the sample as receptive, pre-receptive, or post-receptive and recommends adjusted embryo transfer timing.²³²⁴

ERA is used in the context of IVF frozen embryo transfer. The premise is that some women have a displaced WOI, meaning the standard transfer timing does not align with peak endometrial receptivity, and that personalizing the timing will improve live birth rates.

The published RCT evidence does not support that premise for unselected IVF patients. A randomized clinical trial published in JAMA (2022) compared receptivity-timed transfer against standard timing in 767 patients. Live birth occurred in 58.5% of the ERA-timed group versus 61.9% in the standard-timing group. The difference was not statistically significant (rate ratio 0.95; 95% CI, 0.79 to 1.13). ERA-guided timing did not improve live birth outcomes.⁸⁶

An earlier observational study (ref-25) reported improved outcomes in a retrospective cohort with recurrent implantation failure. Observational findings in selected populations cannot establish that ERA works for the broader population of IVF patients. The RCT is the higher-quality evidence.²⁵

ERA does not assess the underlying causes of implantation failure. It evaluates endometrial gene expression at a single time point and proposes a timing adjustment. ERA does not identify or treat the conditions that directly impair implantation: chronic endometritis, adenomyosis, submucosal fibroids, and polyps. Root-cause evaluation of implantation failure requires a different workup.²⁶

Open full entry →

CD138 (Syndecan-1) immunohistochemistry is a specialized staining technique applied to endometrial biopsy specimens to identify plasma cells, which are pathognomonic (definitively diagnostic) for chronic endometritis.²⁶ CD138 is a transmembrane proteoglycan specifically expressed on plasma cell membranes. Standard histologic staining (H&E) misses plasma cells at clinically significant rates; CD138 immunostaining substantially improves detection sensitivity, making it the current diagnostic standard when chronic endometritis is suspected.²⁶ Diagnostic thresholds vary by laboratory, but most published protocols flag one or more CD138-positive plasma cells per high-power field as abnormal. In the RRM workup, CD138 testing is considered particularly in couples with recurrent pregnancy loss or repeated implantation failure, where an undetected chronic endometritis may be a treatable contributing cause.

Open full entry →

EMMA and ALICE are molecular diagnostic tests that analyze the endometrial microbiome from a biopsy sample. EMMA (Endometrial Microbiome Metagenomic Analysis) measures the composition of bacteria present in the endometrium, including the proportion of Lactobacillus species, which research associates with better implantation outcomes, and the presence of dysbiotic organisms. ALICE (Analysis of Infectious Chronic Endometritis) identifies specific pathogenic bacteria associated with chronic endometritis, a condition linked to recurrent implantation failure and recurrent pregnancy loss.⁶⁵

The two tests are typically ordered together and can be run from a single endometrial biopsy sample, often alongside ERA as a combined panel. The theoretical basis rests on evidence that the endometrial microbiome is not sterile and that its composition may influence the likelihood of successful implantation.⁶⁵²⁶

The published evidence in this area is observational and preliminary. The 2016 Moreno study established that a non-Lactobacillus-dominant endometrial microbiota correlated with lower implantation and pregnancy rates in IVF patients. This finding generated interest in microbiome-targeted treatment, including probiotic and antibiotic protocols guided by EMMA and ALICE results. Controlled trial data supporting this approach remain limited. No published RCT has established the clinical utility of routine endometrial microbiome testing.⁶⁵

EMMA and ALICE are used in the context of IVF workup for recurrent implantation failure. They do not address the structural, hormonal, or immunological causes of implantation failure that constitute the core of root-cause evaluation. For patients with suspected chronic endometritis, the more established diagnostic standard is endometrial biopsy with CD138 immunohistochemistry, which identifies plasma cell infiltration as the histologic marker of the condition.

Open full entry →

PGT-A (Preimplantation Genetic Testing for Aneuploidy) is a laboratory procedure performed on an embryo biopsy during IVF to screen for chromosomal aneuploidy before transfer. Cells are removed from the trophectoderm of a blastocyst and analyzed by next-generation sequencing or array comparative genomic hybridization to determine chromosomal copy number. Embryos classified as euploid (chromosomally normal) are selected for transfer; aneuploid embryos are typically discarded or frozen and not transferred.

PGT-A is marketed as a tool to improve IVF success rates by transferring only chromosomally screened embryos. The evidence for routine use in good-prognosis patients does not support that claim. A multicenter randomized clinical trial (the STAR trial, Fertil Steril 2019) assigned 661 good-prognosis patients to either PGT-A-based embryo selection or morphology-based selection. By intention-to-treat analysis, ongoing pregnancy rates at 20 weeks were 41.8% in the PGT-A group (138/330) versus 43.5% in the morphology group (144/331). The difference was not statistically significant.⁵⁹

The mechanism behind this finding is important to understand. PGT-A can improve per-transfer success rates by removing aneuploid embryos from the queue. It does not improve cumulative outcomes because it simultaneously reduces the number of embryos available for transfer. Embryos discarded as aneuploid include a proportion of mosaic embryos: those with both normal and abnormal cells. Mosaic embryos have produced healthy live births. The decision to discard them based on trophectoderm biopsy results carries clinical and ethical weight that the per-transfer success metric does not capture.⁵⁹

PGT-A is specific to IVF. It applies only when embryos are created outside the body and biopsied before transfer. Natural conception, which RRM supports and facilitates, does not involve embryo creation outside the body, embryo biopsy, or chromosomal selection. The question PGT-A is designed to answer does not arise in restorative care.

Open full entry →

AMH is a glycoprotein produced by granulosa cells of small antral ovarian follicles. Its serum level reflects how many small follicles are currently active in the ovaries. That is a snapshot of this cycle's follicular activity, not a fixed inventory or a permanent verdict on reproductive potential.

What AMH does not measure is equally important. It does not measure egg quality, follicle quality, or how well ovulation is functioning. For natural conception, one competent follicle per cycle is the target. A single well-developed, well-supported follicle is sufficient.

AMH's significance as a "low" number is largely anchored to protocols requiring multiple egg retrieval. That is the IVF context. An RRM clinician asks a different question: what is this cycle's follicle doing? The total pool size is a starting point for the workup, not the answer.

A low AMH result is a diagnostic signal. The question is why. Age is one factor. But autoimmune conditions, prior ovarian surgery, endometriosis, vitamin D deficiency, and thyroid dysfunction can all reduce AMH before age alone explains it. AMH can change. A meta-analysis found DHEA supplementation significantly raised serum AMH in women with diminished ovarian reserve.⁷⁷ Treating correctable contributors is the first step.

AMH also has a ceiling problem. In PCOS, AMH is often markedly elevated because many small follicles accumulate without maturing. A high number is not simply reassuring. It reflects arrested follicle development that warrants investigation.

In RRM practice, AMH is interpreted alongside AFC, cycle chart patterns, timed hormonal panels, and a follicle maturation study when indicated. AMH also has a developmental role: it is produced by Sertoli cells in males during fetal development and drives regression of the Müllerian ducts. This dual origin is why AMH appears in male factor evaluation as a marker of Sertoli cell function. The number alone is not the diagnosis. It is the beginning of the workup.

Open full entry →

AFC (Antral Follicle Count) is a transvaginal ultrasound measurement taken in the early follicular phase that counts small, fluid-filled follicles visible in both ovaries, typically 2 to 10 mm in diameter. The total count from both ovaries is the AFC. It reflects the number of follicles beginning development at the start of that cycle and serves as a marker of ovarian reserve alongside AMH and FSH.⁷⁷¹⁰¹

A lower AFC indicates fewer follicles beginning recruitment that cycle. Like AMH, AFC is a marker, not a diagnosis. The same number carries different clinical meaning depending on the patient's age, history, and other findings. A low AFC in a 38-year-old with a history of ovarian surgery is a different clinical picture than the same count in a 28-year-old with unexplained cycle irregularity. Context drives interpretation.

AFC varies more across cycles than AMH and is sensitive to technique, equipment calibration, and the timing within the follicular phase. A single AFC should not anchor irreversible conclusions about prognosis. Serial measurements across two or three cycles provide a more reliable picture of the ovary's typical recruitment pattern.

The count of follicles at the start of a cycle does not determine whether ovulation will be successful that cycle. Natural conception requires one well-developed follicle that ruptures and releases a healthy oocyte at the right time. The follicle maturation study tracks dynamic follicle growth and rupture through serial ultrasound. AFC tells the clinician what the ovary is starting with. The follicle maturation study tells what actually happens.¹⁰¹

When AFC is low, clinicians evaluate for correctable contributors: thyroid dysfunction, endometriosis affecting ovarian tissue, autoimmune conditions, and the suppressive effect of prior hormonal medications on follicle recruitment. A low AFC combined with other ovarian reserve markers and cycle chart data supports identification of what is driving the finding.

Open full entry →

Ovarian reserve describes the pool of follicles currently available in the ovaries, estimated through surrogate markers: AMH, AFC, and basal FSH. Clinicians cannot count oocytes directly. These markers are proxies for follicular activity, not a permanent verdict on reproductive potential. Low AMH or low AFC signals a smaller-than-average visible follicular pool. It does not explain why, and it does not close the door on natural conception. One competent follicle per cycle is all that is needed.

Each marker captures something different. AMH reflects the number of small growing follicles actively producing the hormone. AFC counts the antral follicles visible on early-cycle ultrasound. Basal FSH rises as the pituitary increases its recruitment signal to a depleted follicular pool. No single marker is definitive. Used together, they build a picture of current ovarian function.

Low reserve markers are a starting question, not a finishing answer. In RRM, the evaluation looks for correctable contributors to the decline. Autoimmune thyroid disease accelerates follicle loss and responds to thyroid optimization. Vitamin D deficiency suppresses AMH and is correctable with repletion. Endometriosis causes direct ovarian damage through endometriomas and surgical scarring. Excision addresses the structural source. In documented low-DHEA-S cases, a meta-analysis of 8 studies found DHEA supplementation significantly raised AMH in women with diminished ovarian reserve.⁷⁷ These are starting points for investigation, not triage criteria for bypassing the diagnosis.

For women with premature ovarian insufficiency (POI), reserve assessment is part of a broader workup including genetic screening and autoimmune evaluation. For women with diminished ovarian reserve (DOR) without a POI diagnosis, identifying and addressing the underlying driver is the first clinical priority. An RRM clinician reads reserve markers alongside cycle chart data, a follicle maturation study, timed hormonal panels, and systemic workup. The number points toward the question. The workup builds the answer.

Open full entry →

Follicle development is the process by which a cohort of ovarian follicles is recruited each cycle, one dominant follicle is selected and matures to ovulatory size, and the remaining follicles regress through atresia. Under rising FSH stimulation during the follicular phase, a group of antral follicles begins to grow. By cycle days 5 to 7, one follicle achieves dominance through greater FSH receptor density and local estrogen production. That dominant follicle expands to approximately 18 to 24 mm, produces rising estradiol, and triggers the midcycle LH surge. The LH surge initiates the cascade that ends in follicle rupture, oocyte release, and corpus luteum formation.

The quality of the ovulatory event depends on the quality of follicle development. A follicle that does not reach adequate size before rupture produces a less mature oocyte and a smaller corpus luteum. A smaller corpus luteum means lower progesterone output across the luteal phase. That is how a deficiency in the follicular phase produces luteal phase deficiency even in a cycle that appeared ovulatory on a basal body temperature chart.¹¹¹

Serial transvaginal ultrasound across the periovulatory window, called a follicle maturation study, makes follicle development visible. It documents growth rate, dominant follicle size at the LH surge, and whether the follicle actually ruptures. That last point matters: a follicle can luteinize without releasing the oocyte, a condition called LUF syndrome, which standard hormone tests cannot detect. The sonographic ovulation classification system identifies six additional ovulatory disorder patterns beyond LUF.

Normal follicle development is also a downstream marker of antral follicle count adequacy, thyroid function, and nutritional status. When follicle development is disordered, identifying the underlying cause matters before any intervention is designed. The Peak Day correlates with the moment of follicle rupture and oocyte release, anchoring cycle-timed diagnostics to the ovulatory event itself.

Open full entry →

The Peak Plus Series is a NaProTechnology and Creighton Model protocol of serial serum progesterone draws timed to specific days after the identified Peak Day, designed to characterize progesterone production across the full arc of the luteal phase rather than at a single point in time.

Standard reproductive workups rely on a single progesterone draw timed to mid-cycle by calendar estimate. That approach produces a single data point with no reference to where in the luteal arc the sample was obtained. It cannot confirm that the Peak Day was correctly identified, nor can it distinguish an adequate luteal phase from a deficient one at different phases of luteal activity.

The Peak Plus Series uses the identified Peak Day as a biological anchor rather than a calendar date. Draws are obtained across both the early and late post-Peak phase, generating a longitudinal profile of corpus luteum output.⁷⁸ The protocol also provides an early-luteal reference point that can confirm whether ovulation occurred, separate from whether the luteal phase was hormonally adequate.⁸¹

This multi-draw approach identifies patterns of luteal phase deficiency that a single mid-luteal draw cannot resolve: early-luteal deficits, late-luteal drop-offs, and integrated insufficiency across the phase.⁴⁴⁴⁵ Corpus luteum deficiency may contribute to any of these patterns. The profile also reflects the quality of follicle development that preceded ovulation: a poorly developed follicle produces a structurally compromised corpus luteum.

Because the protocol is anchored to the biological Peak Day identified through Creighton Model charting, it requires NaProTechnology training and cycle chart data to execute. Calendar-based timing produces misaligned draws and unreliable results.

Open full entry →

Sonographic ovulation classification is a serial transvaginal ultrasound framework, developed within NaProTechnology practice, that characterizes the quality of the periovulatory event and distinguishes anatomically normal ovulation from six distinct pathological patterns and one anovulatory variant.

An LH surge confirms that the ovulatory signal fired. It does not confirm that the follicle was mature, ruptured fully, released the oocyte intact, or formed a structurally adequate corpus luteum. Serial periovulatory ultrasound captures what actually occurred at the follicle after the LH surge.⁷⁸

Normal ovulation requires a dominant follicle reaching adequate mean diameter at rupture, a positive cumulus oophorus sign confirming oocyte-cumulus complex release, and complete follicle collapse. Deviation from any criterion defines a specific disorder category. The classification identifies eight patterns: anatomically normal ovulation; Luteinized Unruptured Follicle Syndrome (LUF), in which the follicle luteinizes without releasing the oocyte; Immature Follicle Syndrome, in which the follicle ruptures before reaching adequate size; Partial Rupture Syndrome, in which follicle collapse is incomplete over the expected timeframe; Delayed Rupture Syndrome, in which rupture occurs but is spread across an abnormally prolonged window; mature follicle with absent or retained cumulus oophorus; Afollicularism, in which no follicle reaches dominance; and Empty Follicle Syndrome, in which the cumulus oophorus sign is absent despite apparent follicle development.

Each pattern carries distinct implications for fertility and maps to a specific mechanism. LUF produces an apparent luteal phase with no oocyte available for fertilization. Immature follicle rupture reduces oocyte quality and corpus luteum progesterone output. Partial and delayed rupture affect gamete release and may produce pelvic adhesions over time. Afollicularism and empty follicle syndrome represent the most severe end of the spectrum, overlapping with anovulatory cycle physiology.

A follicle maturation study is the ultrasound series that generates this classification. Classification drives intervention: different ovulatory disorders have different root causes, and identifying the precise pattern is the first step toward addressing it.

Open full entry →

Transcervical catheterization of the fallopian tubes (TCFT) is a procedure that advances a specialized catheter-guidewire system through the cervix and uterine cavity to the uterotubal junction, under fluoroscopic guidance, to diagnose and clear partial proximal tubal occlusion. It is performed in conjunction with selective salpingography and intratubal pressure measurement, which together distinguish true mechanical obstruction from spasm or contrast artifact.⁸⁴

Proximal tubal occlusion identified on standard HSG is frequently over-diagnosed. Spasm, debris, and incomplete contrast filling produce false-positive blocks. TCFT does not simply confirm or deny patency: it measures tubal resistance before and after catheterization. If pressure normalizes after the procedure, a true partial obstruction was present and cleared. If pressure remains elevated, the obstruction is complete and requires further surgical evaluation.

Published data show that over 75% of partially obstructed tubes return to normal patency following catheterization.⁸⁴ The procedure is timed to the proliferative phase of the cycle. For couples with proximal tubal factor infertility, TCFT restores the anatomical pathway for natural conception without surgical intervention. Where obstruction is complete rather than partial, TCFT findings inform the decision for surgical recanalization via fallopian tube recanalization.¹⁶¹

TCFT is distinct from generic tubal cannulation techniques in its integration of pressure monitoring throughout the procedure. That measurement component converts a binary open-or-closed assessment into graded patency data, making it a diagnostic procedure as well as a therapeutic one. The cycle-timed execution aligns the procedure with the window of maximal tubal accessibility and reproducible pressure baselines.

Open full entry →

Intratubal pressure (ITP) is a quantitative measure of fallopian tube patency obtained by recording the pressure required to advance contrast through the tube during selective hysterosalpingography, converting the standard binary open-or-closed assessment into graded resistance data.

Standard HSG reports tubes as patent or blocked. That binary tells clinicians nothing about the degree of obstruction, whether a partial block is amenable to catheterization, or whether an apparently patent tube is functioning at abnormal resistance. ITP measurement addresses all three questions with a single continuous variable.

Published reference data from the foundational ITP study correspond pressure measurements to distinct patency states ranging from freely patent through partial obstruction to complete obstruction.⁸⁴ Pressure at or above the threshold for partial obstruction triggers transcervical catheterization of the fallopian tubes. Post-catheterization ITP measurement confirms whether the obstruction resolved or persists, providing a procedural endpoint that anatomy alone cannot supply.

ITP measurement is performed as part of selective salpingography and pairs with HSG imaging to guide restorative tubal intervention. Graded patency assessment allows clinicians to intervene before a couple with tubal factor infertility is directed toward tube bypass. Where ITP confirms complete obstruction, the data supports the clinical case for surgical evaluation, including fallopian tube recanalization or assessment for hydrosalpinx. The measurement is a decision tool: it replaces assumption with data.

Open full entry →

Surgical Techniques

Excision surgery is the complete surgical removal of endometriotic tissue by cutting it out at the margins, including lesion depth, rather than only destroying the surface. The operating surgeon resects each lesion from surrounding tissue under direct visualization, removing the disease in full. This stands in contrast to ablation and fulguration, which destroy only the visible surface while leaving deeper implants intact.

The clinical case for excision rests on outcome data. A cohort comparison found that excision improved outcomes across all 63 symptom measures evaluated, with improvements ranging from 28% to 46%.²⁷ Ablation, in the same comparison, marginally improved period pain (11.3%) and heavy bleeding (8.5%) while worsening 23 of 24 quality-of-life measures.²⁷ A separate analysis found significantly greater reductions in dysmenorrhea, dyschezia, and chronic pelvic pain with excision at 12 months.²⁸ For ovarian endometrioma specifically, excisional surgery produces superior outcomes compared to ablative approaches, with lower recurrence rates.³⁸

Excision also serves the reconstructive goal. Thorough disease removal reduces inflammatory burden, which has downstream effects on pelvic anatomy, tubal function, and implantation environment. The surgical approach typically pairs lesion excision with careful attention to adhesion prevention, preserving pelvic architecture rather than simply reducing visible disease.

For couples pursuing fertility after endometriosis surgery, the completeness of excision matters. Disease left behind continues to progress. The surgical goal is to treat the anatomy, not mask the condition.

Open full entry →

Fulguration, ablation, and cauterization are techniques that destroy endometriotic tissue at the surface using electrical energy, laser, or heat, without removing the underlying lesion. The tissue is burned or vaporized in place. Because the destruction is superficial, lesion depth is not addressed and the tissue is not extracted for pathologic confirmation.

Comparative evidence shows consistent disadvantages against excision. In a cohort study, ablation produced only marginal improvement in period pain (11.3%) and heavy bleeding (8.5%), while worsening 23 of 24 quality-of-life measures tracked.²⁷ Excision in the same population improved all 63 symptom measures evaluated.²⁷ A separate analysis confirmed significantly greater reductions in dysmenorrhea, dyschezia, and chronic pelvic pain with excision at 12 months compared to ablation.²⁸ For ovarian endometrioma, excisional surgery produces lower recurrence rates than ablative techniques.³⁸

The higher recurrence associated with ablation reflects incomplete disease removal. Lesions with depth below the peritoneal surface retain viable tissue after surface destruction. This tissue can continue to cycle, bleed, and generate adhesions. Absence of excised specimen also means no histologic diagnosis, which matters when confirming disease and ruling out atypical findings.

Fulguration and ablation remain common in general gynecologic settings, but the evidence supports excision as the surgical standard for endometriosis when symptom resolution and fertility preservation are the goals.²⁹

Open full entry →

Adhesiolysis is the surgical division and removal of adhesions: bands of scar tissue that form between pelvic organs and surfaces following inflammation, prior surgery, or infection. Adhesions can distort pelvic anatomy, restrict organ mobility, occlude the fallopian tubes, and contribute to chronic pelvic pain and infertility. Adhesiolysis restores normal anatomical relationships by carefully separating and excising these fibrous attachments.

The procedure is performed under direct visualization, most commonly via laparoscopy. The surgeon identifies and divides adhesive bands, distinguishing between filmy adhesions that separate easily and dense fibrous adhesions requiring sharp dissection. Careful hemostasis during lysis is critical: bleeding surfaces promote new adhesion formation, creating a cycle that careful surgical technique aims to interrupt.⁸⁰

Adhesion reformation is a recognized challenge after pelvic surgery. Techniques developed to minimize it include meticulous tissue handling, thorough hemostasis, reduction of peritoneal trauma, and the use of anti-adhesion barrier materials placed at the close of surgery. This combined approach forms the basis of near-adhesion-free reconstructive pelvic surgery.⁸⁰

Adhesiolysis is frequently performed alongside other restorative pelvic procedures: excision of endometriosis, myomectomy, tubal reconstruction, or correction of anatomical defects. The goal is not simply to lyse scar tissue but to restore normal pelvic anatomy as a foundation for improved function and, where indicated, fertility.

Open full entry →

Anti-adhesion barriers are materials placed during or at the close of pelvic surgery to physically separate tissue surfaces during the early healing period, reducing the formation of postoperative adhesions. When two traumatized peritoneal surfaces are in contact during healing, the resulting fibrin matrix can organize into permanent fibrous adhesions. Barrier materials interrupt this contact, giving each surface time to re-epithelialize independently.

Several categories of barrier materials are used in clinical practice. Oxidized regenerated cellulose (Interceed) and sodium hyaluronate-carboxymethylcellulose membrane (Seprafilm) are bioresorbable barriers approved for use in abdominal and pelvic surgery. Hyaluronic-acid-based gels provide a similar function in a more conformable form. Expanded polytetrafluoroethylene (ePTFE) membrane has been used in reconstructive pelvic surgery with published data showing reductions in adhesion reformation scores over serial evaluation.⁸⁰ The choice of material depends on the anatomy being protected, surgeon experience, and availability.

Barriers are an adjunct to technique, not a replacement for it. The primary determinants of adhesion formation are tissue trauma, bleeding, and ischemia at the surgical site. Meticulous hemostasis and minimal peritoneal damage reduce the substrate for adhesion formation; barriers act on what remains. In reconstructive pelvic surgery, barriers are used in combination with thorough hemostasis and careful tissue handling as part of a systematic approach to adhesion prevention.⁸⁰

For patients whose fertility or pelvic anatomy has been compromised by adhesive disease, the use of anti-adhesion strategies at the time of surgery is clinically significant. Adhesion reformation after lysis can restore the original anatomical problem within weeks. Barrier placement is one component of a broader effort to make surgical gains durable.

Open full entry →

Tubal ligation reversal (tubo-tubal anastomosis) is a microsurgical procedure that reconnects the segments of the fallopian tube separated or occluded during prior sterilization, restoring natural tubal patency and allowing natural conception to resume. The surgery involves precise re-anastomosis of the two tubal ends under magnification, with meticulous attention to lumen alignment and mucosa-to-mucosa apposition. It can be performed laparoscopically, robotically, or via mini-laparotomy.

Pregnancy rates after microsurgical reversal range from 57% to 84% across published series, with outcomes strongly associated with the woman's age at time of reversal and the length of remaining tube available for reconstruction.³²³³ The type of original sterilization also matters: clip and ring ligations preserve more tube length and yield higher reversal success than coagulation or segmental resection methods.³⁰³¹ Women under 37 at time of reversal have the highest cumulative pregnancy rates in comparative series.

Tubal ligation reversal is a restorative procedure: it addresses the anatomical barrier directly, restoring the reproductive tract to normal function. This is distinct from in vitro fertilization, which bypasses the fallopian tube entirely and removes fertilization from its natural environment. For women under 40 without additional fertility factors, published data support tubal reversal as an effective pathway to pregnancy.³²³³

Assessment before reversal includes evaluation of remaining tubal length, the partner's semen analysis, and the woman's ovarian reserve. Both partners contribute to the outcome, and the pre-surgical evaluation reflects that. Age at reversal is the single strongest predictor of success, and timing relative to that factor is a central part of the clinical conversation.

Open full entry →

Vasectomy reversal is microsurgical reconnection of the vas deferens after prior vasectomy, restoring the pathway for sperm to reach the ejaculate and enabling natural conception. Two techniques exist. Vasovasostomy joins the cut ends of the vas deferens directly and applies to most cases. Vasoepididymostomy bypasses the vas deferens and connects directly to the epididymis; surgeons must use it when secondary epididymal obstruction has developed upstream, a complication more common with longer obstructive intervals. The choice is made intraoperatively based on fluid analysis and is not determined in advance.

Outcomes depend heavily on the interval between vasectomy and reversal. The Vasovasostomy Study Group analyzed 1,469 microsurgical reversals and reported overall patency of 86% and pregnancy in 52% of couples with available follow-up data. Stratified by obstructive interval: under 3 years yielded 97% patency and 76% pregnancy; 3 to 8 years yielded 88% and 53%; 9 to 14 years yielded 79% and 44%; 15 or more years yielded 71% and 30%.¹⁵⁸ Female partner age is an independent determinant of cumulative pregnancy outcome and should be evaluated alongside the male obstructive interval.

Vasectomy reversal is the restorative approach to post-vasectomy fertility. It addresses the obstruction directly. The alternative, surgical sperm retrieval combined with intracytoplasmic sperm injection (ICSI), circumvents the vas entirely and removes the female partner from natural conception, requiring ovarian stimulation and embryo transfer procedures that carry their own risks. When the couple is counseled together and the female partner has no significant fertility concerns, restoration of the vas pathway is the cause-based approach.

Both partners require evaluation before any surgical decision. Male factor, female factor, and the couple's goals all shape the clinical picture.

Open full entry →

Fallopian tube recanalization (tubal cannulation) is a minimally invasive procedure that restores patency to a proximally blocked fallopian tube by passing a small catheter transcervically through the uterine cavity and into the tube under fluoroscopic or hysteroscopic guidance. Proximal tubal occlusion, located near the uterotubal junction, is distinct from distal disease and is frequently caused by mucus plugging, amorphous debris, or inflammatory fibrosis. A significant proportion of apparent proximal occlusions identified on HSG are not true anatomical blocks; recanalization resolves these in many cases in a single outpatient procedure without surgery.

Clinicians perform the procedure via selective salpingography: they guide a catheter to the blocked cornual ostium, dye is injected under pressure to confirm the location, and a guide wire or small catheter is advanced to open the occlusion. Intratubal pressure measurement before and after cannulation confirms successful recanalization.⁸⁴ When combined with hysteroscopy, the clinician can visualize the ostium directly. When performed under fluoroscopy in an interventional radiology setting, it can be done without general anesthesia.

Because proximal tubal occlusion accounts for a meaningful proportion of tubal-factor infertility diagnoses, recanalization matters as a restorative option. It avoids the surgical morbidity of open tubal anastomosis and preserves the tube for natural conception attempts afterward. Recurrence of occlusion is possible, and a repeat HSG or sonohysterogram after adequate recovery time confirms ongoing patency before attributing persistent infertility to tubal causes.

See also: selective salpingography, transcervical catheterization, HSG, tubal-factor infertility, intratubal pressure.

Open full entry →

Neosalpingostomy is a laparoscopic surgical procedure that creates a new opening at the fimbriated (distal) end of a fallopian tube that has become blocked or destroyed, typically by a hydrosalpinx. The companion procedure, fimbrioplasty, reconstructs and restores a partially obstructed or agglutinated fimbrial end where some tissue remains viable. Both address distal tubal disease, which differs anatomically and etiologically from proximal occlusion. Pelvic inflammatory disease, prior infection, and endometriosis-related adhesions are the most common causes of distal damage.

Outcomes after neosalpingostomy depend on the severity of tubal damage at the time of surgery. A review of 402 laparoscopic fimbrioplasty and neosalpingostomy cases found an overall intrauterine pregnancy rate of 26.1%, with outcomes strongly tied to disease stage and adhesion score: stage 1 (mild) disease yielded a 63% pregnancy rate, compared to 15% for stage 3 and 0% for stage 4. In the absence of adnexal adhesions the pregnancy rate was 73.9%; in severe adhesion cases it fell to 8.8%.¹⁵⁹ These numbers make patient selection central. Neosalpingostomy in mild-to-moderate distal disease is a meaningful restorative option. In severe, extensively damaged tubes, the clinical calculus shifts.

The restorative principle here is tube preservation over tube removal. Removing a hydrosalpinx and proceeding directly to IVF circumvents the tube entirely. It does not restore function; it bypasses the organ. Neosalpingostomy pursues the opposite goal: recreating a functional tube so the couple can conceive without external reproductive technology. Whether the tube is surgically worth repairing depends on the degree of fimbrial tissue remaining, the presence and density of adhesions, tubal wall thickness, and overall pelvic anatomy. These factors are assessed intraoperatively and cannot always be predicted from imaging alone.

Ectopic pregnancy risk is elevated after neosalpingostomy and varies with the extent of tubal damage. Early pregnancy monitoring with beta-hCG and ultrasound is standard following any tubal surgery. Recurrence of distal obstruction or hydrosalpinx formation over time is also possible, particularly in moderate-to-severe cases.

See also: hydrosalpinx, tubal-factor infertility, microsurgery, operative laparoscopy, fallopian tube anatomy.

Open full entry →

Laparoscopic Ovarian Wedge Resection (LOWR) is a surgical procedure in which a wedge-shaped section of androgen-producing ovarian cortex is removed laparoscopically to normalize hormonal balance and restore ovulation in select patients with PCOS. The procedure reduces ovarian androgen production, which in PCOS drives the cycle of elevated LH, follicular arrest, and anovulation. LOWR has been performed using microsurgical technique with the goal of restoring spontaneous ovulation while avoiding the ovarian hyperstimulation risk associated with pharmacologic ovulation induction. In NaProTECHNOLOGY practice, LOWR is considered a surgical option for patients whose ovulation fails to respond to medical management. Clinicians performing LOWR use careful hemostasis and adhesion prevention to preserve ovarian reserve and reduce post-surgical scarring risk.

Open full entry →

Hysteroscopic isthmocele repair is a minimally invasive surgical procedure that addresses a cesarean scar defect (isthmocele or niche) by resecting the thin residual myometrial layer at the defect's inferior edge from inside the uterine cavity, reducing the niche depth and improving drainage of retained menstrual blood. Surgeons perform the procedure with a resectoscope or operative hysteroscope, without abdominal incisions. It represents the less invasive of the two primary surgical approaches to isthmocele correction.¹⁵¹⁷

Patient selection governs which cases are appropriate for the hysteroscopic route. A residual myometrial thickness of at least 2.5 to 3 mm at the defect is generally required before hysteroscopic resection; thinner walls carry a risk of bladder injury or perforation during the procedure. The primary indication is symptomatic postmenstrual spotting or abnormal uterine bleeding attributable to blood pooling in the niche, rather than fertility concern alone. When the presenting complaint is primarily bleeding and the wall thickness is sufficient, the hysteroscopic approach can resolve symptoms with shorter recovery time than laparoscopic repair.³⁴⁴³

The limitation of the hysteroscopic approach is that it does not reconstruct the uterine wall. It shaves the defect rather than closing it. Residual myometrial thickness after the procedure may be no greater than before, and the structural integrity of the lower uterine segment for future pregnancy is not restored. For couples who desire subsequent pregnancy, particularly after a previous uterine rupture, uterine scar dehiscence, or when myometrial thickness is already marginal, laparoscopic repair with full-thickness reconstruction offers more complete correction.³⁴¹²⁸

See also: isthmocele, isthmocele repair (laparoscopic), operative hysteroscopy.

Open full entry →

Laparoscopic isthmocele repair is surgical correction of a cesarean scar defect via laparoscopic access, involving excision of the fibrotic niche tissue and multilayer reconstruction of the uterine muscular wall at the lower uterine segment. Unlike the hysteroscopic approach, laparoscopic repair directly restores wall thickness and structural integrity by closing the defect in anatomical layers. This distinguishes it as the preferred technique when fertility preservation is the clinical goal or when residual myometrial thickness is below safe thresholds for hysteroscopic resection.¹⁵¹⁶

The indication for laparoscopic over hysteroscopic repair turns primarily on two factors: residual myometrial thickness and reproductive intent. When myometrial thickness at the defect measures less than 3 mm, the uterine wall is too thin to safely proceed hysteroscopically without risk of perforation or bladder injury. Laparoscopic resection removes the fibrotic scar, freshens the margins, and closes the defect in layers under direct visualization. The result is a repaired uterine wall capable of bearing a subsequent pregnancy at the lower uterine segment, rather than a thinned niche where scar dehiscence or rupture risk remains elevated.³⁴⁴³

Surgeons employ combined laparoscopic-hysteroscopic approaches in complex cases, where the hysteroscope defines the defect margins from inside while the laparoscope performs the repair from outside. This dual-access technique improves precision in cases where the defect borders are irregular or where simultaneous evaluation of the uterine cavity is clinically useful.¹²⁸ The published evidence linking isthmocele to secondary infertility, implantation failure, and early pregnancy loss supports surgical correction in couples pursuing subsequent pregnancies where the defect is the identified contributing factor.

Recovery is longer than after hysteroscopic repair, and an interval before attempting pregnancy is generally recommended to allow sufficient healing of the reconstructed wall. The timing of conception attempts after repair is determined by the clinician based on operative findings, the extent of reconstruction, and individual healing indicators rather than by a fixed protocol.

See also: isthmocele, isthmocele repair (hysteroscopic), operative laparoscopy, operative hysteroscopy.

Open full entry →

Myomectomy is the surgical removal of uterine fibroids (leiomyomas) while preserving the uterus.¹⁸³ A restorative approach favors myomectomy over hysterectomy when fibroids are contributing to infertility, recurrent pregnancy loss, or abnormal uterine bleeding, because the goal is to restore normal uterine anatomy rather than remove the organ.

Three main approaches exist, selected based on fibroid location, size, and number. Hysteroscopic myomectomy addresses fibroids that have grown into the uterine cavity (submucosal type) and is performed through the cervix without abdominal incision. Laparoscopic myomectomy removes subserosal or intramural fibroids through small abdominal ports, allowing faster recovery than open surgery. Open myomectomy (laparotomy or mini-laparotomy) is used for large, numerous, or deeply intramural fibroids where laparoscopic access is limited.

Restoring the uterine cavity matters for fertility. Submucosal fibroids that distort the cavity are associated with implantation failure and early pregnancy loss. Removing them corrects the structural problem at its source. The restorative principle applies: restore function, then allow conception to proceed on its own terms.

Open full entry →

Microsurgery is a surgical technique that uses optical magnification, either through loupes or an operating microscope, paired with fine instruments and delicate suture materials to work on small or fragile anatomical structures.¹⁸⁴ In reproductive surgery, microsurgical principles include minimal tissue trauma, precise hemostasis, tension-free anastomosis, and meticulous layer-by-layer closure.

Microsurgery is fundamental to tubal ligation reversal, where reconnecting the two cut ends of the fallopian tube requires alignment at the millimeter scale. It is equally central to vasectomy reversal, where the vas deferens lumen may be less than one millimeter in diameter. Microsurgical technique also underlies the precision handling required in near adhesion-free reconstructive pelvic surgery, where gentle tissue management directly influences postoperative adhesion formation.

Outcomes following microsurgical tubal reanastomosis are well-documented. A 2023 systematic review and meta-analysis reported pregnancy rates following microsurgical tubal anastomosis comparable to those seen with other reconstructive approaches.¹⁸⁴ Earlier prospective series confirm the technique is durable.³²³³ The skill of the surgeon and the length of remaining tube after reversal are the two primary determinants of outcome.

Open full entry →

Mini-laparotomy is a small-incision open abdominal surgical approach, typically using a horizontal incision of 3 to 7 cm placed low on the abdomen, that provides direct access to pelvic structures when a laparoscopic approach is not suitable. It occupies a practical middle ground: more access than laparoscopy can offer in certain cases, substantially less morbidity than a full laparotomy.

Indications for mini-laparotomy in pelvic surgery include extensive adhesive disease that limits laparoscopic visualization, very large fibroids or ovarian masses, or anatomy distorted enough that working through ports creates unacceptable risk. It is often paired with the principles of near adhesion-free reconstructive pelvic surgery, because open access allows more thorough irrigation, more precise barrier placement, and better control of hemostasis in complex cases.

In tubal reversal and other reconstructive procedures, some surgeons prefer mini-laparotomy over laparoscopy because the magnification and hand control available at an open field supports the fine suture work that microsurgery demands. The choice between approaches depends on the individual patient's anatomy, prior surgical history, and the surgeon's training.

Open full entry →

PEARS (Pelvic Excision And Repair Surgery) is a form of plastic reconstructive surgery of the pelvis developed by Dr. Thomas Hilgers at the Pope Paul VI Institute.⁷⁸ The name reflects the procedure's dual mandate: complete excision of pelvic disease and systematic anatomic repair.

In PEARS, endometriosis is excised rather than ablated. This is not a technical preference. Ablation destroys the surface of a lesion; excision removes it entirely, including the base. Disease masked by destruction continues to progress. Disease removed is gone.²⁸

Excision is only half the procedure. The repair component applies a layered system of anti-adhesion measures: micro-monopolar or CO₂-laser technique, Prolene imbricating closure of the peritoneum and ovarian cortex with rough edges inverted internally, heparinized Ringer's lactate irrigation, and talc-free hydro-pack bowel isolation. The imbricating closure leaves only smooth, glistening serosa exposed to the peritoneal cavity. This matters because post-operative adhesions are a leading cause of secondary infertility after pelvic surgery.

PEARS applies across the full range of pelvic pathology: peritoneal endometriosis, ovarian endometriomas, polycystic ovaries, fibroids, fallopian tube disease, and adhesive disease.⁷⁸ The goal is not symptom relief. The goal is anatomic restoration of fertility.

Open full entry →

Near Adhesion-Free Reconstructive Pelvic Surgery (NARPS) is a surgical approach developed to systematically minimize the formation of new adhesions during and after complex pelvic surgery.⁸⁰ The central premise is that while postoperative adhesion formation cannot be eliminated entirely, it can be reduced substantially through deliberate, technique-level choices at every stage of the operation.

NARPS applies principles of magnification, sharp rather than blunt dissection, continuous peritoneal irrigation, careful hemostasis, and placement of anti-adhesion barriers at closure. Each element targets a known mechanism of adhesion formation: desiccation, ischemia, bleeding, and peritoneal trauma. No single step accounts for the outcome. The reduction comes from applying all of them consistently.

The 2010 outcomes paper documented three distinct phases of refinement over 23 years: Phase I (1987 to 1993, 26 patients), Phase II (1994 to 2005, 44 patients), and Phase III (2006 to 2009, 25 patients).⁸⁰

Postoperative adhesion scores declined progressively across the three phases, reflecting measurable improvement with each iteration of the technique. The data establish that a near-adhesion-free result is a documented clinical target, not a marketing claim.

NARPS is closely associated with pelvic excision and repair surgery. Where that entry describes the procedure applied to specific pathology, NARPS describes the set of technical principles governing how that procedure is performed. The two concepts work together: one names what is done, the other names how it is done to protect the tissue afterward.

Open full entry →

Key Conditions Addressed by RRM

Infertility is the failure to achieve a clinical pregnancy after 12 months of regular unprotected intercourse, or after 6 months for women aged 35 and older. The World Health Organization estimates infertility affects approximately 17.5% of adults globally, or roughly 1 in 6 people.¹¹² Primary infertility refers to couples who have never achieved pregnancy. Secondary infertility refers to those who have previously conceived but cannot again. See Secondary Infertility for the distinct clinical picture that condition presents.

In the RRM framework, infertility is not a diagnosis. It is a symptom. The 12-month threshold identifies couples who need a workup, not couples who have a condition called infertility. The condition causing the delay is what needs the name. Calling it unexplained infertility is not a diagnosis either. It is an admission that the workup has not yet found the answer. RRM treats that as an incomplete evaluation, not a settled one.

The causes are distributed across both partners. Male factor is solely responsible in approximately 20% of couples and contributes alongside female factors in another 30 to 40%. A couple-based workup evaluates both from the first appointment. See Male Factor Infertility and Semen Analysis.

On the female side, common identifiable contributors include endometriosis, PCOS, luteal phase deficiency, tubal factor, thyroid dysfunction, and hormonal abnormalities identified through cycle-timed diagnostics. RRM approaches each of these as a treatable root cause. The goal is diagnosis followed by correction, not bypass. A comprehensive evaluation in RRM maps the cause before any treatment begins.³⁵

Open full entry →

Recurrent Pregnancy Loss (RPL) is defined as two or more clinical pregnancy losses before 20 weeks of gestation. RPL is clinically distinct from isolated early pregnancy loss: a single loss is common and often attributable to sporadic chromosomal error, while recurrent loss warrants systematic evaluation for treatable maternal and paternal contributors. Assessment includes peripheral karyotype analysis of both partners, antiphospholipid antibody testing, uterine anatomical evaluation (SHG, HSG, or hysteroscopy), thyroid and prolactin screening, and evaluation for hereditary thrombophilias. RRM pursues identification of underlying conditions including hormonal (progesterone deficiency, thyroid dysfunction), anatomical (isthmocele, septum, fibroids), immunologic (APS, NK cell activity), and metabolic factors. RPL affects an estimated 2 to 5% of couples attempting pregnancy.³⁶³⁷

Open full entry →

Endometriosis is a chronic inflammatory condition in which tissue similar to the endometrium grows outside the uterine cavity, most commonly on the ovaries, fallopian tubes, pelvic peritoneum, and uterosacral ligaments. It affects approximately 1 in 10 women of reproductive age, and up to 50% of women presenting with infertility.²⁸ Despite this prevalence, the median time from symptom onset to diagnosis is 9 years,⁹⁸ a delay driven by normalized dismissal of pelvic pain and dysmenorrhea as routine. Endometriosis causes inflammation, adhesion formation, distorted pelvic anatomy, and impaired tubal and implantation function, all of which affect both the woman's health and a couple's fertility. RRM's standard surgical treatment is laparoscopic excision surgery, which demonstrates significantly greater improvement across symptom domains compared to ablation.²⁸ Hormonal suppression after surgery masks disease activity without treating the underlying condition: it does not stop disease progression. For complex pelvic disease, clinicians may employ PEARS, NARPS, or S-MAP techniques alongside adhesion prevention.

Open full entry →

An endometrioma is an ovarian cyst formed when endometriotic tissue implants on or within the ovary and fills with old menstrual blood, producing the characteristic dark-brown "chocolate cyst" appearance. Endometriomas are not benign bystanders. They destroy healthy follicular tissue, reduce ovarian reserve, and impair oocyte quality by creating an inflammatory, iron-rich environment within the ovary itself.¹¹⁵

Medical management does not resolve endometriomas. Suppressive medications shrink the cyst while treatment continues, but the lesion returns after discontinuation and ovarian damage accrues in the interim. Excision surgery is the standard endorsed in RRM: laparoscopic cystectomy with complete removal of the cyst wall. A 2024 Cochrane review confirms excision reduces recurrence rates compared to drainage and ablation.³⁸ A 2023 RCT found timing of excision within the cycle influences outcomes and tissue preservation.¹¹⁶

The ovarian reserve impact of surgery itself must be weighed. Cystectomy can reduce the follicular pool, particularly in bilateral or recurrent cases. This makes surgical decision-making in reproductive-age women consequential. In RRM practice, clinicians evaluate endometrioma management in the context of endometriosis stage, reserve markers, and fertility goals. Surveillance without timely treatment is not neutral: untreated endometriomas carry their own progressive damage to surrounding tissue. Every delay is a decision.

Open full entry →

PCOS (Polycystic Ovary Syndrome) is the most common endocrine disorder in reproductive-age women, affecting approximately 10-13% of this population worldwide.³⁹ Diagnosis requires two of three Rotterdam criteria: oligo- or anovulation, clinical or biochemical signs of hyperandrogenism (elevated androgens causing acne, hirsutism, or irregular cycles), and polycystic ovarian morphology on ultrasound.⁹⁴ Insulin resistance, present in the majority of affected women regardless of BMI, is a central pathophysiologic driver that sustains androgen overproduction, follicular arrest, and anovulation. In NaProTECHNOLOGY and RRM practice, PCOS is approached restoratively: lifestyle modification and dietary changes to address insulin resistance (a 5% reduction in body weight can restore ovulation in overweight patients), insulin sensitization with agents such as metformin or myo-inositol, cycle charting and ovulation monitoring, targeted hormonal support, and in refractory cases, laparoscopic ovarian wedge resection. Long-term hormonal suppression is not a restorative treatment for PCOS.

Open full entry →

PCOS phenotypes are the four distinct clinical subtypes of polycystic ovary syndrome (PCOS), defined by the 2003 Rotterdam consensus based on which combination of three diagnostic criteria a patient presents. The three criteria are hyperandrogenism (clinical or biochemical), ovulatory dysfunction, and polycystic ovarian morphology (PCOM) on ultrasound. A PCOS diagnosis requires any two of the three. That two-of-three requirement produces four possible combinations, each designated a phenotype.⁹⁴³⁹

Phenotype A carries all three features and represents the most pronounced metabolic and hormonal disruption, with the highest rates of insulin resistance and androgen excess. Phenotype B presents with hyperandrogenism and ovulatory dysfunction but lacks polycystic morphology; its metabolic risk profile closely mirrors Phenotype A. Phenotype C includes hyperandrogenism and polycystic morphology with ovulation preserved, producing a milder metabolic picture. Phenotype D presents with ovulatory dysfunction and polycystic morphology only, without hyperandrogenism, and carries the lowest metabolic risk of the four.³⁹

Phenotype identification matters because treatment response varies substantially across subtypes. Phenotypes A and B tend to require insulin sensitization and metabolic correction before ovulatory function stabilizes. Phenotype C may respond to targeted hormonal support without a full metabolic workup. Phenotype D often responds to ovulation support with less aggressive intervention. Treating every PCOS presentation identically, without phenotyping, is how patients cycle through years of management without meaningful resolution.⁹⁴

Open full entry →

Myo-inositol is a naturally occurring carbocyclic sugar that functions as a secondary messenger in insulin signaling and follicle-stimulating hormone (FSH) pathways within ovarian tissue. Its role in reproductive physiology centers on insulin sensitization: disrupted inositol metabolism is a recognized feature of the insulin resistance seen across PCOS phenotypes, particularly Phenotypes A and B, where hyperandrogenism and metabolic dysfunction overlap.⁴¹⁴²

In women with PCOS, myo-inositol supplementation has been studied for its effects on menstrual cycle regularity, hormonal parameters, and ovarian function. Evidence supports improvements in LH-to-FSH ratios, reductions in androgen levels, and restoration of more regular ovulation in anovulatory patients.⁴¹⁴²

Myo-inositol has also been studied in the context of ovarian stimulation protocols, where it appears to support oocyte quality and metabolic markers.⁴⁰ The available evidence base is strongest for metabolic and hormonal endpoints in PCOS; evidence for clinical pregnancy rate improvement is less consistent across studies, and no specific dose regimen is universally established.⁴²

Open full entry →

An isthmocele (also called a cesarean scar defect or uterine niche) is a myometrial deficiency at the anterior wall of the lower uterine segment, occurring at the site of a prior cesarean scar where the uterine wall failed to heal with full thickness. The defect creates a pouch where menstrual blood pools and drains slowly, producing the characteristic symptom of prolonged post-menstrual brown spotting. Blood retained in the niche creates a microenvironment hostile to sperm transit and may impair embryo implantation, contributing to secondary infertility and elevated early pregnancy loss risk in women with an inadequate residual myometrial wall.¹⁵¹⁶³⁴

Transvaginal ultrasound (TVUS) and saline infusion sonohysterography (SIS) are the preferred initial imaging tools. SIS allows direct measurement of defect dimensions and residual myometrial thickness (RMT), which is the critical variable driving repair decisions. Hysteroscopy provides direct intracavitary visualization and can be both diagnostic and operative in a single procedure.⁴³¹⁷¹⁸

Repair approach depends on defect severity, RMT, and the patient's fertility goals. Hysteroscopic repair addresses the defect from within the uterine cavity and is well suited for symptom control when the myometrial wall is adequate. Laparoscopic repair involves excision of the defect with multi-layer reconstruction of the uterine wall, and is the preferred approach when wall integrity is compromised or when future pregnancy is desired. Complex defects may require a combined approach using both techniques simultaneously.¹⁵³⁴

Open full entry →

Luteal Phase Deficiency (LPD) is a hormonal condition in which the corpus luteum produces insufficient progesterone, the luteal phase is too short, or the endometrium fails to respond adequately to progesterone, impairing implantation and early pregnancy support. The most common causes are impaired follicular development leading to an under-capable corpus luteum, hypothyroidism, hyperprolactinemia, and disrupted GnRH pulsatility. The NaPro post-Peak duration threshold for a short luteal phase is 8 days, not the older 11-day BBT-phase criterion from the Vollman/Jones era. These measured different endpoints with different methods.⁴⁴⁴⁵

In RRM practice, LPD is diagnosed from cycle-timed progesterone measurements anchored to the Peak Day. The Peak+3 progesterone level confirms ovulation and establishes early luteal function. A result of 2.3 ng/mL or above confirms ovulation has occurred. A result of 3.0 ng/mL or above indicates an absolute period of postovulation infertility has begun. Values below these thresholds warrant evaluation before further cycle-timed treatment.⁸¹ The Peak+3 through Peak+11 series provides the integrated hormonal picture. See Sonographic Ovulation Classification for ultrasound correlates used alongside progesterone values to characterize ovulation quality.

Hilgers identified five distinct LPD subtypes, each with a different mechanism and treatment target.⁷⁸ Type I combines a short post-Peak phase with low end-luteal progesterone. Type II shows normal duration but suboptimal integrated progesterone output. Type III is a late-drop pattern in which progesterone collapses 50% or more relative to peak luteal value before the phase ends. Type IV presents as an early-luteal deficit where progesterone fails to rise adequately from Peak+3. Type V is an isolated luteal estradiol deficit; see Cooperative Estrogen Replacement Therapy (CERT) and Cooperative Progesterone Replacement Therapy (CPRT) for the relevant hormonal support approaches. When the deficit originates specifically from inadequate corpus luteum output, see Corpus Luteum Deficiency (CLD). LPD is treatable. Accurate cycle charting combined with targeted hormonal evaluation identifies the subtype and directs the corrective approach.

Open full entry →

The Luteal Phase (LP) is the second half of the menstrual cycle, beginning at ovulation and ending at the onset of menstruation or, if conception occurs, continuing under the hormonal rescue of early pregnancy. It is defined clinically by the transformation of the ruptured follicle into the corpus luteum, which secretes progesterone and estradiol to prepare the endometrium for implantation. In a healthy cycle, the luteal phase typically spans 12 to 16 days.⁴⁴

Progesterone is the defining hormone of the luteal phase. It shifts the endometrium from proliferative to secretory, creates the biochemical environment necessary for embryo adhesion, and suppresses uterine contractility. A luteal phase that is too short or marked by inadequate progesterone output impairs all three of these functions. The result is either failure to conceive or early pregnancy loss before the couple knows a conception occurred.

In RRM practice, the luteal phase is evaluated using cycle-timed progesterone measurements drawn at specific points relative to Peak Day. A single random progesterone draw has limited diagnostic value; the parabolic shape of progesterone secretion across the phase means that timing relative to ovulation is everything. Multiple measurements in a single cycle, or serial evaluation across cycles, reveal patterns that a snapshot cannot.

Luteal phase evaluation is a core component of the root cause diagnosis in couples presenting with infertility or recurrent pregnancy loss. Shortened luteal phase, abnormal progesterone patterns, and deficient estradiol in the luteal phase are all treatable findings. Identifying them requires charting. Without it, clinicians are working from incomplete data.

Open full entry →

The corpus luteum (CL) is a temporary endocrine structure that forms from the ruptured follicle after ovulation and produces the progesterone required to prepare the endometrium for implantation. It also secretes estradiol in moderate amounts. Without an adequately functioning corpus luteum, the endometrial environment cannot support implantation, and early pregnancy cannot be sustained.⁴⁴

If fertilization occurs, hCG from the implanting trophoblast binds to CL receptors and rescues the structure from its programmed regression, sustaining progesterone production until the placenta assumes that function at approximately 8 to 10 weeks of gestation.¹²² If fertilization does not occur, the CL degenerates over 10 to 14 days, progesterone falls, and menstruation follows. The length and hormonal output of the luteal phase directly reflect corpus luteum function.

Inadequate CL function is the mechanism underlying Corpus Luteum Deficiency (CLD), a distinct subtype of luteal phase deficiency. In RRM, CL function is assessed through cycle-timed progesterone measurements in the post-peak phase. A structurally normal cycle chart with a short or inadequately supported post-peak phase is a clinical signal. The corpus luteum is not a passive structure: it reflects upstream follicular development, the hormonal environment of the cycle, and the adequacy of the LH surge. Treating CL deficiency without investigating those upstream contributors addresses the signal but not the source.

Open full entry →

Luteinized Unruptured Follicle (LUF) syndrome is a condition in which the dominant follicle undergoes luteinization, signaling progesterone production, without physically rupturing to release the oocyte. Ovulation appears to have occurred by hormonal parameters, and menstrual cycles typically proceed at normal intervals, yet fertilization cannot take place because the egg was never released. LUF syndrome is a clinically underappreciated contributor to infertility that goes undetected without serial ultrasound monitoring across the cycle.³

Diagnosis requires sonographic confirmation. Serial follicle tracking documents the growth of the dominant follicle to expected mature size, followed by signs of luteinization such as increased echogenicity and structural change within the follicle wall, without the collapse and fluid release that accompanies true rupture. The follicle persists where an empty, collapsed structure would normally follow ovulation.³

LUF syndrome may occur intermittently, not in every cycle, which adds to its diagnostic complexity. A single cycle of monitoring that captures a normal ovulation does not exclude it. Because LUF cycles produce progesterone, luteal-phase charting alone cannot distinguish them from ovulatory cycles without ultrasound. Identifying LUF syndrome converts a clinically "unexplained" infertility presentation into a diagnosable, addressable finding.

Open full entry →

Anovulatory cycles are menstrual cycles in which the ovaries do not release an egg, though bleeding may still occur and be mistaken for a normal period. Anovulation is one of the most common causes of female infertility, accounting for roughly 30% of cases. The absence of ovulation means the corpus luteum never forms, progesterone is not produced, and the luteal phase does not occur.¹¹⁷

Common causes include polycystic ovary syndrome (PCOS), hyperprolactinemia, hypothyroidism, hypothalamic dysfunction (from excessive exercise or very low body weight), and perimenopause. Each cause has distinct hormonal fingerprints, and distinguishing them matters. Treating PCOS-driven anovulation is not the same as treating prolactin-driven anovulation. The cause determines the protocol.

In RRM, anovulation is identified through cycle charting (absence of a post-peak phase on the CrMS chart), serial follicular ultrasound, and targeted hormonal panels timed to the cycle. Charting data reveals the pattern cycle by cycle. Without it, clinicians are working without the most basic diagnostic information. Ovulation is a sign of health.¹¹⁸ When it is absent, RRM clinicians investigate the reason rather than bypass the system.

Open full entry →

A shortened luteal phase is a post-ovulatory phase lasting fewer than 11 days, measured from the day of confirmed ovulation (Peak Day) through the onset of the next menstruation. The luteal phase exists to sustain the hormonal environment needed for implantation: the corpus luteum produces progesterone, and a curtailed phase compresses the window available for endometrial preparation and embryo attachment. Shortened luteal phase is one differential within the broader evaluation of luteal phase deficiency.⁴⁴⁴⁵

A number of underlying mechanisms can produce a shortened luteal phase. Inadequate corpus luteum function, premature luteolysis, and disruptions in LH pulsatility following ovulation are among the recognized contributors. Luteal phase duration can also vary cycle to cycle in the same individual, so a single short cycle does not establish the pattern; consistent measurement across multiple cycles is needed to characterize it as a recurring finding.¹¹¹⁴⁴

The clinical significance depends on the degree of shortening and whether hormonal adequacy across the post-Peak phase accompanies the abbreviated duration. Shortened phase length and insufficient progesterone production often co-occur but are evaluated independently. Cycle charting combined with serial hormone measurement across the post-Peak phase provides the clinical picture needed for an accurate differential.⁴⁵¹¹¹

Open full entry →

Tubal factor infertility is infertility caused by structural or functional damage to the fallopian tubes, including proximal or distal occlusion, peri-tubal adhesions, post-infectious scarring, and tube-damaging sequelae of prior surgery.⁴⁷ It accounts for a substantial proportion of female-factor diagnoses and is frequently under-investigated when couples are routed toward assisted reproduction before anatomy has been fully evaluated.

The fallopian tube is not a passive conduit. Ciliated epithelium drives ovum transport, the ampullary segment is the site of fertilization, and intratubal pressure dynamics matter for normal gamete transit.⁸⁴ Pathology at any segment disrupts a specific physiologic process. Identifying which segment is affected, by what mechanism, and to what degree guides surgical planning.

Restorative surgical options exist for most anatomic patterns of tubal disease. Proximal occlusion may respond to fallopian tube recanalization or selective salpingography. Mid-segment damage from prior sterilization is addressable by microsurgical tubal anastomosis.^3233184 Distal disease and fimbrial damage may be corrected by neosalpingostomy when the underlying tube retains adequate architecture.¹⁵⁹ A hysterosalpingogram (HSG) combined with intratubal pressure measurement gives clinicians a more complete picture of tubal function than imaging alone.⁸⁴

A diagnosis of tubal factor is not a default referral to bypass. The restorative question is always: can the structure be repaired, and can function be restored? Couples benefit from a complete tubal anatomy evaluation before any irreversible decision is made.

Open full entry →

Hydrosalpinx is a distally occluded, fluid-filled fallopian tube resulting from prior infection, endometriosis, or adhesive disease that seals the fimbrial end.⁴⁷ The accumulated serosal fluid is not inert: it is biochemically hostile to embryo implantation, and its retrograde flow into the uterine cavity disrupts the endometrial environment.

The implantation-impairing effect of hydrosalpinx fluid is well-documented in the reproductive medicine literature. When a hydrosalpinx is present, clinicians evaluating fertility cannot treat only the uterus or ovaries in isolation. The tube is a clinically active variable.

The restorative surgical option is neosalpingostomy: opening and reconstructing the occluded fimbrial end when the underlying tube retains sufficient mucosal integrity and wall architecture to support function.¹⁵⁹ When the tube is too damaged for reconstruction, selective salpingectomy removes the source of fluid while preserving the opposite tube and the uterine cavity. Surgical decision-making depends on tube quality, not a default protocol.

Open full entry →

The fallopian tube is a paired muscular and ciliated structure, roughly 10 to 12 centimeters in length, connecting each ovary to the uterine cavity and serving as the site of fertilization and early embryo transport.⁴⁶⁴⁷ Its function depends on intact mucosal cilia, coordinated muscular contractions, and normal secretory activity across all four anatomic segments.

Each segment has a distinct clinical role. The interstitial segment passes through the uterine wall and is the narrowest portion, relevant in proximal occlusion. The isthmic segment is narrow, approximately 3 centimeters, and is the preferred anastomosis site after mid-segment sterilization because of its favorable tissue characteristics. The ampullary segment is the widest and longest portion and the primary site of fertilization; it is also the most common location for ectopic pregnancy. The infundibulum and fimbriae form the open distal end, capturing the released ovum at ovulation; fimbrial damage is the primary cause of hydrosalpinx.⁴⁷

Ciliated epithelium throughout the tube actively drives ovum transport toward the uterus. Loss of ciliation from infection, inflammatory disease, or endometriosis impairs transport even when the tube appears patent on imaging. Patency and function are not the same finding.

Open full entry →

Pelvic adhesions are bands of fibrous scar tissue that form between pelvic structures following inflammation, infection, endometriosis, or prior surgery, tethering organs that should move freely relative to one another. They distort anatomy, restrict tubal and ovarian mobility, impair sperm and ovum transport, and generate chronic pain through mechanical traction on innervated tissue.

Adhesions are a common finding in reproductive-age women with a history of endometriosis, pelvic infection, or prior abdominal surgery. They are frequently present in women labeled as having unexplained infertility, because adhesive disease is invisible on ultrasound and HSG and only becomes apparent at laparoscopy.

The surgical approach is adhesiolysis: precise division and removal of adhesive bands under magnification, combined with placement of anti-adhesion barriers to reduce reformation.⁸⁰ The goal is to restore normal tissue relationships and mobility, not simply to separate structures. Techniques developed within near-adhesion-free pelvic surgery protocols prioritize minimizing peritoneal trauma at every step of the procedure to reduce the adhesion burden that surgery itself can generate.⁸⁰

Open full entry →

Adenomyosis is a condition in which endometrial-like glands and stroma are present within the myometrium (uterine muscle wall), causing the uterus to enlarge and the junctional zone to thicken. The condition causes heavy periods, dysmenorrhea, dyspareunia, intermenstrual bleeding, and impaired fertility. It can also be asymptomatic and discovered incidentally.⁴⁸⁴⁹

Fertility impact is significant. A meta-analysis found women with adenomyosis had a 28% lower probability of clinical pregnancy and more than twice the odds of miscarriage (OR 2.17) compared to women without the condition.⁴⁸

In RRM practice, clinicians evaluate adenomyosis as a contributor to luteal phase deficiency, heavy bleeding patterns, and recurrent pregnancy loss. Hormonal support targeting progesterone deficiency addresses the endometrial environment. For focal adenomyomas, surgical resection is considered when hormonal measures are insufficient. Suppressive medications mask symptoms without addressing disease progression. The RRM approach targets the underlying pathophysiology.

Open full entry →

Uterine fibroids, or leiomyomas, are benign smooth-muscle tumors of the uterus that are classified by their anatomic location, which directly determines their fertility impact.¹⁸³ They are among the most common findings in reproductive-age women and range from clinically insignificant to a primary driver of implantation failure and pregnancy loss depending on their size, number, and relationship to the uterine cavity.

Location is the critical variable. Submucosal fibroids project into the uterine cavity and carry the highest fertility burden: they alter endometrial blood flow, distort the implantation surface, and impair embryo retention.¹⁸³ Intramural fibroids occupy the muscular wall and affect fertility when they are large enough to distort the cavity or compress the interstitial tubal segment. Subserosal fibroids project outward from the uterine surface and have the least direct impact on implantation, though large subserosal masses can impair tubal mobility or contribute to pelvic pain.

Fertility-preserving surgical removal, myomectomy, is the standard restorative intervention when fibroids are contributing to reproductive dysfunction. Route depends on location: submucosal fibroids accessible to the cavity are addressed via operative hysteroscopy; intramural or subserosal fibroids require operative laparoscopy or mini-laparotomy based on size and depth. The goal is to restore normal uterine architecture before attributing infertility or pregnancy loss to other causes.

Open full entry →

A uterine septum is a fibromuscular band of tissue that partially or completely divides the uterine cavity, arising from incomplete resorption of the Mullerian ducts during fetal development. It is the most common congenital uterine anomaly. A septum does not alter the external uterine contour, distinguishing it from a bicornuate uterus.

Poor vascular supply in the septum tissue impairs embryo implantation and placentation. Recurrent pregnancy loss is the most common clinical presentation. Some women also experience preterm labor or abnormal fetal position in later pregnancy.

Saline infusion sonohysterography and 3D transvaginal ultrasound are standard first-line imaging. Operative hysteroscopy provides definitive characterization and correction in the same procedure. The diagnostic goal is to confirm a septum rather than a different Mullerian anomaly before planning repair.

Hysteroscopic metroplasty resects the septum and restores a unified uterine cavity. The procedure is minimally invasive and preserves the myometrium. Studies document improved pregnancy continuation rates following resection in women with prior pregnancy loss.¹⁹⁴¹⁷ Couples with confirmed septum and recurrent loss should be evaluated for repair before a next conception attempt.

A uterine septum is a structural, correctable cause of pregnancy loss. It is not an unexplained one. Evaluation for co-existing conditions is appropriate: intrauterine adhesions can develop after any uterine instrumentation, and submucosal fibroids may coexist and compound cavity distortion.

Open full entry →

Intrauterine adhesions (Asherman's syndrome) are bands of scar tissue that form inside the uterine cavity, binding the walls together and disrupting the endometrial lining. They develop after uterine trauma: most commonly a dilation and curettage (D&C), uterine surgery, or severe intrauterine infection. Severity ranges from thin, filmy adhesions across a small segment of the cavity to dense fibrotic obliteration of most or all of it.¹⁷¹⁸

The most common symptoms are amenorrhea or markedly reduced menstrual flow following a uterine procedure, cyclic pelvic pain without outward menstrual flow, and infertility or recurrent pregnancy loss. Some women have no symptoms at all despite clinically significant adhesions.

Hysteroscopy is the gold standard for diagnosis and staging. Saline infusion sonohysterography and HSG can suggest adhesions but cannot grade them precisely. Diagnostic hysteroscopy reveals the extent, location, and density of adhesions under direct visualization.

Operative hysteroscopy with adhesiolysis is the restorative treatment. The surgeon divides and removes the adhesions under direct vision, re-establishing cavity architecture. Post-surgical hormonal support to promote endometrial regrowth and follow-up office hysteroscopy are standard components of the restorative approach.⁵¹

Asherman's syndrome is a correctable structural cause of infertility and pregnancy loss. Recurrent pregnancy loss evaluation should include uterine cavity assessment, particularly in women with prior uterine procedures. Related structural conditions, including uterine septum and isthmocele, may coexist and warrant evaluation in the same workup.

Open full entry →

Chronic Endometritis (CE) is a persistent, low-grade inflammatory condition of the endometrial lining caused by abnormal bacterial colonization (e.g., Enterococcus, E. coli, Streptococcus). CE is often subclinical with no obvious symptoms. It significantly impairs endometrial receptivity and is strongly associated with recurrent implantation failure and recurrent pregnancy loss. Diagnosis requires office hysteroscopy (strawberry-pattern micropolypoid endometrium) confirmed by CD138 immunohistochemistry on endometrial biopsy. Treatment uses targeted antibiotics (typically doxycycline, amoxicillin, or based on culture). A cohort study found the biopsy and treatment group had significantly higher rates of pregnancy (HR 2.28) and live birth (HR 2.76) compared to hysteroscopy-only controls.⁵¹²⁶

Open full entry →

Antiphospholipid Syndrome (APS) is an acquired autoimmune disorder in which the immune system produces antibodies against phospholipid-binding proteins, creating a hypercoagulable state that damages placental blood flow and causes thrombotic events. The three characteristic antibodies are lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies.⁵²

Diagnosis requires both a clinical event and laboratory confirmation. The clinical criteria are vascular thrombosis or a recognized pattern of pregnancy morbidity: three or more early pregnancy losses, one or more unexplained losses after ten weeks, or one or more preterm births before thirty-four weeks from placental insufficiency. Laboratory criteria require at least one characteristic antibody confirmed on two separate occasions twelve or more weeks apart. A single positive test is not sufficient for diagnosis.³⁷

In pregnancy, APS-driven clotting in the placental vasculature disrupts nutrient and oxygen delivery to the developing embryo. This mechanism underlies APS-associated recurrent pregnancy loss, fetal growth restriction, and late pregnancy loss. APS is one of the most clearly defined and treatable immune causes of recurrent pregnancy loss.

Anticoagulation during pregnancy reduces thrombotic injury to the placental vasculature. Major reproductive medicine guidelines support anticoagulant therapy for obstetric APS.⁵² The specific approach is individualized based on clinical history, antibody profile, and the evaluation of the treating clinician.

Women with APS who have experienced pregnancy loss are not experiencing unexplained loss. They have a diagnosable, treatable condition. RRM clinicians evaluate for APS as part of a thorough recurrent pregnancy loss workup. Related conditions include autoimmune and thrombophilic disorders, inherited thrombophilias, and natural killer cell dysregulation.

Open full entry →

Autoimmune and thrombophilic disorders are a category of conditions, acquired and inherited, that elevate clotting risk or disrupt immune tolerance in ways that impair implantation, placentation, and early pregnancy maintenance. They are among the identifiable, treatable causes of recurrent pregnancy loss that thorough evaluation can uncover. The category spans two overlapping groups: autoimmune conditions such as antiphospholipid syndrome and autoimmune thyroid disease, and inherited thrombophilias such as Factor V Leiden, the prothrombin G20210A mutation, and protein C or S deficiency.³⁷⁷⁵

Inherited thrombophilias alter coagulation factor activity, increasing the likelihood of clot formation in small vessels including the placental vasculature. Not all carriers experience adverse pregnancy outcomes. Clinical severity depends on mutation type, zygosity, and the presence of other risk factors. Evaluation through targeted testing can identify these conditions before a subsequent pregnancy attempt.⁷⁵

On the autoimmune side, antiphospholipid syndrome is the most thoroughly characterized immune cause of pregnancy loss. Thyroid autoimmunity contributes as well: antithyroid antibodies are associated with elevated miscarriage rates even when thyroid hormone levels remain within normal reference ranges.³⁷ The role of natural killer cell activity at the implantation site is an area of ongoing clinical investigation.

Identifying which specific condition or combination is present determines the management direction. Anticoagulation support, immune modulation, and thyroid optimization address distinct mechanisms. They are not interchangeable. Treatment follows diagnosis, not loss count.⁵²

These conditions are diagnosable. Women with recurrent pregnancy loss who carry these conditions are not experiencing unexplained loss. RRM approaches recurrent pregnancy loss as a diagnostic problem rather than a diagnosis of exclusion. Related entries: thrombophilia, methylated folate and MTHFR.

Open full entry →

Methylated folate (L-methylfolate, or 5-methyltetrahydrofolate) is the biologically active form of folate that cells use directly, without enzymatic conversion. Most prenatal vitamins and fortified foods supply synthetic folic acid, which requires a functional MTHFR enzyme to convert it into usable form. Carriers of common MTHFR gene variants, C677T and A1298C, have reduced MTHFR enzyme activity and convert folic acid less efficiently than those without the variants.

When MTHFR activity is reduced, folate-dependent methylation reactions run less efficiently. One consequence is elevated homocysteine, a byproduct that rises when the remethylation cycle is impaired. Elevated homocysteine carries both thrombophilic properties and potential embryotoxic effects. This links MTHFR variants to recurrent pregnancy loss and to the broader category of autoimmune and thrombophilic disorders evaluated in RPL workups.¹⁹⁵

L-methylfolate bypasses the MTHFR conversion step. Because it is already in the active form, cells can use it regardless of enzyme efficiency. For women with MTHFR variants who may not adequately convert standard folic acid, L-methylfolate supplementation addresses the metabolic gap more directly. The preconception period and early pregnancy are when folate-dependent processes, including DNA synthesis and neural tube development, are most active.

MTHFR variants are common across the general population, far more so than rare thrombophilias like Factor V Leiden. Most carriers have never been tested. The clinical question is whether an individual's folate metabolism is adequate, not simply whether a variant is present. Homocysteine measurement adds useful context alongside genotyping. Related: thrombophilia, antiphospholipid syndrome.

Open full entry →

A varicocele is an abnormal dilation of the pampiniform plexus veins within the scrotum, present in approximately 15% of men in the general population and in 35% or more of men evaluated for infertility.⁵³ The enlarged veins impair the countercurrent heat-exchange mechanism that keeps the testis cooler than core body temperature. This thermal dysregulation suppresses spermatogenesis and amplifies oxidative stress, damaging sperm DNA and reducing both sperm concentration and motility.³⁵

Varicocele is one of the most surgically correctable causes of male factor infertility. Repair results in measurable improvement in semen parameters in the majority of men, and sperm DNA fragmentation decreases significantly following correction of testicular venous outflow.^53545556 Microsurgical subinguinal varicocelectomy carries the highest success rates and the lowest rates of hydrocele formation and recurrence among available techniques.

Varicocele is also associated with OAT syndrome and is a contributing factor in a meaningful proportion of couples presenting with infertility. Restorative andrology evaluates the male partner for varicocele as part of the couple-based workup rather than bypassing the diagnosis with sperm extraction. and oxidative stress.

Open full entry →

Male factor infertility refers to any condition arising from the male partner that reduces a couple's ability to conceive, including abnormalities of sperm count, motility, morphology, sperm DNA integrity, hormone levels, or reproductive anatomy. Male factor is the sole cause in approximately 20% of infertile couples and contributes alongside female factors in a further 20 to 45%.¹²⁵ Evaluating the male partner is not optional in RRM; it is a prerequisite.

Semen analysis is the starting point, but it is not sufficient alone. In a multicenter study of 1,014 couples who refused ART and pursued natural conception, only 13% of men in the isolated male factor subgroup had normal semen parameters by WHO criteria.¹²⁵ Standard semen analysis missed the diagnosis in the majority of cases. The comprehensive andrological evaluation identified treatable conditions in most: male genital tract infection in 43%, genital tract inflammation in 49%, and hypospermatogenesis in 17%. After targeted etiologic treatment, 32.5% of couples in the isolated male factor group achieved natural conception.¹²⁵

RRM evaluates male factor through semen analysis, sperm DNA fragmentation testing, hormonal assessment, and scrotal imaging. When azoospermia is present, the clinical pathway branches based on whether the obstruction is obstructive or secretory: obstructive azoospermia may be surgically correctable, while secretory causes require genetic evaluation before determining whether natural conception is possible. Restorative andrology targets the underlying cause: infection, inflammation, hormonal deficiency, varicocele, or oxidative stress.³⁵

The infertility evaluation is couple-based from the first appointment. Treating female factors without evaluating the male partner is clinically incomplete. RRM clinicians assess both partners simultaneously.

Open full entry →

OAT syndrome (oligoasthenoteratospermia) is a combined sperm parameter deficit defined by three simultaneous abnormalities: low sperm concentration (oligospermia), reduced progressive motility (asthenospermia), and abnormal morphology (teratospermia). Each parameter is measured against WHO 2021 reference values: concentration below 16 million per milliliter, progressive motility below 30%, and normal morphology below 4% by Kruger strict criteria.¹⁷¹ When all three fall below threshold together, the combined deficiency is termed OAT syndrome.

The triad is not a disease in itself; it is a signal that underlying pathology is impairing spermatogenesis. Common drivers include varicocele, oxidative stress, hormonal insufficiency, genital tract infection, and genetic factors. Identifying the cause determines whether restoration is feasible. OAT syndrome that goes unexplored leaves correctable conditions untreated and couples without a meaningful path forward.

In the restorative approach to male factor infertility, OAT syndrome prompts a systematic evaluation of both partners rather than a direct referral for ICSI. Treating the underlying cause can improve parameters enough for natural conception. and restorative andrology.

Open full entry →

Azoospermia is the complete absence of sperm in the ejaculate, confirmed on at least two separate semen analyses after centrifugation.¹⁹³ It affects approximately 1% of men in the general population and up to 15% of men evaluated for infertility. The condition is classified into two mechanistically distinct categories: obstructive azoospermia (OAZ) and non-obstructive azoospermia (NOA).

In obstructive azoospermia, sperm production is intact but outflow is blocked. Common causes include prior vasectomy, congenital bilateral absence of the vas deferens (CBAVD), epididymal obstruction, and ejaculatory duct obstruction. For men with post-vasectomy OAZ, microsurgical vasectomy reversal is the restorative option. It restores the anatomical pathway rather than extracting sperm for laboratory use. In non-obstructive azoospermia, impaired spermatogenesis is the underlying problem. Causes include testicular failure, chromosomal abnormalities, hormonal insufficiency, and, in some cases, correctable factors such as varicocele. Varicocele repair has improved spermatogenesis in select NOA patients, which is a restorative option worth evaluating before pursuing extraction.⁵³

Surgical sperm retrieval (TESE or microTESE) can locate focal sperm production in some NOA cases, but the harvested sperm are used in ICSI. That is a bypass pathway, not a restorative one. Clinicians evaluating azoospermia within a restorative framework prioritize identifying correctable causes first. Both partners are assessed in parallel, since female factor evaluation shapes the urgency and direction of the male workup. and restorative andrology.

Open full entry →

Oxidative stress is a cellular imbalance in which reactive oxygen species (ROS) production exceeds the body's antioxidant defenses, causing damage to lipids, proteins, and DNA.³⁵ At physiological concentrations, ROS participate normally in folliculogenesis, oocyte maturation, sperm capacitation, and early embryo development. When that balance tips toward excess, the same molecules become destructive.

In male reproductive biology, pathological ROS levels damage sperm membrane lipids, reduce motility, and fragment sperm DNA. Varicocele is a primary driver of this excess through thermal dysregulation and impaired venous drainage.³⁵⁵⁷ In female reproductive biology, oxidative stress is implicated in the peritoneal environment of endometriosis, contributing to impaired follicle development and reduced sperm DNA integrity after fertilization.⁵⁸

The restorative orientation treats the source of excess ROS rather than compensating for its effects in the laboratory. Correcting varicocele, resolving active pelvic inflammatory disease, and addressing modifiable lifestyle factors all reduce oxidative burden through the underlying mechanism. Measuring and addressing oxidative stress in both partners is a component of the couple-based evaluation. and antioxidant therapy.

Open full entry →

Sperm DNA fragmentation (extended) refers to the assay methods used to measure strand breaks and chromatin damage in sperm DNA beyond what standard semen parameters detect. The principal platforms are SCSA (Sperm Chromatin Structure Assay), TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling), COMET assay, and sperm chromatin dispersion (SCD). Each measures DNA damage through a different mechanism, and each carries a distinct sensitivity profile.¹⁹²¹ The clinical concern threshold varies by assay; no single universal cutoff applies across platforms.

Elevated DNA fragmentation index (DFI) is independently associated with reduced natural conception rates, lower pregnancy rates following intrauterine insemination, increased miscarriage risk, and impaired embryo development.¹⁹²⁰ A standard semen analysis can appear normal while DFI is significantly elevated. The two assessments measure different aspects of sperm quality.

Elevated DFI typically has a cause. Oxidative stress is the most common driver, often traceable to varicocele, genital tract infection, or modifiable lifestyle factors.²¹²² Correcting the source reduces fragmentation. That is the restorative orientation: identify what is damaging the DNA, not simply extract sperm that bypasses it.

DFI testing is a component of the male evaluation in couple-based infertility workups where standard semen parameters are insufficient to explain poor outcomes. and oxidative stress.

Open full entry →

Hormonal abnormalities are disruptions in the reproductive endocrine system that impair follicle development, ovulation, luteal function, or early pregnancy support. The hormones most frequently evaluated in reproductive medicine include FSH, LH, estradiol, progesterone, prolactin, TSH, and AMH. Each operates within a tightly regulated feedback network. A disorder in one axis typically propagates through others, which is why isolated single-hormone testing outside cycle context misses the clinical picture.⁸⁹

The FSH and LH axis governs follicular recruitment and the ovulatory trigger. Chronically elevated FSH signals diminished ovarian reserve; tonically elevated LH is a hallmark of PCOS. Estradiol and progesterone govern the proliferative and secretory phases of the endometrial cycle respectively. When progesterone production is insufficient in the luteal phase, implantation is compromised even when ovulation occurred. This is the clinical picture of luteal phase deficiency.

Two additional axes deserve direct attention. TSH outside the optimal range for conception, even within standard laboratory normal limits, is associated with reduced fertility and increased miscarriage risk.⁶⁸ Elevated prolactin disrupts the hypothalamic-pituitary axis, suppresses LH and FSH pulsatility, and can prevent ovulation entirely; this is hyperprolactinemia.¹¹⁹ AMH reflects the pool of recruitable follicles; low AMH indicates diminished ovarian reserve and may signal diminished ovarian reserve (DOR) or, in severe reduction before age 40, premature ovarian insufficiency (POI).⁷⁷

RRM clinicians characterize hormonal abnormalities as signs of an underlying condition rather than endpoints in themselves. The question is not simply whether a value is out of range, but why. Identifying root causes, whether hypothyroidism, hyperprolactinemia, ovulatory dysfunction, or metabolic disruption, allows directed evaluation and targeted support rather than bypass of the failing system.

Open full entry →

Hypothyroidism is a condition of insufficient thyroid hormone production, most commonly caused by autoimmune Hashimoto's thyroiditis in iodine-sufficient regions. It is diagnosed by elevated TSH with low or normal free T4. Subclinical hypothyroidism is a milder form: TSH is elevated while free T4 remains within normal range. Both conditions affect reproductive function. Subclinical hypothyroidism is associated with ovulatory dysfunction, impaired implantation, and increased miscarriage risk even when symptoms are absent.¹¹³

Thyroid autoantibodies compound the risk independently of TSH. A meta-analysis found that euthyroid women with thyroid peroxidase antibodies (TPO-Ab) had significantly higher rates of miscarriage and preterm birth compared to antibody-negative women.¹¹⁴ This matters clinically: a woman with normal TSH but elevated TPO-Ab is not in the clear. Antibody status is part of a complete TSH screening picture.

RRM screens thyroid function and antibody status in all infertility and recurrent pregnancy loss evaluations. The clinical threshold for intervention is typically set lower than conventional population norms, because the evidence supports more aggressive optimization in women attempting conception. A Cochrane review of thyroxine replacement in subfertile women with subclinical hypothyroidism or autoimmune thyroid disease found mixed results across trials, underscoring that treatment decisions require individual clinical judgment rather than a blanket protocol.¹⁰²

Untreated hypothyroidism also affects the luteal phase. Thyroid hormone is necessary for normal progesterone production and corpus luteum function. Women presenting with luteal phase deficiency or recurrent early pregnancy loss warrant thyroid evaluation before any hormonal support protocol is initiated. Treating the thyroid first, when indicated, corrects the upstream deficiency rather than compensating for it downstream.

Open full entry →

Hyperprolactinemia is an elevated serum prolactin level that suppresses pulsatile GnRH secretion, reducing LH and FSH and disrupting ovulation. The result is anovulatory cycles, shortened or absent luteal phases, and impaired fertility. Galactorrhea (spontaneous nipple discharge) may accompany elevated prolactin but is not always present.¹¹⁹

Common causes include pituitary microadenoma (prolactinoma), hypothyroidism, and certain medications (antipsychotics, metoclopramide, some antihypertensives). Physiologic causes include pregnancy and breastfeeding. Identifying the cause matters: hypothyroidism-driven hyperprolactinemia resolves with thyroid treatment. Medication-induced elevation resolves when the offending drug is discontinued. Prolactinoma is treated with dopamine agonists under appropriate clinical supervision.³

In RRM, hyperprolactinemia is screened in all infertility evaluations. Elevated prolactin is not dismissed as a minor finding. It is a documented cause of luteal phase deficiency and infertility that responds to targeted treatment. The RRM approach identifies the underlying cause and addresses it directly rather than bypassing the disrupted hormonal axis.¹¹⁹

Open full entry →

Premature Ovarian Insufficiency (POI) is the loss of normal ovarian function before age 40, characterized by amenorrhea, elevated FSH, and reduced estrogen production. The diagnosis requires two FSH measurements above 25 IU/L taken at least four weeks apart in the context of menstrual irregularity or absence before age 40.⁷³ POI is distinct from diminished ovarian reserve (DOR), where reserve is reduced but follicular activity continues, and from natural menopause, which occurs in the fifth decade.

POI affects approximately 1% of women under 40. Known causes include autoimmune conditions, chromosomal variants (notably fragile X premutation), and iatrogenic damage from chemotherapy or radiation. In the majority of cases the cause remains unidentified. AMH testing can detect declining ovarian reserve earlier than FSH elevation and may help predict progression toward POI, though AMH values carry significant individual variability.¹²⁰ Intermittent ovarian activity occurs in a meaningful proportion of women with established POI, which is why the contemporary term "insufficiency" replaced the older "failure."

The primary health priorities in POI are estrogen replacement to protect bone density and cardiovascular health, and evaluation of thyroid and adrenal autoimmunity, which co-occur more frequently in this population.⁷³ Because POI touches every dimension of the hormonal axis, full evaluation avoids the error of treating FSH elevation in isolation. Where spontaneous conception is possible due to residual follicular activity, identifying and supporting that window is clinically meaningful within an ovarian reserve framework.

Open full entry →

Diminished Ovarian Reserve (DOR) is a reduction in the quantity and, often, the quality of the remaining egg supply in the ovaries relative to what is expected for a woman's age. DOR is most commonly age-related, but it can occur prematurely due to prior ovarian surgery, autoimmune conditions, endometrioma, genetic factors, or prior gonadotoxic treatment. It does not make pregnancy impossible. It makes it more urgent to act, and more important to understand why reserve is low.¹²⁰

DOR is assessed through three markers used together, not in isolation: serum anti-Müllerian hormone (AMH), antral follicle count (AFC) on ultrasound, and cycle day 3 FSH. No single marker is definitive. A 2017 JAMA study found that AMH and AFC did not predict natural conception rates in older reproductive-age women as precisely as commonly assumed, underscoring the importance of individualized evaluation over thresholds alone.¹⁰¹

In RRM, a DOR diagnosis prompts investigation, not resignation. Clinicians evaluate for treatable contributors: autoimmune activity, endometrioma, thyroid dysfunction, oxidative burden, and nutritional deficiencies. Where modifiable factors exist, they are addressed. See Ovarian Reserve for interpretation of reserve markers in clinical context and DHEA supplementation for one studied supportive strategy in DOR.³

Open full entry →

Insulin resistance is a state in which cells fail to respond normally to insulin, requiring progressively higher circulating insulin levels to achieve normal glucose uptake. In reproductive medicine, insulin resistance is most clinically significant in PCOS, where it is present in an estimated 50 to 70% of affected individuals regardless of body weight.³⁹ The mechanism linking insulin resistance to ovulatory dysfunction is direct: hyperinsulinemia stimulates ovarian theca cells to overproduce androgens, which disrupts follicle maturation and suppresses ovulation.

This pathway explains a significant portion of the anovulatory infertility seen across PCOS phenotypes, including lean PCOS where insulin resistance may be present without BMI elevation.⁹⁴ Androgen excess shortens the follicular phase, impairs mucus quality, and can disrupt the luteal phase, creating a compounding effect on cycle competence. Understanding insulin resistance as the upstream metabolic driver reframes PCOS from a hormone disorder to a metabolic condition with hormonal consequences.¹⁹⁶

Interventions targeting insulin sensitivity can restore ovulation in some women independently of significant weight change.⁴² Myo-inositol has a documented role in improving insulin signaling in PCOS and is among the nutritional options with published clinical evidence.⁴¹ Because insulin resistance compounds hormonal abnormalities across multiple axes, addressing metabolic function is part of root-cause evaluation rather than an adjunct to it.

Open full entry →

Secondary infertility is the inability to conceive after 12 months of regular, unprotected intercourse (or 6 months for women 35 or older) in a couple who has previously achieved at least one pregnancy, regardless of the outcome of that prior pregnancy. It is more common than many clinicians acknowledge. And it is too often met with the worst possible clinical response: reassurance that prior success means nothing is wrong.

Something has changed. New conditions arise after a first pregnancy. Cesarean section creates a uterine scar; a niche or isthmocele at the scar can impair implantation and cause secondary infertility, a finding confirmed by endoscopic repair restoring conception in affected patients.¹²⁸ Operative delivery or retained products of conception can cause intrauterine adhesions consistent with Asherman's syndrome. Postpartum thyroiditis, occurring in up to 10% of postpartum women, can produce persistent hypothyroidism that goes undetected until it is framed as the cause of secondary infertility. Endometriosis can develop or progress between pregnancies. Male factor can change: varicocele, illness, and hormonal shifts all affect semen parameters over time.

RRM approaches secondary infertility as a fresh clinical question rather than a continuation of the prior one. The diagnostic picture from a prior conception does not carry forward unchanged, and reassurance based on prior success can delay the workup that would identify what has changed. The couple presenting today may have a different underlying pathology than the couple who conceived two years ago.³

The infertility is real. The evaluation should be, too.

Open full entry →

"Unexplained infertility" is a clinical label assigned when standard evaluation, which typically includes semen analysis, ovulation assessment, hormonal screening, and tubal patency testing, returns normal results. It affects an estimated 15 to 25% of couples presenting for infertility care. RRM does not accept this as a final diagnosis. In RRM, unexplained means undiagnosed.

The diagnostic yield of a full RRM evaluation demonstrates why. In one Canadian family practice cohort, unexplained infertility dropped from 40% of presenting patients to 1% after NaProTechnology evaluation.¹²⁶ The same evaluation identified low progesterone in 62%, low luteal estrogen in 50%, and anovulation in 14% of patients who had previously been told nothing was wrong.¹²⁶ The label persisted because the standard workup did not look for what RRM looks for.

Conditions routinely missed by standard evaluation include luteal phase deficiency detectable only through serial post-peak progesterone profiling, subclinical ovulation disorders visible only on targeted ultrasound, Stage I to II endometriosis (present in up to 47% of women with unexplained infertility who undergo diagnostic laparoscopy),¹²⁷ chronic endometritis, immune dysregulation, and male factor oxidative stress not captured by routine semen analysis.

A comprehensive evaluation through cycle-timed diagnostics is the RRM answer to the unexplained label. The goal is a diagnosis. When the evaluation is thorough, unexplained infertility almost disappears as a category. The question shifts from "why won't it happen?" to "what have we not looked for yet?"

Open full entry →

Time to pregnancy (TTP) is the number of months from the start of unprotected intercourse attempting conception to the achievement of a confirmed pregnancy, and it is the primary population-level measure of couple fecundability. In couples with normal fertility using fertility-aware, timed intercourse, studies estimate that approximately 81% conceive within 6 cycles and 92% within 12 cycles.¹⁹⁷ These probabilities decline with advancing age. When a couple has not conceived after 12 months of appropriately timed attempts, or 6 months at age 35 or older, infertility evaluation is indicated.⁸⁷

TTP depends substantially on whether intercourse is timed to the fertile window. Couples who cannot identify the peak day of their cycle, or who are not using fertility-focused intercourse, may show extended TTP for behavioral rather than pathological reasons. Accurate TTP reporting requires that couples know when they began attempting and whether attempts were cycle-timed. This distinction matters clinically: extended TTP in the absence of cycle tracking may reflect missed fertile windows rather than underlying disease.

In restorative reproductive medicine, TTP is most meaningfully interpreted as a cumulative outcome over a defined treatment horizon rather than a per-cycle metric. Published NaProTechnology cohort data report outcomes at 24 and 36-plus months, reflecting the time required for diagnosis, treatment of underlying conditions, and physiological restoration.⁹³ This differs from procedural approaches that report per-transfer or per-cycle success rates, a framing that does not capture couples who discontinued treatment. TTP over a full treatment horizon is the relevant comparison metric for couples evaluating care pathways at mature reproductive age.

Open full entry →

Cervical factor infertility is the inability to conceive due to cervical mucus that is absent, insufficient in quantity, hostile in quality, or structurally compromised in a way that prevents sperm from reaching the upper reproductive tract. Cervical mucus serves as both a transport medium and a biological filter during the fertile window. When mucus is inadequate, sperm cannot survive the cervical environment long enough to reach the fallopian tubes. This makes cervical function an essential but frequently underassessed variable in fertility evaluation.⁷⁴

The most common causes include hormonal insufficiency, particularly low estrogen in the follicular phase, prior cervical procedures such as LEEP or cone biopsy that reduce mucus-producing glandular tissue, chronic cervical inflammation, and structural cervical abnormalities. Because estrogen drives mucus proliferation in the pre-peak phase, any condition that impairs estrogen production or action can reduce mucus volume and quality. This means cervical factor is frequently a downstream expression of hormonal abnormalities rather than an isolated structural problem.⁶⁸

Identification begins with cycle charting. Women trained in fertility awareness track mucus pattern and quantity, which allows the clinician to assess whether poor cervical mucus is present and at which phase of the cycle it is most deficient. Reaching the peak day with adequate mucus is the observable endpoint of a competent follicular estrogen surge. Where deficiency is identified, addressing the underlying hormonal or structural cause is the appropriate focus. Correcting follicular deficiency may restore cervical function without direct cervical intervention.

Open full entry →

Poor cervical mucus production is a reduction in the quantity, quality, or fertile-window duration of cervical mucus that impairs sperm ascent and reduces the effective fertile window. Fertile-type mucus, characterized by clear, fluid, stretchy secretions, creates a biological channel for sperm transport and filters morphologically abnormal sperm. When this mucus is absent or limited, fertilization potential falls even when ovulation is otherwise occurring.⁷⁴

In the Creighton Model FertilityCare System, clinicians identify poor cervical mucus through standardized mucus descriptors and the mucus cycle score. The CrMS recognizes a limited mucus cycle as a biomarker signaling insufficient estrogen stimulation of the cervical crypts, prior cervical procedure, chronic infection, or other anatomic causes. Identifying the specific pattern is the first step toward addressing the cause.

Underlying causes include follicular deficiency, surgical disruption of the cervical crypts (conization, LEEP), chronic cervicitis, and medications that reduce mucus quality. The cause determines the direction of evaluation. A chart showing a limited mucus pattern is a clinical lead, not a dead end.

Open full entry →

Endometrial thickness is the measurement of the uterine lining obtained by transvaginal ultrasound, assessed at defined points in the menstrual cycle to evaluate implantation potential. A trilaminar (three-layer) pattern in the preovulatory phase indicates coordinated estrogen stimulation of the endometrium. Thickness below an adequate preovulatory range is associated with reduced implantation potential, though exact thresholds vary by population and cycle type.⁸⁷

Causes of thin endometrium include prior uterine instrumentation (dilation and curettage, hysteroscopic procedures), intrauterine adhesions (Asherman syndrome), estrogen deficiency, reduced uterine blood flow, and chronic infection. When the clinician identifies thin endometrium, the question is: why? Measurement alone does not answer that question.

Endometrial assessment belongs alongside ovulation timing, hormonal evaluation, and uterine cavity evaluation, not as a standalone number. A normal thickness does not exclude poor receptivity, and low thickness may resolve when the underlying hormonal or anatomic cause is addressed. The window of implantation depends on more than thickness alone, including progesterone-driven secretory transformation of the endometrium after ovulation.

Open full entry →

Endometrial hyperplasia is an overgrowth of the uterine lining caused by prolonged estrogen exposure without adequate progesterone to oppose it. The glands proliferate and crowd, producing abnormal uterine bleeding as the most common presenting symptom. Atypical hyperplasia (also called endometrial intraepithelial neoplasia) carries a significant risk of progression to endometrial adenocarcinoma if left untreated; a long-term cohort study estimated cancer progression in roughly one quarter of cases.²⁰⁶ Non-atypical hyperplasia carries substantially lower cancer risk and often resolves with hormonal correction.

The root cause is hormonal imbalance. Chronic anovulation, PCOS, obesity, exogenous estrogen without progesterone, and estrogen-secreting tumors are the common drivers. Cycle charting identifies anovulatory cycles and disrupted luteal phase patterns early, before hyperplasia is established. The hormonal context is visible in the chart before it becomes visible on biopsy.

Progesterone therapy reverses many cases of non-atypical hyperplasia by countering the unopposed estrogen state. For atypical hyperplasia in women who desire future fertility, intensive progestin therapy with close endometrial surveillance is a recognized option before hysterectomy. Either way, addressing the source of estrogen excess, not just treating the endometrium, is the restorative principle.⁴⁴

Open full entry →

The window of implantation (WOI) is the hormonally defined period during the secretory phase of the menstrual cycle when the endometrium becomes receptive to a developing embryo. Receptivity arises from progesterone exposure following ovulation, which triggers secretory transformation of the endometrial lining. Without adequate ovulation and normal corpus luteum function, the secretory transformation is incomplete and receptivity is impaired.⁴⁴

The WOI falls within the mid-to-late post-peak phase. Standardized cycle charting with identified peak day provides a reliable reference point for locating this window in natural cycles. In women with recurrent implantation failure, endometrial receptivity testing (ERA) can detect a displaced WOI, though evidence on whether ERA-guided timing improves live birth rates is mixed.⁸⁶²⁵

A restorative framework asks whether the underlying hormonal environment, particularly progesterone production after ovulation, is sufficient to support endometrial transformation. Named restorative methods such as NaProTechnology assess this directly through luteal phase evaluation and post-Peak progesterone profiling using the peak-plus series. The WOI is a consequence of cycle physiology: when the cycle is healthy, the window opens on time.

Open full entry →

Postpartum fertility refers to the return of ovulatory cycles and conception potential following childbirth, a process shaped significantly by breastfeeding behavior and the hormonal transition out of the postpartum state. Breastfeeding suppresses ovulation through sustained prolactin elevation, delaying cycle return by weeks to months depending on feeding frequency and exclusivity. The lactational amenorrhea method (LAM) relies on this biology: exclusive breastfeeding, amenorrhea, and age of the infant under six months together provide highly effective contraception, with effectiveness exceeding 98% when all three criteria apply.²⁰⁷

The first post-postpartum cycles are often anovulatory, particularly in the transition phase as breastfeeding frequency decreases. A return of menstruation does not guarantee a return of ovulation, and the first ovulation frequently precedes the first visible bleed. Cycle charting during the postpartum transition documents this return accurately, distinguishing true ovulatory cycles from anovulatory bleeding.⁸⁷

Women who experienced anovulatory cycles before pregnancy may return to that pattern after it. Postpartum thyroiditis, a recognized cause of transient hypothyroidism following delivery, can disrupt cycle resumption. Retained placental fragments, uterine scar defects from prior cesarean delivery, and hyperprolactinemia are additional treatable causes of delayed or impaired cycle return. Fertility charting makes these distinctions clinically visible.

Open full entry →

Chronic pelvic pain (CPP) is persistent or recurrent pain in the pelvis lasting six months or longer, unrelated to menstruation alone, that causes functional impairment or requires medical care. It is not a diagnosis. It is a symptom that demands one. CPP can arise from endometriosis, adenomyosis, pelvic adhesions, interstitial cystitis, irritable bowel syndrome, or pelvic floor dysfunction, and more than one cause often operates at the same time.^[208]

The underlying source is frequently missed when evaluation stops at symptom management. Endometriosis is a common finding at laparoscopy for CPP, yet many patients remain undiagnosed for years because subtle and deeply infiltrating lesions can be invisible to standard laparoscopic technique. Near-contact laparoscopy detects lesions that conventional visualization misses.

Identifying the etiology changes the treatment. Excision of endometriosis, lysis of adhesions, or surgical correction of structural contributors addresses the root cause rather than blunting the pain signal. Pelvic floor physical therapy is part of the evaluation when musculoskeletal dysfunction contributes to the pain picture, as it frequently does alongside other pathology. Diagnostic laparoscopy remains the standard for definitive identification of intraperitoneal causes.

Open full entry →

Luteinizing Hormone (LH) is a glycoprotein gonadotropin secreted by the anterior pituitary in a pulsatile pattern, responsible for two essential events: the mid-cycle LH surge that triggers the ovulatory cascade, and ongoing stimulation of the corpus luteum to produce progesterone after ovulation.

The LH surge initiates follicle rupture within 36 to 40 hours. Urinary ovulation predictor kits detect this surge and are commonly used to estimate fertile-window timing. Surge detection alone does not confirm ovulation. In LUF syndrome, the surge occurs normally while the follicle fails to rupture. A follicle maturation study using serial ultrasound confirms actual follicle rupture; an LH test cannot.

Basal LH on cycle day 2 or 3 is part of an RRM hormonal panel. An elevated LH-to-FSH ratio is one finding consistent with PCOS. Persistently elevated LH outside the expected surge window can reflect hypothalamic disruption, stress, or thyroid dysfunction. Without cycle chart data anchoring the timing, a single LH value is difficult to interpret. That is the clinical problem with random-day hormone draws. Chart-based evaluation removes that ambiguity.

LH is also relevant in male reproductive evaluation. In men, pulsatile LH stimulates Leydig cells to produce testosterone. Evaluation of the male partner includes LH alongside FSH and testosterone when spermatogenesis is abnormal.

Open full entry →

Follicle-Stimulating Hormone (FSH) is a glycoprotein gonadotropin secreted by the anterior pituitary gland in response to hypothalamic GnRH pulses, with the primary function of stimulating ovarian follicle recruitment and maturation during the follicular phase of the cycle. Each cycle, FSH recruits a cohort of follicles. One typically becomes dominant and proceeds to ovulation. That process depends on an FSH rise that begins in the late luteal phase of the prior cycle, well before menstruation starts.

Basal FSH, drawn on cycle day 2, 3, or 4, is a standard component of an ovarian reserve panel. An elevated basal FSH signals that the pituitary is working harder than normal to recruit follicles. This reflects reduced ovarian sensitivity, often an early indicator of declining reserve. The threshold for "elevated" varies by laboratory and by age, and a single elevated value carries less weight than a persistently rising trend across multiple cycles.

FSH must be read alongside AMH, AFC, and estradiol drawn on the same day. Estradiol elevated on day 3 can suppress FSH artificially, masking the true reserve picture. A normal FSH with elevated estradiol is not reassuring. The panel is only interpretable together.

A large study of women 30 to 44 years old found that elevated FSH was independently associated with infertility across all age groups, confirming its relevance beyond the IVF context where it is most commonly discussed.¹⁰¹

In men, FSH stimulates Sertoli cells and supports spermatogenesis. Elevated FSH in a man with low sperm counts often signals primary testicular failure. That finding changes the clinical approach entirely and is part of why male factor evaluation belongs at the first visit, not as an afterthought.

Open full entry →

Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the syncytiotrophoblast immediately after implantation, and it is the hormone detected by all standard pregnancy tests. Its first biological role is to rescue the corpus luteum from regression, sustaining progesterone production until the luteo-placental shift at approximately 8 to 10 weeks of gestation. Without this rescue signal, the corpus luteum involutes and progesterone falls, ending the pregnancy before the placenta is ready to take over steroid production.

Structurally, hCG closely resembles LH. It binds the same receptors. This structural similarity is the basis for two therapeutic applications in RRM practice: exogenous hCG can substitute for the mid-cycle LH surge to trigger ovulation, and serial post-Peak injections can provide ongoing luteal phase support when corpus luteum function is suboptimal. Both are cycle-timed, cause-based interventions. The goal is supporting what the body is trying to do, not overriding it.

In recurrent pregnancy loss, hCG supplementation in early pregnancy has been studied as a support strategy. Quenby and Farquharson published a randomized controlled trial of 81 women with idiopathic recurrent loss. In women with oligomenorrhea, hCG supplementation raised the pregnancy success rate from 40% to 86%, a statistically significant improvement. No benefit was seen in women with regular cycles.⁶⁰ The implication for RRM practice: cycle type matters. Evaluation before treatment matters.

Serial quantitative hCG levels in early pregnancy are a critical early monitoring tool. A doubling time slower than expected, or a plateau, prompts investigation rather than watchful waiting. That proactive posture is part of what distinguishes RRM care in early pregnancy.

Open full entry →

Natural killer (NK) cells are lymphocytes of the innate immune system with two populations relevant to reproductive medicine: circulating NK cells (CD56dim), which perform immune surveillance in the bloodstream, and uterine NK cells (CD56bright), which are the predominant immune cells in the endometrium during the secretory phase and early pregnancy.^[209]

Uterine NK cells support normal placentation. They facilitate trophoblast invasion and drive spiral artery remodeling, both essential for adequate blood flow to the developing pregnancy. Without this remodeling, placentation is shallow and downstream pregnancy complications rise.^[209]

Elevated uterine NK cell activity has been associated with implantation failure and recurrent pregnancy loss in a subset of patients, though clinical testing and optimal management remain areas of active investigation rather than settled protocol.^[37] Chronic endometritis, an infection-related inflammatory state, may alter the local immune environment in ways that affect NK cell behavior.^[26] The relationship between the endometrial microbiota, uterine NK activity, and implantation is an emerging area of study.^[65]

RRM clinicians may factor uterine immune evaluation into the workup of unexplained implantation failure or recurrent pregnancy loss as part of a broader assessment.

Open full entry →

Premenstrual syndrome (PMS) is a pattern of cyclical physical, cognitive, and emotional symptoms that appear in the luteal phase of the menstrual cycle and resolve with or shortly after the onset of menses. Common features include irritability, mood lability, bloating, breast tenderness, fatigue, and difficulty concentrating. The defining characteristic is the cyclical pattern: symptoms appear predictably after ovulation and clear with menstruation.^[66]

Severity exists on a spectrum. The severe end, characterized by marked mood disruption and functional impairment, meets criteria for premenstrual dysphoric disorder (PMDD) as defined by DSM-5. Distinguishing PMS from PMDD, and both from conditions that worsen premenstrually (such as perimenstrual exacerbation of a mood disorder), requires prospective symptom tracking across at least two cycles.^[66]

The cyclical pattern points directly to luteal phase function as the clinical question to investigate. Progesterone levels in the post-peak phase, thyroid function, and nutritional status are among the areas clinicians evaluate in women with significant premenstrual symptoms. Evidence from controlled trials supports a role for progesterone-based intervention in luteal phase support for PMS, though the literature reflects ongoing investigation rather than a single settled approach.^[67] Fertility charting provides the cycle-phase precision that retrospective calendar estimates cannot, allowing clinicians to correlate symptom timing precisely with hormonal phase.

When PMS symptoms are severe or disabling, evaluation of luteal phase deficiency and thyroid function is a logical starting point. The peak day and post-peak phase charting markers provide the reference frame for identifying when in the cycle symptoms begin.

Open full entry →

Thyroid-Stimulating Hormone (TSH) is secreted by the anterior pituitary gland and regulates the thyroid's output of thyroxine (T4) and triiodothyronine (T3). When thyroid hormone output falls, TSH rises. When output is excessive, TSH falls. It is the primary screening marker for thyroid dysfunction.

Standard laboratory reference ranges for TSH span roughly 0.5 to 4.5 mIU/L. "Within normal limits" is not the same as "optimal for reproduction." A cross-sectional study of 239 women found that those with unexplained infertility had significantly higher TSH levels than women whose infertility was attributable solely to severe male factor, even though all TSH values fell within the normal assay range.⁶⁸ That finding matters clinically: a TSH of 3.8 mIU/L may not prompt treatment from a general practitioner. An RRM clinician reads that same value as a potential contributor to cycle dysfunction.

For women attempting to conceive, many RRM clinicians target a TSH below 2.5 mIU/L. This threshold is grounded in evidence linking higher normal-range TSH to anovulation, luteal phase deficiency, and miscarriage risk.

TSH alone is not sufficient. Evaluation for reproductive thyroid dysfunction should include free T4, free T3, and thyroid antibodies. A Cochrane review found that subfertile women with euthyroid autoimmune thyroid disease may benefit from thyroxine replacement even when TSH is near-normal, though the evidence remained limited at the time of publication.¹⁰² Autoimmune thyroid disease can impair fertility and increase miscarriage risk through mechanisms independent of TSH level.

Open full entry →

Body Mass Index (BMI) is a numerical index calculated by dividing weight in kilograms by height in meters squared (kg/m²), used as a population-level screening tool for weight-related health risk. The World Health Organization classifies BMI below 18.5 as underweight, 18.5 to 24.9 as normal range, 25.0 to 29.9 as overweight, and 30.0 or above as obese. BMI does not measure body composition or metabolic health directly, and its limitations are well documented at the individual level.^[69]

Both extremes of BMI impair fertility. At the low end, insufficient energy availability drives hypothalamic amenorrhea and anovulation. At the high end, insulin resistance and hyperinsulinemia drive anovulatory cycles and androgen excess, the core metabolic disruption in many cases of PCOS. Subfertility risk rises with deviation from the normal range in both directions.^[69]

Obesity is also associated with elevated miscarriage risk and lower cycle-based pregnancy rates. The mechanism is metabolic. Adipose tissue acts as an endocrine organ, generating estrogen excess, disrupting the hypothalamic-pituitary-ovarian axis, and amplifying insulin resistance. Addressing underlying metabolic dysfunction through lifestyle modification treats the root cause rather than bypassing it.^[70]

BMI appears alongside hormonal abnormalities in the evaluation of couples with unexplained infertility. It contextualizes findings from cycle charting and informs decisions about nutritional and lifestyle intervention. The goal is restoring the conditions for normal ovulation, not simply achieving a target weight.

Open full entry →

Molimina (from Latin: exertions) is a cluster of mild, predictable premenstrual symptoms that reflect normal luteal-phase progesterone activity. Typical features include slight breast tenderness, a sense of pelvic fullness, mild fluid retention, subtle mood shifts, and premenstrual mucus changes. These symptoms arise because the corpus luteum is producing progesterone. They resolve when menstruation begins.²²⁰

Molimina is a positive physiologic sign. Its presence in a predictable cycle pattern correlated with peak day timing supports ovulation. Its absence, particularly in cycles that appear outwardly regular, raises clinical suspicion for anovulatory bleeding or a deteriorating luteal phase. Research data show that absence of molimina has high specificity for ovulatory disturbance, while its presence alone does not confirm adequate ovulation.²²⁰

Molimina is distinct from PMS. PMS is a symptomatic excess: disproportionate mood disturbance or physical symptoms that impair function. Molimina is the body registering normal luteal activity at a low level. The distinction matters clinically. Eliminating all premenstrual awareness with suppressive medications masks a signal that carries diagnostic value. The chart captures it.¹⁰⁰

In fertility charting, consistent molimina recorded alongside mucus observations and peak day over multiple cycles builds a pattern. Loss of molimina across successive cycles, or its absence from the beginning, is a charted finding that informs the clinical picture rather than a detail to dismiss.

Open full entry →

Clinical Endorphin Deficiency (CED) is a clinical pattern, formalized within NaProTechnology by Dr. Thomas W. Hilgers, characterized by chronic pelvic pain, mood symptoms including depression and anxiety, and difficulty recovering from physical or emotional stress. The pattern reflects dysfunction in the endogenous opioid system: beta-endorphins and related opioid peptides modulate GnRH pulsatility at the hypothalamic level, with downstream effects on LH and FSH secretion and on ovarian function.⁷⁸ When endorphin tone is insufficient, that neuroendocrine signaling breaks down in ways that are clinically recognizable before they show up cleanly on standard hormone panels.

Diagnosis is made by clinical pattern recognition, not by a numeric threshold or a single assay result. The clinician weighs the symptom cluster: chronic pelvic pain, perimenstrual mood changes, poor tolerance of physical stress, and sometimes a history that looks like PMS or chronic pelvic pain that has resisted standard explanations. The absence of a definitive biomarker does not mean the pattern is speculative. It means the field is still catching up to what clinicians trained in NaProTechnology have observed in practice for decades.

Low-dose naltrexone (LDN) is the canonical therapeutic option for CED. LDN works by transiently occupying opioid receptors; the brief blockade triggers a compensatory upregulation of endogenous opioid production, increasing beta-endorphin availability in the period between doses.²⁴¹ Published trials of LDN in chronic pain conditions, including fibromyalgia and multiple sclerosis, document both its pain-modulating effects and its tolerability profile.⁹⁰⁹¹ For additional detail on mechanism and outcomes data, see Low-Dose Naltrexone (LDN).

The specific agent, dose, duration, and clinical indication for any individual patient remain a judgment made by the treating clinician based on the full clinical picture. NaProTechnology-trained clinicians consider LDN alongside other approaches suited to the patient's hormonal and symptom profile. CED does not have a single treatment protocol; it has a clinical framework for recognizing that the endogenous opioid system is a relevant target, and that addressing it may resolve symptoms that suppressive approaches have masked without correcting.

Open full entry →

Thrombophilia is an inherited or acquired condition that shifts the balance of the coagulation system toward clot formation, increasing the risk of pathological thrombosis. Inherited forms include Factor V Leiden, prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, protein S deficiency, and MTHFR variants associated with elevated homocysteine. The acquired form most relevant to reproductive medicine is antiphospholipid syndrome (APS), an autoimmune condition that generates antibodies against phospholipid-binding proteins.^[75]

Thrombophilia is implicated in recurrent pregnancy loss and placental insufficiency. Thrombosis in the placental vasculature can impair blood flow during critical windows of placental development. Not all thrombophilias carry the same reproductive risk; the degree varies with the specific mutation, zygosity, and additional risk factors.^[37][52]

Anticoagulation, when indicated, addresses a specific physiological mechanism: preventing thrombotic occlusion of placental vessels.^[52] MTHFR variants deserve particular mention. They are common, often found incidentally, and their independent contribution to pregnancy loss remains debated. Methylated folate addresses homocysteine elevation when MTHFR variants contribute to hyperhomocysteinemia. The decision to treat requires individualized evaluation, not a reflex response to a lab result.

Thrombophilia evaluation is part of the workup for recurrent pregnancy loss in cause-focused reproductive care.

Open full entry →

Early pregnancy loss (EPL) is the spontaneous loss of a clinically confirmed pregnancy before 13 weeks of gestation. It is the most common complication of pregnancy, affecting approximately 10 to 20% of confirmed pregnancies. The majority of isolated losses result from chromosomal aneuploidy in the embryo, and a single loss in an otherwise healthy couple carries a reasonable prognosis for subsequent success without intervention.¹²⁹

The picture changes with recurrence. Two or more losses define Recurrent Pregnancy Loss (RPL), a clinically distinct entity with a different differential diagnosis and a different evaluation protocol. A couple with two losses is not simply unlucky twice. The probability of a chromosomal explanation for both losses is low enough that a systematic search for treatable maternal and paternal factors is warranted.

Treatable causes of early pregnancy loss include corpus luteum deficiency and progesterone insufficiency, thyroid dysfunction, uterine structural abnormalities (septum, submucous fibroids, isthmocele), antiphospholipid syndrome, inherited thrombophilias, and chronic endometritis. A treatment strategy that systematically addresses thyroid function, thrombophilia, immune dysregulation, and uterine environment has demonstrated significantly improved live birth rates in women with recurrent loss compared to expectant management alone.¹³⁰

RRM does not respond to early pregnancy loss with reassurance and a directive to try again. The first loss is acknowledged. The second triggers evaluation. The evaluation is systematic, not checklist-driven. Each identified finding becomes a treatment target. The hCG trajectory of each subsequent pregnancy is monitored closely, with early support initiated when deficiency is identified.

Early pregnancy loss is distinguished from biochemical pregnancy (hCG-positive with no ultrasound confirmation) and from stillbirth (fetal loss at or after 20 weeks). Each category carries its own clinical framework. RRM does not collapse them.

Open full entry →

Corpus Luteum Deficiency (CLD) is a condition in which the corpus luteum produces insufficient progesterone to adequately support the endometrium for implantation and early pregnancy maintenance. CLD names the anatomical source of the deficit: the corpus luteum itself is underperforming. This distinguishes it from Luteal Phase Deficiency (LPD), which describes the hormonal pattern. CLD is the structural cause; LPD is the measurable consequence. A clinician can observe LPD on a progesterone profile without identifying CLD as the origin, and treat downstream without correcting upstream.

The clinical significance of CLD in infertile populations is frequently missed by standard workup. In one cohort of infertile couples undergoing RRM evaluation, 0% had been diagnosed with corpus luteum deficiency prior to their RRM assessment. After comprehensive cycle-timed evaluation, 71% received the diagnosis.¹³² Standard infertility workups use a single mid-luteal progesterone draw. That single number is insufficient to characterize corpus luteum function. The corpus luteum produces progesterone in a pulsatile pattern across the luteal phase. A single measurement can look normal while the integrated progesterone output across the phase is inadequate.

NaProTechnology identifies CLD through multiple cycle-timed progesterone measurements across the post-Peak phase rather than a single draw. A flat, declining, or consistently low progesterone curve identifies corpus luteum failure specifically.¹³¹ Treatment addresses both the luteal phase directly and, when indicated, the follicular phase that preceded it: corpus luteum quality depends heavily on follicular development. A follicle that was small, grew slowly, or ruptured prematurely produces a suboptimal corpus luteum. Optimizing follicle development before ovulation is part of the upstream correction. Post-ovulation support is timed to the cycle chart via Peak-plus series monitoring rather than a calendar estimate.

CLD is a common finding in couples with unexplained infertility and in women with early pregnancy loss. The role of the hCG signal from the early embryo in rescuing and extending corpus luteum function adds another layer to the diagnostic picture: if the embryo's hCG output is insufficient, the corpus luteum may fail even when its own capacity is intact. Evaluating both sides of the corpus luteum-embryo signaling axis is an RRM diagnostic priority in couples with early loss.

Open full entry →

Empty Follicle Syndrome (EFS) is an ovulation disorder in which the dominant follicle reaches mature size and ruptures appropriately, yet no oocyte is recovered at the expected reproductive event.⁷⁸ Serial ultrasound demonstrates apparent follicular growth and collapse, but the cycle’s reproductive outcome fails at the oocyte level.

This pattern was first characterized in IVF aspiration cycles, then extended to spontaneous, unstimulated cycles by Dr. Thomas W. Hilgers as part of the follicle-maturation-study protocol within NaProTechnology.⁷⁸ In that context, the diagnosis rests on the full sonographic picture observed across serial scans, not on any single measurement or threshold. The follicle performs its visible function. The reproductive event does not follow.

EFS is distinct from anovulation and from afollicularism. In EFS, follicular development proceeds and collapse occurs. The failure is at a different level: no viable oocyte accompanies that collapse. It is also distinct from Immature Follicle Syndrome, where the follicle ruptures before reaching maturity, and from Partial Rupture Syndrome, where collapse is incomplete.

The diagnosis requires serial follicle maturation study ultrasound. Cycle charting alone cannot detect it. EFS sits within Hilgers’ sonographic classification of ovulation disorders as a discrete, diagnosable entity. For couples with otherwise unexplained infertility, identifying this pattern is a concrete step toward understanding why conception has not occurred.

Open full entry →

Immature Follicle Syndrome (IFS) is an ovulation disorder in which the dominant follicle ruptures before reaching the size associated with follicular maturity, preventing reliable release of a fully developed oocyte.⁷⁸ A follicle that collapses prematurely cannot support normal oocyte development or adequate corpus luteum formation.

Dr. Thomas W. Hilgers classified IFS as a named anatomic ovulation defect within his sonographic system for evaluating cycle quality, developed through the NaProTechnology follicle-maturation-study protocol.⁷⁸ Diagnosis is made by a trained sonographer observing the full serial scan picture across the periovulatory window: the dominant follicle collapses before the pattern consistent with mature follicular development is established. The specific diagnostic criteria reside in the follicle-maturation-study protocol training. No single measurement defines the diagnosis in isolation.

IFS is distinct from Delayed Rupture Syndrome, where the follicle reaches maturity but rupture is late. It is distinct from Empty Follicle Syndrome, where the follicle reaches expected size but produces no oocyte. And it is distinct from Partial Rupture Syndrome, where rupture begins but does not complete.

Premature rupture produces a smaller, less functional corpus luteum. That structural deficit drives luteal phase deficiency and elevates the risk of early pregnancy loss even when conception occurs. Fecundity is reduced in affected cycles even when cycle charting appears to show normal ovulation timing. Serial follicle maturation study ultrasound identifies the pattern. Restorative ovulation support protocols within NaProTechnology address follicular maturation directly, targeting the defect at its source.

Open full entry →

Partial Rupture Syndrome (PRS) is an ovulation disorder in which the dominant follicle decreases in size at the expected time of ovulation but does not fully collapse, leaving a partial cystic residual rather than completing the rupture process.⁷⁸ Rupture initiates but stalls. The oocyte-cumulus complex is not fully expelled.

Dr. Thomas W. Hilgers formalized PRS as a distinct sonographic entity within the NaProTechnology follicle-maturation-study protocol.⁷⁸ The diagnosis is made by trained sonographers reviewing serial ultrasound images across the periovulatory window: the pattern of partial size decrease without full collapse distinguishes PRS from normal ovulation, and from the other rupture-spectrum disorders classified in this system. No specific collapse threshold in millimeters or time interval defines the diagnosis in isolation.

PRS occupies a specific position within Hilgers’ sonographic classification of ovulation disorders. It is distinct from Luteinized Unruptured Follicle Syndrome, where no collapse occurs at all. It is distinct from Delayed Rupture Syndrome, where full collapse eventually occurs but later than expected. And it is distinct from Empty Follicle Syndrome, where collapse appears complete but no oocyte is recovered.

The corpus luteum that forms from a partially ruptured follicle is structurally compromised. Subnormal corpus luteum function follows, with reduced progesterone output across the post-Peak phase. Fecundity in affected cycles is reduced even when the cycle chart shows apparently normal ovulation timing. Serial follicle maturation study ultrasound names the defect. Chart observation alone cannot distinguish PRS from a normal ovulatory cycle.

Open full entry →

Delayed Rupture Syndrome (DRS) is a sonographic ovulation disorder, developed and formalized by Dr. Thomas W. Hilgers within NaProTechnology, in which the dominant follicle collapses later than the timing of the woman's charted Peak Day observation would predict.⁷⁸ Rather than rupturing in close proximity to Peak Day, the follicle persists for a measurable interval beyond the expected window before eventually collapsing.

Serial ultrasound across the periovulatory window is required to identify the pattern. The follicle is present and morphologically mature on the scan preceding expected ovulation, then documents delayed collapse on a later scan. DRS is distinct from Luteinized Unruptured Follicle Syndrome, in which no rupture occurs at all, and from Partial Rupture Syndrome, in which the follicle partially collapses but fails to complete. In DRS, rupture does eventually occur, but at a time that diverges from the Peak Day signal.

The clinical consequence is a timing mismatch. Couples timing intercourse based on Peak Day are directing that effort toward a window that does not align with actual ovulation. Apparent regularity on the chart does not signal normal ovulatory timing. DRS is classified within Hilgers' sonographic classification of ovulation disorders and carries implications for periovulatory hormonal function, including the LH surge and subsequent corpus luteum quality.

Identifying DRS requires a follicle maturation study. The diagnosis cannot be made from chart data alone. Restorative evaluation targets the underlying endocrine mechanism so that the timing of actual ovulation can be correlated with fertile-phase observations and, where indicated, addressed through appropriate NaProTechnology-based ovulation support.

Open full entry →

Afollicularism is a sonographic ovulation disorder, developed and formalized by Dr. Thomas W. Hilgers within NaProTechnology, in which the cycle proceeds with regular menstrual bleeding but serial follicular ultrasound reveals the absence of meaningful follicular development across the entire periovulatory window.⁷⁸ No dominant follicle forms. No ovulation occurs.

Afollicularism occupies the most severe position within Hilgers' sonographic classification of ovulation disorders. Cycle length may be normal. A Peak Day pattern may appear on the Creighton chart. Menses arrive as expected. None of those external signals discloses the absence of a developing follicle, which is why afollicularism is invisible without imaging data from a follicle maturation study.

The distinction from related disorders is important. Anovulatory cycles may develop a follicle that fails to rupture. In afollicularism, the follicular recruitment phase does not produce a follicle of sufficient development to classify as dominant. This distinguishes afollicularism from Luteinized Unruptured Follicle Syndrome and from follicular deficiency, which presents with measurable but suboptimal follicular growth rather than an absence of recruitment.

The finding may reflect severely diminished ovarian reserve, including premature ovarian insufficiency, or other endocrine disruption requiring evaluation. A restorative workup explores the underlying mechanism rather than bypassing it. The diagnosis confirms that the cycle, despite its external regularity, offers no biological opportunity for conception until the cause is identified and addressed.

Open full entry →

Follicular Deficiency is a clinical RRM concept describing an ovulatory pattern in which the dominant follicle reaches adequate size and ruptures on schedule but does not produce sufficient hormonal output to support fertilization and implantation. The defect is functional, not anatomic. The follicle looks normal on ultrasound. It ruptures. The problem is invisible to imaging and only becomes legible through the hormonal record the cycle leaves behind.⁷⁸ This distinguishes it from the four named ovulation disorders in Hilgers' Sonographic Ovulation Classification: luteinized unruptured follicle, immature follicle syndrome, afollicularism, and empty follicle syndrome.

The diagnostic window is the post-Peak hormonal picture. RRM clinicians evaluate Peak+7 estradiol and progesterone as integrated markers of what the follicle actually produced. A well-functioning follicle generates a corpus luteum capable of sustaining adequate mid-luteal hormone levels. When Peak+7 estradiol falls below target range, or when progesterone is suboptimal despite an otherwise ovulatory cycle with a clear Peak Day, follicular deficiency is the explanation the chart alone cannot provide. Serial follicle maturation study ultrasound, read alongside cycle-timed blood work, gives clinicians the combined picture needed to make the diagnosis.¹¹¹

The downstream consequence is luteal phase deficiency. The corpus luteum is only as capable as the follicle that preceded it. A follicle with inadequate estradiol output cannot generate a corpus luteum with full progesterone-secreting capacity. Luteal hormonal support that addresses progesterone alone does not resolve the problem at its source. That failure pattern, when luteal rescue does not restore normal Peak+7 values, is itself diagnostic. The deficit begins in the follicular phase and propagates forward. Follicular deficiency is a recognized hidden contributor to luteal insufficiency, recurrent early pregnancy loss, and short luteal phase in cycles that carry no other obvious diagnosis.

The restorative approach targets follicular development directly. The corpus luteum, the luteal hormones, and the implantation environment are all downstream of a follicle that functions. Treat the follicle. The rest of the cycle can follow.

Open full entry →

Menopause is the permanent cessation of menstruation, defined by 12 consecutive months of amenorrhea without an alternative clinical cause. In industrialized populations, the mean age at menopause is approximately 51 to 52 years, with a typical physiologic range of 45 to 55 years.²¹⁸ The biological basis is depletion of ovarian follicles: estradiol production falls to persistently low levels, and FSH rises in sustained elevation as the pituitary attempts to drive an ovarian response that no longer comes.

Menopause is a physiologic life stage, not a disease. The hormonal shifts that accompany it, including changes in estradiol, progesterone, FSH, and LH, carry downstream effects on bone density, cardiovascular health, vasomotor regulation, and mood. These effects vary substantially between individuals, and restorative-aligned care approaches them as discrete, evaluable conditions rather than an inevitable burden of aging. Hormone therapy is one tool for managing menopausal symptoms; it is not the only one, and decisions are made relative to each person's clinical picture and values.⁷³

When menopause occurs before age 40, it meets criteria for Premature Ovarian Insufficiency (POI), which carries a distinct clinical profile and warrants a different clinical pathway.

Open full entry →

Premenopause is the reproductive life stage preceding perimenopause, spanning the years of regular ovulatory cycling from adolescence through the late thirties or early forties. Hormonal patterns during premenopause are comparatively stable: estradiol and progesterone follow predictable monthly rhythms, FSH remains within normal range, and AMH sits at or near its lifetime peak. This is the window of highest natural fertility for most women.

Cycle charting during premenopause builds a baseline record that becomes diagnostically valuable later. Changes in mucus quality, cycle length, post-peak phase duration, or premenstrual spotting appear in the chart years before they produce symptoms severe enough to prompt a clinical visit. For RRM clinicians, a woman's premenopausal charting history is a longitudinal dataset, not just a contraceptive tool.⁸⁹

Premenopause ends when the cycle begins to shift into the variable, hormonally volatile pattern that characterizes Perimenopause. The transition is biological, not calendar-defined.

Open full entry →

Perimenopause is the biological transition period preceding menopause, typically spanning 4 to 10 years, during which ovarian function declines progressively and menstrual cycle patterns become irregular. The staging criteria established by the Stages of Reproductive Aging Workshop (STRAW+10) define early perimenopause by variable cycle length and late perimenopause by cycles 60 or more days apart, concluding at the final menstrual period.²¹⁸ This transition follows biology, not a specific calendar age, though it most commonly begins in the mid-forties.

Hormonally, perimenopause brings volatility rather than simple decline. FSH rises irregularly, AMH falls progressively as the ovarian follicle pool depletes, estradiol fluctuates widely between cycles, and anovulatory cycles become more frequent.⁷⁷ This hormonal instability produces the vasomotor symptoms, sleep disruption, and mood changes commonly associated with the menopausal transition.

Fertility does not end at the onset of perimenopause. Ovulation still occurs, and conception remains possible, though the probability of successful pregnancy declines as anovulatory cycles increase and egg quality diminishes with advancing follicle depletion. Couples who do not wish to conceive should understand that contraceptive needs persist until 12 consecutive months of amenorrhea confirm Menopause. For couples pursuing pregnancy during perimenopause, the clinical evaluation differs from care in younger women, with particular attention to ovarian reserve, cycle quality, and the frequency of ovulatory cycles.

Open full entry →

Mature reproductive age is a clinical designation for women aged 35 and older who are attempting pregnancy, acknowledging that fertility potential, egg quality, and time-to-pregnancy change meaningfully as the ovarian reserve that was built across childhood declines with accelerating pace through the mid-thirties and beyond. The designation does not imply a fertility cliff. It signals that a couple presenting at this stage benefits from greater clinical urgency and diagnostic depth.

The biological changes are real and measurable. Oocyte aneuploidy rates rise with age, extending time-to-pregnancy and increasing early pregnancy loss. AMH and antral follicle count both decline, reflecting the shrinking ovarian follicle pool. Cycle regularity may remain intact while egg quality and fertilization potential fall. These changes confront every clinician working with older reproductive-age couples, regardless of the care model.¹⁰¹

Restorative care produces meaningful outcomes in this population. A 2025 single-center cohort study of 1,310 infertile couples treated with NaProTechnology, in which the mean age of women was 35.0 years (SD 4.4), reported an adjusted cumulative take-home baby rate of 62.1%. Age-stratified rates were 53.3% for women aged 36 to 40 and 24.4% for women over 40.^14,93 These results came from a population with unfavorable prognostic factors, including prolonged infertility duration and prior ART attempts in more than a quarter of couples. Both partners receive evaluation from the outset; male factor is solely responsible in approximately 20% of infertile couples and contributes in an additional 30 to 40%.¹⁹³

Open full entry →

Overlapping Disciplines

Reproductive Endocrinology is the study of hormonal regulation of reproduction, encompassing the hypothalamic-pituitary-gonadal axis and its effects on ovulation, implantation, and pregnancy maintenance. As a conventional subspecialty, Reproductive Endocrinology and Infertility (REI) developed with close ties to assisted reproductive technology, making IVF a central clinical pathway for many fellowship-trained practitioners. Restorative reproductive medicine, in practices such as NaProTechnology and NeoFertility, applies the same endocrine science to a different goal. Hormonal evaluation is timed to cycle phases identified through cycle-timed diagnostics rather than drawn on arbitrary calendar dates, and findings direct restorative treatment rather than bypass procedures. Conditions such as hypothyroidism, hyperprolactinemia, diminished ovarian reserve, and hormonal abnormalities that contribute to infertility or pregnancy loss are identifiable through targeted endocrine workup and are treated at the source.²³ Key hormones in this evaluation include FSH, LH, TSH, and hCG, each interpretable only within the context of the cycle phase at the time of the draw.

Open full entry →

Reproductive Immunology is the study of immune system contributions to implantation failure, recurrent pregnancy loss, and fertility-related conditions. Research in this field has clarified several immune pathways relevant to reproductive outcomes. Antiphospholipid syndrome (APS) elevates thrombotic risk at implantation sites and is a treatable cause of recurrent pregnancy loss.⁵² Elevated uterine natural killer cell activity and autoimmune and thrombophilic disorders appear in a subset of couples with otherwise unexplained implantation failure.³⁷ Chronic endometritis disrupts the endometrial environment and associates with recurrent implantation failure and pregnancy loss.²⁶ The endometrial microbiome is an adjacent area of investigation: microbial imbalance in the uterine environment correlates with implantation outcomes independent of structural pathology.⁶⁵ RRM clinicians may incorporate reproductive immunology evaluation when the clinical picture suggests an immune contributor, particularly in couples with recurrent pregnancy loss or thrombophilia.

Open full entry →

Restorative Andrology is an approach to male fertility evaluation and treatment that prioritizes identifying and correcting the underlying causes of male factor infertility rather than bypassing them with sperm-retrieval procedures. Male factor is the sole cause of infertility in approximately 20% of couples and a contributing factor in another 30-40%.¹⁹³ Identifiable and correctable causes include varicocele (the most common treatable male factor), sperm DNA fragmentation, oxidative stress, hormonal imbalance, and ductal obstruction.¹⁹³⁵⁵³ Surgical correction restores the male partner's contribution to natural conception where anatomy or obstruction is the underlying problem.⁵³¹²⁵ Vasectomy reversal is a restorative option for couples where prior vasectomy is the barrier. Full semen analysis per WHO reference criteria is the starting point for male evaluation.¹⁷¹ Restorative andrology stands in contrast to the standard convention of proceeding directly to ICSI, which bypasses male pathology without treating it and carries procedural risks of its own.⁶³

Open full entry →

Minimally Invasive Gynecologic Surgery (MIGS) is a recognized gynecologic subspecialty focused on laparoscopic, hysteroscopic, and robotic surgical techniques for treating disorders of the female reproductive tract.¹⁸⁵¹⁸⁶ MIGS fellowship-trained surgeons complete structured advanced training in operative laparoscopy and hysteroscopy after residency, with dedicated focus on tissue-sparing and minimally invasive approaches to complex gynecologic pathology.

Procedures within the MIGS domain include excision of endometriosis, adhesiolysis, operative hysteroscopy for intrauterine pathology, laparoscopic myomectomy, and tubal surgery. Robotic-assisted laparoscopy and mini-laparotomy fall within the MIGS skill set for cases where standard laparoscopic access is limited.

MIGS training is directly relevant to restorative reproductive surgery. Fertility-sparing technique and precise pathology management, rather than organ removal, are central to NaProTechnology surgical care and IIRRM-trained reconstructive practice. A surgeon's MIGS training speaks to competence in the laparoscopic and hysteroscopic procedures these named-method approaches frequently use, including excision surgery for endometriosis, operative hysteroscopy for uterine cavity pathology, and near adhesion-free reconstructive pelvic surgery.¹⁰

Open full entry →

Cycle-Timed Diagnostics is the principle of ordering hormonal panels, ultrasound studies, and other diagnostic tests at cycle phases identified through fertility charting rather than on arbitrary calendar dates. The menstrual cycle is not hormonally uniform. Reproductive hormone levels vary substantially by cycle phase, and drawing blood outside the relevant phase can return values that appear normal while masking a real abnormality. Conversely, a value drawn in a phase-inappropriate window may flag as abnormal when it reflects normal cyclic variation. When clinicians know where a patient is in her cycle through FABM charting, they can order tests at the phases where each analyte carries diagnostic meaning. This principle transforms charting from a family planning tool into a clinical diagnostic instrument.³¹¹⁷ The luteal phase, the peak day event, and the follicle maturation study are examples of charting landmarks that anchor diagnostic timing. Named methods such as NaProTechnology and NeoFertility have formalized cycle-timed testing into structured diagnostic protocols; the specific phase-timing and test sequences each method uses are defined within those methods. Acyclic testing, in which blood is drawn without reference to cycle phase, remains the default in most conventional fertility workups. RRM clinicians consider this approach insufficient when cycle-phase-dependent hormones are under evaluation.

Open full entry →

Pelvic floor physical therapy (PFPT) is a specialized rehabilitation discipline that evaluates and treats musculoskeletal contributors to chronic pelvic pain, dyspareunia, voiding and bowel dysfunction, and post-surgical or postpartum pelvic floor impairment. Pelvic floor therapists assess hypertonic or hypotonic pelvic floor muscles, myofascial trigger points, scar tissue restrictions, and neuromuscular coordination patterns. Treatment addresses the physical layer of conditions that also have gynecologic or hormonal contributors.²⁰⁸

For patients with endometriosis and chronic pelvic pain, pelvic floor dysfunction frequently coexists with the underlying disease. Adhesions, inflammatory lesions, and guarding responses alter muscle tone and neuromuscular coordination. A randomized controlled trial in women with deep infiltrating endometriosis found that pelvic floor muscle physiotherapy produced significant improvements in urinary, bowel, and sexual function compared to controls.²²¹ A 2025 systematic review and meta-analysis confirmed that physical rehabilitation reduces endometriosis and adenomyosis-related symptom burden, with locally applied techniques showing the strongest effect.²²²

PFPT is not an alternative to gynecologic evaluation. It is adjunct care. Surgery addresses the anatomical source of disease. PFPT addresses the neuromuscular sequelae. Post-excision patients often benefit from pelvic floor rehabilitation to resolve guarding and scar tissue restrictions that persist after excision. The same applies after adhesiolysis or other pelvic reconstructive procedures.

Indications for referral to a pelvic floor therapist include chronic pelvic pain with a musculoskeletal component, dyspareunia, postpartum pelvic floor recovery, and voiding or bowel dysfunction. Evaluation by a pelvic floor therapist typically includes internal and external assessment of tone, trigger points, and functional movement patterns.

Open full entry →

FertilityCare Practice is the named-method clinical discipline that integrates Creighton Model FertilityCare System charting instruction with NaProTechnology medical evaluation. A FertilityCare Practitioner (FCP) is a credentialed educator who teaches CrMS charting to clients, follows their charts longitudinally, and communicates findings to the NaProTechnology Medical Consultant who directs medical care. The FCP role is the instructional backbone of the NaProTechnology model: the clinical data that drives diagnosis flows through CrMS charting, and accurate charting requires consistent FCP support.⁷⁶⁴ FertilityCare Practitioners are credentialed through the American Academy of FertilityCare Professionals (AAFCP). The FertilityCare practice model is distinct from the NaProTechnology Medical Consultant role: the FCP instructs and monitors charting; the physician evaluates and treats. Other RRM methods have parallel educator structures: FEMM Teachers, Marquette instructors, and sympto-thermal educators serve comparable instructional functions within their respective clinical systems. Fertility charting is the shared foundation across all of these models.

Open full entry →

Functional and nutritional medicine is a whole-person approach to health that addresses micronutrient status, metabolic function, gut health, blood-sugar regulation, sleep, stress, and weight as root contributors to reproductive outcomes. Rather than treating fertility as a single-organ question, this approach recognizes that ovulation, implantation, and early pregnancy maintenance depend on systemic metabolic conditions. Deficiencies in folate, vitamin D, zinc, iron, omega-3 fatty acids, and B vitamins, as well as elevated inflammatory markers and uncontrolled insulin resistance, can each disrupt the hormonal signaling that governs the reproductive cycle.³

In restorative reproductive care, nutritional and metabolic assessment is not an afterthought. RRM clinicians who incorporate functional medicine may evaluate these factors as part of the diagnostic picture, addressing modifiable contributors that standard workups frequently overlook. Insulin resistance is a relevant example: it disrupts LH pulsatility, ovarian androgen production, and endometrial receptivity, yet it often goes undetected unless a clinician looks for it deliberately.

Body weight and adiposity affect hormone metabolism, ovarian reserve signaling, and implantation. Antioxidant status matters for oocyte and sperm quality alike. Methylated folate is relevant for couples with MTHFR variants, where standard folic acid supplementation may not achieve adequate tissue levels. These are not fringe considerations; they are well-documented physiological mechanisms with published reproductive relevance.

Functional and nutritional medicine does not replace surgical or hormonal evaluation where those are indicated. It adds a dimension to the assessment that supports genuine root-cause care. For couples working with restorative clinicians, it connects to the broader goal of body literacy: understanding what the body needs to function well, not just managing the downstream effects when it does not.

Open full entry →

A FertilityCare Practitioner (FCP) is a credentialed educator trained to teach the Creighton Model FertilityCare System to individuals and couples. FCPs are not physicians. Their role is to teach accurate observation of biological cycle markers, support clients in building a standardized chart record, and identify patterns that warrant referral to a medical consultant. The credential is issued through the FertilityCare Centers of America training program.⁷

The FCP role is the entry point into NaProTechnology care. A chart built over several cycles is the primary clinical data set the physician needs. Without it, cycle-based diagnostic evaluation cannot proceed. The FCP builds that record. The physician reads it. These are distinct functions, and neither is redundant.⁶⁴

FCPs support clients pursuing pregnancy, spacing pregnancies, and managing health conditions that respond to cycle observation. In all three contexts, the task is the same: teach accurate mucus cycle observation, support consistent charting, and communicate chart findings to the clinical team. The FCP does not prescribe or diagnose. The NaProTechnology Medical Consultant carries the diagnostic and prescriptive role.

Finding an FCP is typically the first step for couples who want to pursue Creighton Model-based care. The fertility chart the FCP helps build is the foundation of the clinical workup that follows.

Open full entry →

A NaProTechnology Medical Consultant (NFPMC) is a physician who has completed formal postgraduate training in NaProTechnology through an accredited program. Training routes include the fellowship at the Pope Paul VI Institute for the Study of Human Reproduction and the AAFCP Medical Consultant program. The credential is distinct from standard OBGYN or reproductive endocrinology training. It requires coursework in Creighton Model chart interpretation, NaPro diagnostic protocols, and NaPro surgical approaches.⁶⁴

The NFPMC is distinct from a FertilityCare Practitioner (FCP). The FCP teaches cycle observation and builds the chart. The NFPMC receives that chart, runs the diagnostic workup, orders cycle-timed hormone panels, interprets results, prescribes, and performs surgical intervention when indicated. The physician and the practitioner function as a team. Neither replaces the other.

The chart is the primary clinical data set in NaProTechnology care. An NFPMC working without Creighton chart data is working without the diagnostic foundation the system requires. Patients frequently search for a "NaPro doctor," "NaPro OBGYN," or "NaPro surgeon." All of these describe the NFPMC role.

The NFPMC role bridges FertilityCare practice and full restorative reproductive medicine evaluation. For couples seeking a full diagnostic workup grounded in cycle data, the NFPMC is the physician who carries that workup forward.

Open full entry →

Transdermal estrogen is estradiol delivered through the skin via patch, gel, or cream, bypassing first-pass hepatic metabolism. Unlike oral estrogen, which passes through the liver before reaching systemic circulation, transdermal delivery maintains estradiol-to-estrone ratios closer to premenopausal physiological levels. This pharmacokinetic difference reduces hepatic stimulation of coagulation factors, C-reactive protein, and triglycerides, which has clinical relevance for women with thrombophilic risk factors, metabolic concerns, or elevated cardiovascular risk.²³⁰

In the context of hormone replacement therapy for menopause or premature ovarian insufficiency, transdermal estrogen is one delivery option among several. The choice of route, formulation, and duration is guided by clinical context, individual risk profile, indication, and the patient's own response. Dosing decisions belong to that individual clinical conversation, not to a general definition.

Transdermal estrogen also has limited applications in restorative care outside of menopause management. Low estrogen can impair cervical mucus quality. When a clinician has identified a poor cervical mucus pattern as contributing to subfertility, and the evaluation has pointed to low estrogen as a cause, targeted estrogen support is one option a clinician may consider. This is a cycle-charting-informed clinical decision, not a general recommendation. It requires documented indication and ongoing monitoring of hormonal response.

Restorative care addresses underlying contributors before defaulting to systemic hormone replacement. For women approaching perimenopause with symptoms, lifestyle, nutrition, and a thorough hormonal evaluation come first. Transdermal estrogen, when used, is one tool in that picture, not the starting point.

Open full entry →

Follicle stimulation refers to the use of pharmacological agents to recruit follicle development and support ovulation in cycles where the natural process is absent or inadequate. Two principal agent classes are used: oral agents, including clomiphene citrate (a selective estrogen receptor modulator) and letrozole (an aromatase inhibitor); and injectable gonadotropins, preparations containing FSH alone or FSH combined with LH. The appropriate agent class depends on the underlying ovulatory disorder, the clinical method being applied, and how the patient's cycle is being monitored. A 2014 randomized trial in the New England Journal of Medicine found letrozole superior to clomiphene for live birth rates in women with PCOS-related anovulation.⁷⁶

Before stimulation is considered, a restorative evaluation asks why ovulation is not occurring. Anovulatory cycles have distinct causes: insulin resistance, thyroid dysfunction, hyperprolactinemia, diminished ovarian reserve, and others. Cycle charting via a fertility awareness-based method supplies the longitudinal picture that a single hormone draw cannot. Treating the underlying cause often restores ovulation without pharmacological stimulation. When stimulation is indicated, named methods like NaProTechnology select the agent and the monitoring approach based on the specific ovulatory disorder rather than applying a one-size protocol.

Cycle monitoring during stimulation is standard. A follicle maturation study tracks follicle growth, identifies poor response early, and guides the decision to add an HCG trigger. Monitoring also reduces the risk of multi-follicular development, which carries meaningful implications when the clinical goal is natural conception rather than oocyte retrieval.

Follicle stimulation in this context is fundamentally different from controlled ovarian hyperstimulation (COH) used in ART protocols. COH intentionally recruits multiple follicles for retrieval and fertilization outside the body. See IVF vs. RRM for a direct comparison of these paradigms. The pharmacological agents may overlap. The clinical objective does not. Restorative stimulation targets one well-developed follicle to support conception within the couple, not to bypass the process that failed.³⁹⁹⁴

Open full entry →

The Broader RRM Framework

NaProTECHNOLOGY (NaPro) is the most established and extensively studied approach within Restorative Reproductive Medicine, developed by Dr. Thomas Hilgers at the Pope Paul VI Institute and built on the Creighton Model FertilityCare System. RRM is the broader paradigm: it describes any medical approach that diagnoses and treats the root causes of reproductive dysfunction in cooperation with normal physiology, without bypassing or suppressing it. NaPro practitioners may or may not identify their work under the RRM label. Other approaches sharing this philosophy include: NeoFertility, Marquette Method-based medical management, and FEMM-based care. All share a common framework: biomarker data from cycle charting guides cycle-timed evaluation, root-cause diagnosis, and restorative treatment. None use suppressive medications as primary therapy or bypass conception through assisted reproductive technology.¹

Open full entry →

Intrauterine insemination (IUI) is a procedure in which washed and concentrated sperm are deposited directly into the uterine cavity via a thin catheter, timed to coincide with ovulation. Fertilization, if it occurs, takes place in the fallopian tube. IUI bypasses the cervical environment but does not involve handling eggs outside the body. It is less technically demanding than IVF and does not require egg retrieval or laboratory fertilization. Indications include donor sperm use, mild male factor infertility, cervical factor infertility, and some cases of undiagnosed subfertility. Per-cycle pregnancy rates vary substantially by age, sperm parameters, and underlying cause.

IUI addresses the delivery of sperm. It does not evaluate or treat the condition that made that re-routing necessary. A couple with sperm DNA fragmentation, a cycle disorder, or undiagnosed pelvic pathology will have those problems after IUI just as before. From a restorative standpoint, bypassing the cervical filter is a procedural workaround, not a diagnosis or a resolution. The underlying question, why is this couple not conceiving, remains unanswered.

RRM-aligned methods do not employ IUI. Instead, clinicians identify the most fertile days in a woman's cycle through continuous charting, optimize hormonal and structural conditions in both partners, and time fertility-focused intercourse to the peak day and surrounding days. Baseline evaluation includes both partners: a semen analysis for the male partner alongside cycle and hormonal assessment for the female partner. If male factor is confirmed, the cause, not just the delivery route, is what gets evaluated.

Open full entry →

In vitro fertilization (IVF) is a form of assisted reproductive technology in which oocytes are retrieved from the ovaries following controlled ovarian hyperstimulation, fertilized with sperm in a laboratory culture dish, and the resulting embryo or embryos transferred to the uterus. RRM does not perform IVF. The distinction is not merely procedural. IVF bypasses the reproductive system rather than restoring it: the underlying anatomical, hormonal, and immunologic conditions that prevented conception remain uncorrected after the procedure. RRM's position is that those underlying conditions, in most couples, are diagnosable and treatable. Controlled hyperstimulation routinely produces more embryos than will be transferred in a single cycle. Embryos not transferred may be frozen, donated, used for research, or discarded. Each of those outcomes is a consequential decision, not a logistical one. Known risks include ovarian hyperstimulation syndrome (OHSS),⁹⁵ elevated rates of preterm birth and low birthweight compared to spontaneous conception,⁹⁶ and multiple pregnancy when more than one embryo is transferred. Per-cycle live-birth rates decline substantially with advancing maternal age; HFEA registry data show IVF live-birth rates of approximately 22% per embryo transferred for women aged 35-37, falling further at older ages.⁹⁷ The question RRM asks is different: not how to work around a failing reproductive system, but what is causing it to fail, and whether that cause can be corrected. See IVF vs. RRM: Key Conceptual Distinctions and NaProTECHNOLOGY for the restorative alternative.

Open full entry →

IVF vs. RRM is a conceptual comparison framework that contrasts two fundamentally different paradigms for treating infertility: assisted reproductive technology, which bypasses the reproductive system, and restorative reproductive medicine, which identifies and treats the underlying causes preventing natural conception. The distinction is not a matter of degree. It is a difference in the question being asked. IVF asks: how do we produce a pregnancy despite the barrier? RRM asks: what is the barrier and can it be resolved?

Assisted reproductive technology works by extracting eggs, fertilizing them in a laboratory, and transferring resulting embryos into the uterus. The couple's underlying diagnosis, whether endometriosis, luteal phase deficiency, male factor infertility, or an undiagnosed cause, does not need to be resolved for the procedure to proceed. The technology works around the physiology. Restorative reproductive medicine takes the opposite position: the physiology is the starting point. Cycle-charting data, hormonal evaluation, and targeted diagnostics identify what is functioning suboptimally. Treatment corrects it. Conception occurs naturally.

Outcome data support both approaches, but they measure different things. The Fertilitas Study (n=1,310 couples) reported a 50% adjusted take-home baby rate at 24 months and 62.1% at 36 months or more in a NaProTechnology cohort.¹⁴⁹³ A 2025 retrospective evaluation of a single RRM clinic (n=187 couples) reported a 41% crude live-birth rate, with RRM singleton pregnancies showing less than half the preterm delivery rate of IVF singleton pregnancies per SART and CDC registry benchmarks.²¹⁹ These are not head-to-head randomized trials. They establish that restorative care achieves clinically meaningful conception rates in couples who have not yet undergone IVF, including couples with previous IVF failure.

The perinatal risk profile also differs. ART pregnancies carry elevated rates of preterm birth, low birth weight, and multiple gestation compared to naturally conceived pregnancies, even when singleton outcomes are analyzed separately.⁹⁶ This is not a reason to refuse ART when it is the only option a couple has been offered. It is a reason to ask first whether restorative care was evaluated. The question matters because many couples presenting with “unexplained infertility” have diagnosable, treatable conditions that were never investigated. Undiagnosed is not the same as unexplained. Related entries: corrective vs. bypass approach, ART, ICSI, IUI, OHSS.

Open full entry →

Patient-centered care is a healthcare orientation that places the individual's values, preferences, expressed needs, and active participation at the center of clinical decision-making, while ensuring information transparency and coordination across providers. The framework identifies several interconnected dimensions of care quality: respecting patient preferences, providing emotional support, ensuring access to information, involving family and close partners, and maintaining continuity across the care team.

RRM aligns naturally with this framework. The restorative approach treats the couple as the clinical unit of evaluation: both partners receive a systematic workup, and care decisions reflect the goals, values, and expressed priorities of the couple together. Cycle charting places biometric data directly in the hands of the patient rather than behind a laboratory portal, making the information a shared clinical resource rather than a clinician-held interpretation.⁸⁹ This orientation reflects a principle that runs throughout restorative care: the body generates information that belongs to the person living in it.

The informational dimension of patient-centered care carries particular weight in reproductive medicine, where diagnoses are often delayed, dismissed, or bypassed in favor of procedural interventions that do not address the underlying condition. A care model that treats patients as partners in understanding their own physiology starts from a diagnostic question rather than a procedural one: what is happening, and why?¹

Open full entry →

Couple-based treatment is the clinical principle that both partners are evaluated and treated as a unit when infertility or recurrent pregnancy loss is the concern. Male factor is the sole cause of infertility in approximately 20% of couples and a contributing factor in another 30 to 40%.¹⁹³ Evaluating only the female partner means a significant portion of root causes go unaddressed from the first appointment.

This is not a courtesy inclusion. It reflects the biology. Cycle-charting data and female hormonal evaluation inform the female contribution. Semen analysis, sperm DNA integrity, and male hormonal workup inform the male contribution. Both are necessary before a complete picture of the couple's fertility can emerge.⁸⁷

Couple-based treatment also addresses the emotional asymmetry that develops when only one partner is the patient. When both partners are clinically visible, the investigation belongs to both. That changes how couples carry the process.

Open full entry →

Adhesion prevention refers to the set of surgical strategies employed before, during, and after pelvic surgery to minimize the formation of post-operative adhesions. Adhesions form when tissue surfaces that were separated by surgery heal in contact with each other. They can distort anatomy, impair tubal function, and contribute to chronic pelvic pain and infertility.

A multi-component approach is the standard in restorative pelvic surgery. Surgical technique is the primary determinant: meticulous hemostasis, gentle tissue handling, magnification to reduce collateral trauma, and thorough peritoneal irrigation all reduce the inflammatory stimulus for adhesion formation. Excision is preferred over fulguration precisely because it removes lesions with defined margins rather than burning and leaving devitalized tissue behind.⁸⁰

Anti-adhesion barriers provide a second layer of protection by physically separating tissue surfaces during the critical early healing window. Options include oxidized regenerated cellulose, sodium hyaluronate and carboxymethylcellulose membranes, and hyaluronic acid gels applied at closure. The choice of barrier depends on the surgical site and the extent of reconstruction required.⁸⁰

Published NaProTechnology surgical series document progressive reduction in adhesion scores over decades of systematic barrier use, reflecting the cumulative effect of technique refinement alongside barrier application.⁸⁰ The goal across all approaches is a pelvis that heals cleanly, with anatomy preserved and tubal function restored.

Open full entry →

Antioxidant therapy is the use of compounds that neutralize reactive oxygen species (ROS) to reduce oxidative damage in the reproductive system. Oxidative stress occurs when ROS production exceeds the body's antioxidant defenses. In the reproductive system, excess ROS damages sperm DNA, impairs sperm motility, degrades oocyte quality, and disrupts the endometrial environment needed for implantation.³⁵⁵⁷

In male reproductive health, antioxidant support addresses one of the most documented and correctable contributors to sperm DNA fragmentation. Elevated sperm DNA fragmentation is associated with reduced fertilization, increased miscarriage, and failed conception. Reducing oxidative load can improve sperm integrity without surgery or hormonal intervention.³⁵

In female reproductive health, oxidative stress is implicated in endometriosis progression, oocyte quality decline, and luteal phase dysfunction. Antioxidant support targets these mechanisms at the cellular level. Cycle-charting data can help identify timing and context that inform when oxidative burden may be highest.⁵⁷⁵⁸

Specific supplement selection and dosing are determined by individual assessment, not by a standard protocol. The appropriate compounds and quantities vary based on lab findings, clinical context, and the method being applied. That evaluation belongs with the clinician managing the couple's care.

Open full entry →

Nutritional and lifestyle medicine is a clinical framework that addresses the metabolic and behavioral contributors to reproductive health, treating them as root causes rather than background factors. Diet quality, body composition, sleep, stress load, physical activity, and environmental exposures all influence hormone production, cycle regularity, sperm quality, and endometrial function. When these factors are inadequate or dysregulated, fertility is affected in measurable, addressable ways.⁷⁰

Nutritional adequacy matters at the cellular level. Micronutrient deficiencies affect methylation pathways, progesterone synthesis, thyroid function, and immune regulation. Metabolic disruption, including insulin resistance and excess adiposity, alters androgen and estrogen balance in ways that suppress ovulation and impair cycle quality.⁶⁹⁷⁰ These are diagnosable, modifiable conditions.

A restorative approach investigates what each couple eats, how they sleep, and what chronic stressors are present, because these factors interact with every other clinical finding. Cycle-charting data can make the connections visible. A charted cycle showing luteal phase abnormalities, for example, may reflect nutritional gaps or metabolic dysfunction that a hormone panel alone would not fully explain.⁸⁷

Specific supplement protocols and dietary prescriptions are determined by individual clinical evaluation through the method the clinician uses. This entry covers the framework principle. The named methods (NaProTechnology, FEMM, and others) carry the clinical specifics.

Open full entry →

Intracytoplasmic sperm injection (ICSI) is a laboratory procedure in which a single sperm is selected, immobilized, and injected directly into a mature egg using a fine glass needle. It was developed in the early 1990s as a solution for severe male factor infertility where conventional IVF fertilization rates were poor. ICSI bypasses the natural process of sperm-egg recognition and zona pellucida penetration entirely.

ICSI has since expanded well beyond its original indication. It is now applied routinely in IVF cycles even when sperm parameters are normal, often without clear clinical justification. When sperm quality is genuinely impaired, the underlying cause matters. ICSI bypasses the fertilization barrier. It does not identify or correct the condition responsible for the impaired sperm. A varicocele, hormonal imbalance, elevated oxidative stress, or treatable infection can reduce sperm function substantially. Each is identifiable. Most are treatable.

There are recognized risks associated with ICSI that are not always discussed with couples before the procedure. The mechanical injection bypasses natural sperm selection mechanisms that operate during fertilization. Certain genetic risks, particularly in cases of severe male factor, may be transmissible to male offspring. Long-term safety data for offspring conceived via ICSI continues to be evaluated.⁶³ Couples deserve accurate risk information before proceeding.

For couples where male factor is the primary barrier to natural conception, the starting point in restorative care is evaluation of both partners. Semen analysis, hormonal panel, and sperm DNA fragmentation testing identify what is contributing and what is treatable. Where anatomical correction is possible, options such as varicocele repair or vasectomy reversal restore the physiology rather than engineer around it. Restorative andrology is the field that addresses male reproductive function directly.

Open full entry →

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of ovarian stimulation protocols used in ART, in which pharmacologically elevated gonadotropin levels cause the ovaries to produce an excessive number of follicles, triggering systemic vascular and fluid changes that range in severity from mild bloating to life-threatening thromboembolism.⁶² Mild OHSS is common. Severe OHSS requires hospitalization and can involve ascites, pleural effusion, hemoconcentration, and renal impairment. The condition is classified by grade, and major professional society guidelines address its prevention and management.⁹⁵

Women with PCOS face the highest OHSS risk because their ovaries contain large numbers of antral follicles that respond aggressively to exogenous stimulation. The antral follicle count that defines PCOS ovarian morphology is the same feature that predicts exaggerated response to gonadotropins. OHSS risk should be part of any informed consent discussion for women with PCOS who are offered ART. Both partners need accurate risk information before proceeding.

OHSS does not occur in restorative reproductive medicine protocols. NaProTechnology, NeoFertility, and related restorative approaches use low-dose hormonal support calibrated to documented cycle deficiencies, not pharmacologic superstimulation. The goal is to support the cycle the patient already has, not to replace it with an artificially driven one. This is a structural difference in the treatment paradigm, not a difference in medication class.

For women with PCOS and anovulatory cycles, the more fundamental question is whether the hormonal and metabolic contributors to anovulation have been identified and addressed before stimulation for ART is considered. Cycle-charting data, including sonographic ovulation classification and hormonal profiling from follicle maturation monitoring, can document ovulatory function precisely. Many women with PCOS who receive targeted metabolic and hormonal support achieve natural conception without the stimulation pathway that carries OHSS risk.

Open full entry →

Assisted Reproductive Technology (ART) is the umbrella term for medical procedures in which eggs or embryos are handled outside the body to achieve pregnancy. The category includes in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), donor egg and donor sperm cycles, embryo banking, frozen embryo transfer, and gestational surrogacy. Note that intrauterine insemination (IUI), while sometimes grouped colloquially with fertility treatments, does not involve eggs handled outside the body and is classified separately from ART in CDC, HFEA, and SART reporting.⁹⁷

ART procedures are bypass technologies. They achieve pregnancy by working around the reproductive barrier without requiring that barrier to be identified or treated. A woman with undiagnosed endometriosis who undergoes IVF still has endometriosis. A couple with undiagnosed male factor who pursues ICSI still has an undiagnosed male factor. The conception method changes. The underlying condition does not.

RRM and ART reflect opposite premises. ART proceeds from the assumption that the body cannot succeed on its own and builds technology around that assumption. RRM asks why the body has not succeeded, then addresses the answer. These are different questions. They lead to different clinical pathways. Cross-referencing them as alternatives for the same clinical problem understates how differently they frame the problem itself. See corrective vs. bypass approach.

ART carries elevated perinatal risk relative to naturally conceived pregnancies, including higher rates of preterm birth, low birth weight, and multiple gestation. A systematic review of controlled studies confirmed elevated risk for both singletons and twins after assisted conception.⁹⁶ HFEA annual data document the population-level profile across hundreds of thousands of UK treatment cycles.⁹⁷ Patients deserve accurate, age-stratified outcome data before consenting to any ART procedure.

Open full entry →

An oral contraceptive (OC) is a hormone-based medication taken by mouth to prevent pregnancy. Combined oral contraceptives (COCs) contain synthetic estrogen and progestin. Progestin-only pills contain progestin alone. Both work primarily by suppressing pituitary gonadotropin release, which prevents ovulation. The monthly cycle is not regulated by these medications; it is suppressed. What appears as a period during the pill-free interval is a withdrawal bleed, not a naturally occurring menstrual cycle.

OCs are prescribed for contraception and for a range of non-contraceptive indications including painful periods, androgen-related skin conditions, and cycle-associated symptoms in conditions such as PCOS and endometriosis. In each application, the mechanism is the same: cycle suppression. Symptoms may diminish while the medication is active. The underlying condition does not change. RRM clinicians use the term suppressive medications to name this accurately: the disease continues to progress on its own timeline while ovulation and cycle function are held in suspension.⁷¹

Documented risks associated with OC use include venous thromboembolism, mood and libido changes, and effects on bone mineral density and cardiovascular markers. The magnitude of risk varies by formulation, duration of use, and individual factors. These risks are supported by published evidence and deserve clear disclosure as part of any informed prescribing conversation.⁷¹

For couples seeking non-hormonal approaches to family planning or cycle health, Fertility awareness-based methods (FABMs) offer an evidence-based alternative. FABMs work with the observable signs of the cycle rather than suppressing them, and they provide charting data that can be used clinically when reproductive health concerns arise. Body literacy developed through charting is often the entry point into restorative evaluation.

Open full entry →

An intrauterine device (IUD) is a small, T-shaped contraceptive device placed inside the uterine cavity. Two primary types exist: copper and hormonal. The copper IUD works without hormones. Copper ions impair sperm motility and inhibit fertilization. At higher concentrations, copper may also alter the endometrial environment in ways that affect implantation, though the primary mechanism operates before fertilization.

The hormonal IUD releases levonorgestrel, a synthetic progestin, locally into the uterine cavity. It thickens cervical mucus, thins the endometrial lining, and may suppress ovulation in some users, particularly in the first year of use. Whether post-fertilization effects occur is scientifically contested and directly relevant to informed consent for couples who consider fertilization the beginning of a new life.⁷²

Both types carry known side effects. The copper IUD frequently causes heavier menstrual bleeding and increased cramping. The hormonal IUD frequently causes irregular bleeding or amenorrhea. Amenorrhea eliminates menstrual cycle data as a diagnostic source, removing information that restorative clinicians rely on to identify hormonal patterns and underlying conditions. Both types carry a small risk of expulsion, uterine perforation at insertion, and pelvic infection.

Fertility Awareness-Based Methods provide an alternative to intrauterine contraception with equivalent effectiveness when used correctly, without a device, systemic or local hormonal exposure, or the post-fertilization mechanisms that have prompted ongoing scientific and ethical discussion. For couples who want to understand their cycle rather than suppress or override it, FABMs support that goal directly, alongside body literacy and restorative care.

Open full entry →

Hormone replacement therapy (HRT) is the exogenous administration of estrogen, progesterone, or both, to address the decline in hormonal production that occurs during perimenopause, menopause, or in conditions such as premature ovarian insufficiency (POI). HRT reduces vasomotor symptoms (hot flashes, night sweats), slows bone loss, and may lower cardiovascular risk when initiated in the early postmenopausal window. Documented risks include venous thromboembolism and, with combined estrogen-progestogen therapy, a modest increase in breast cancer risk that varies by formulation, duration, and timing of initiation.⁷³

The clinical context matters. A 32-year-old with POI who has no functional ovarian estrogen production faces accelerated bone loss, cardiovascular risk, and neurological consequences without treatment. Guidelines recommend hormone replacement in POI until at least the average age of natural menopause, given the documented risks of untreated estrogen deficiency at a young age. This is physiological replacement for a documented deficiency. It is not the same as administering hormones to suppress normal reproductive function, which is a different clinical goal with a different risk-benefit calculation.

Restorative-aligned perimenopause and menopause care addresses symptoms first through lifestyle, nutrition, and targeted evaluation of the hormonal picture, and considers systemic hormone therapy when the clinical indication is established and the risk profile has been individually assessed. The route of administration, formulation, and duration are each relevant to that risk profile. Transdermal estrogen, for example, avoids the first-pass hepatic effects associated with oral preparations, which has implications for thromboembolism risk.

Open full entry →

Abbreviations and Quick Reference